Author: "Manuela Rizzo" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Manuela Rizzo"' showing total 45 results

Start Over Author "Manuela Rizzo"

45 results on '"Manuela Rizzo"'

1. Aggressive Primary Cutaneous Anaplastic T-Cell Lymphoma Successfully Treated with Autologous Stem Cell Transplant and Brentuximab Vedotin Consolidation: Case Report and Review of the Literature

Author: Luca Guarnera, Federico Meconi, Marco Pocci, Fabiana Esposito, Manuela Rizzo, Vito Mario Rapisarda, Annagiulia Zizzari, Cosimo Di Raimondo, Livio Pupo, Lucia Anemona, and Maria Cantonetti
Subjects: cutaneous lymphoma, anaplastic T-cell lymphoma, autologous stem cell transplant, brentuximab vedotin, Diseases of the blood and blood-forming organs, RC633-647.5
Abstract: Primary cutaneous CD30+ lymphoproliferative disorders include primary cutaneous anaplastic large cell lymphoma (pcALCL) and lymphomatoid papulosis. The prognosis of the disease is usually excellent but, in a minority of cases, it presents with extracutaneous involvement and aggressive behavior. The case we present—relapsed after surgical excision, immunosuppressive therapy, and conventional chemotherapy—is the first one treated with Autologous Stem Cell transplant followed by Brentuximab Vedotin consolidation, a scheme already used for high risk Hodgkin Lymphoma.
Published: 2022
Full Text: View/download PDF

2. New insight into the catalytic -dependent and -independent roles of METTL3 in sustaining aberrant translation in chronic myeloid leukemia

Author: Zaira Ianniello, Melissa Sorci, Lavinia Ceci Ginistrelli, Alessia Iaiza, Marcella Marchioni, Claudia Tito, Ernestina Capuano, Silvia Masciarelli, Tiziana Ottone, Cristina Attrotto, Manuela Rizzo, Luca Franceschini, Stefano de Pretis, Maria Teresa Voso, Mattia Pelizzola, Francesco Fazi, and Alessandro Fatica
Subjects: Cytology, QH573-671
Abstract: Abstract Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by the presence of tyrosine kinase BCR-ABL1 fusion protein, which deregulate transcription and mRNA translation. Tyrosine kinase inhibitors (TKIs) are the first-choice treatment. However, resistance to TKIs remains a challenge to cure CML patients. Here, we reveal that the m6A methyltransferase complex METTL3/METTL14 is upregulated in CML patients and that is required for proliferation of primary CML cells and CML cell lines sensitive and resistant to the TKI imatinib. We demonstrate that depletion of METTL3 strongly impairs global translation efficiency. In particular, our data show that METTL3 is crucial for the expression of genes involved in ribosome biogenesis and translation. Specifically, we found that METTL3 directly regulates the level of PES1 protein identified as an oncogene in several tumors. We propose a model in which nuclear METTL3/METTL14 methyltransferase complex modified nascent transcripts whose translation is enhanced by cytoplasmic localization of METTL3, independently from its catalytic activity. In conclusion, our results point to METTL3 as a novel relevant oncogene in CML and as a promising therapeutic target for TKI resistant CML.
Published: 2021
Full Text: View/download PDF

3. RAAS Inhibitor Prescription and Hyperkalemia Event in Patients With Chronic Kidney Disease: A Single-Center Retrospective Study

Author: Eleonora Riccio, Ivana Capuano, Pasquale Buonanno, Michele Andreucci, Michele Provenzano, Maria Amicone, Manuela Rizzo, and Antonio Pisani
Subjects: hypertension, chronic kidney disease, hyperkalemia, RAAS inhibitor, prevalence, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract: Hyperkalemia is common in patients treated with renin–angiotensin–aldosterone system inhibitors (RAASis), and it represents the main cause of the large gap reported between guideline recommendations and real-world practice in chronic kidney disease (CKD). We conducted a CKD-population-based restrospective study to determine the prevalence of patients with CKD treated with RAASis, incidence of hyperkalemia in patients with CKD treated with RAASis, and proportion of patients with RAASi medication change after experiencing incident hyperkalemia. Among 809 patients with CKD analyzed, 556 (68.7%) were treated with RAASis, and RAASi prescription was greater in stages 2–4 of CKD. Hyperkalemia occurred in 9.2% of RAASi-treated patients, and the adjusted rate of hyperkalemia among patients with stage 4–5 CKD was 3-fold higher compared with patients with eGFR > 60 ml/min/1.73 m2. RAASi treatment was discontinued in 55.3% of the patients after hyperkalemia event (74.2% discontinued therapy, 3.2% received a reduced dose, and 22.6% reduced the number of RAASi drugs). This study shows that the incidence of hyperkalemia is frequently observed in patients with CKD patients with RAASis, and that rates increase with deteriorating levels of kidney function from stages 1 to 3. RAASi medication change following an episode of hyperkalemia occurred in almost half of the patients after experiencing hyperkalemia.
Published: 2022
Full Text: View/download PDF

4. EFFICACY AND SAFETY OF CYCLOPHOSPHAMIDE LOW-DOSE PRE-PHASE CHEMOTHERAPY IN DIFFUSE LARGE B CELL LYMPHOMA WITH GASTROINTESTINAL INVOLVEMENT

Author: Luca Guarnera, Federico Meconi, Roberto Secchi, Maria Rosaria Pascale, Fabiana Esposito, Annagiulia Zizzari, Vito Mario Rapisarda, Manuela Rizzo, Livio Pupo, and Maria Cantonetti
Subjects: Low-dose pre-phase chemotherapy, Diffuse Large B Cell Lymphoma with gastrointestinal involvement, Cyclophosphamide, Diseases of the blood and blood-forming organs, RC633-647.5
Abstract: Introduction Gastric Diffuse large B‐cell lymphoma (DLBCL) is the most common extra-nodal site of lymphoma’s involvement (30%-40% of all extranodal lymphomas and 55%-65% of all gastrointestinal lymphomas). However, gastric localizations are also sometimes found in systemic DLBCL. Gastric complications such as bleeding, perforation and stenosis under chemotherapy are well documented. Methods We retrospectively analyzed 15 patients with newly diagnosed DLBCL with gastrointestinal involvement. Endoscopies were performed in these patients before and after treatment. Treatment consisted in cyclophosphamide low-dose pre-phase chemotherapy before conventional-dose chemotherapy. Results Endoscopy at staging detected ulcers in 12 patients (80%). After low-dose pre-phase chemotherapy GI ulcers healed in 91.6% of cases (1 ulcer detected). After the whole treatment (Low-dose pre-phase + chemotherapy) 9 patients (60%) achieved complete response, 4 patients (26.6%) partial response, 2 (13,3%) patients presented disease progression. The most frequent adverse event was neutropenia (73.3%); the most frequent non hematological adverse event was transaminases elevation (20%). Conclusion Cyclophosphamide low-dose pre-phase chemotherapy resulted a safe and effective way to prevent adverse events in systemic DLBCL with gastrointestinal involvement.
Published: 2022
Full Text: View/download PDF

5. Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial

Author: Ilaria Saltarella, Fortunato Morabito, Nicola Giuliani, Carolina Terragna, Paola Omedè, Antonio Palumbo, Sara Bringhen, Lorenzo De Paoli, Enrica Martino, Alessandra Larocca, Massimo Offidani, Francesca Patriarca, Chiara Nozzoli, Tommasina Guglielmelli, Giulia Benevolo, Vincenzo Callea, Luca Baldini, Mariella Grasso, Giovanna Leonardi, Manuela Rizzo, Antonietta Pia Falcone, Daniela Gottardi, Vittorio Montefusco, Pellegrino Musto, Maria Teresa Petrucci, Franco Dammacco, Mario Boccadoro, Angelo Vacca, and Roberto Ria
Subjects: Angiogenic factors, Multiple myeloma, Overall survival, Progression-free survival, Response rate, Diseases of the blood and blood-forming organs, RC633-647.5, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract: Abstract Background Several new drugs are approved for treatment of patients with multiple myeloma (MM), but no validated biomarkers are available for the prediction of a clinical outcome. We aimed to establish whether pretreatment blood and bone marrow plasma concentrations of major cytokines and angiogenic factors (CAFs) of patients from a phase 3 trial of a MM treatment could have a prognostic and predictive value in terms of response to therapy and progression-free and overall survival and whether these patients could be stratified for their prognosis. Methods Blood and bone marrow plasma levels of Ang-2, FGF-2, HGF, VEGF, PDGF-β, IL-8, TNF-α, TIMP-1, and TIMP-2 were determined at diagnosis in MM patients enrolled in the GIMEMA MM0305 randomized controlled trial by an enzyme-linked immunosorbent assay (ELISA). These levels were correlated both reciprocally and with the type of therapy and patients’ characteristics and with a group of non-MM patients as controls. Results No significant differences were detected between the blood and bone marrow plasma levels of angiogenic cytokines. A cutoff for each CAF was established. The therapeutic response of patients with blood plasma levels of CAFs lower than the cutoff was better than the response of those with higher levels in terms of percentage of responding patients and quality of response. Conclusion FGF-2, HGF, VEGF, and PDGF-β plasma levels at diagnosis have predictive significance for response to treatment. The stratification of patients based on the levels of CAFs at diagnosis and their variations after therapy is useful to characterize different risk groups concerning outcome and response to therapy. Trial registration Clinical trial information can be found at the following link: NCT01063179
Published: 2019
Full Text: View/download PDF

6. Frontline Dasatinib Treatment in a 'Real-Life' Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia

Author: Roberto Latagliata, Fabio Stagno, Mario Annunziata, Elisabetta Abruzzese, Alessandra Iurlo, Attilio Guarini, Carmen Fava, Antonella Gozzini, Massimiliano Bonifacio, Federica Sorà, Sabrina Leonetti Crescenzi, Monica Bocchia, Monica Crugnola, Fausto Castagnetti, Isabella Capodanno, Sara Galimberti, Costanzo Feo, Raffaele Porrini, Patrizia Pregno, Manuela Rizzo, Agostino Antolino, Endri Mauro, Nicola Sgherza, Luigiana Luciano, Mario Tiribelli, Antonella Russo Rossi, Malgorzata Trawinska, Paolo Vigneri, Massimo Breccia, Gianantonio Rosti, and Giuliana Alimena
Subjects: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract: Dasatinib (DAS) has been licensed for the frontline treatment in chronic myeloid leukemia (CML). However, very few data are available regarding its efficacy and toxicity in elderly patients with CML outside clinical trials. To address this issue, we set out a “real-life” cohort of 65 chronic phase CML patients older than 65 years (median age 75.1 years) treated frontline with DAS in 26 Italian centers from June 2012 to June 2015, focusing our attention on toxicity and efficacy data. One third of patients (20/65: 30.7%) had 3 or more comorbidities and required concomitant therapies; according to Sokal classification, 3 patients (4.6%) were low risk, 39 (60.0%) intermediate risk, and 20 (30.8%) high risk, whereas 3 (4.6%) were not classifiable. DAS starting dose was 100 mg once a day in 54 patients (83.0%), whereas 11 patients (17.0%) received less than 100 mg/day. Grade 3/4 hematologic and extrahematologic toxicities were reported in 8 (12.3%) and 12 (18.5%) patients, respectively. Overall, 10 patients (15.4%) permanently discontinued DAS because of toxicities. Pleural effusions (all WHO grades) occurred in 12 patients (18.5%) and in 5 of them occurred during the first 3 months. DAS treatment induced in 60/65 patients (92.3%) a complete cytogenetic response and in 50/65 (76.9%) also a major molecular response. These findings show that DAS might play an important role in the frontline treatment of CML patients >65 years old, proving efficacy and having a favorable safety profile also in elderly subjects with comorbidities.
Published: 2016
Full Text: View/download PDF

7. Erratum: Searches for continuous gravitational waves from 15 supernova remnants and fomalhaut b with advanced LIGO (2019, ApJ, 875, 122)*

Author: A. Parida, S. S. Eikenberry, F. Frasconi, Chris A. Collins, R. Flaminio, Marcus E. Lower, Rosa Poggiani, V. Frey, E. K. Wessel, Nikhil Sarin, Odylio D. Aguiar, I. W. Martin, S. Farinon, P. Raffai, Andrew Matas, C. F. Da Silva Costa, M. A. Okada, G. Rutins, Graham Woan, Sebastiano Bernuzzi, D. Passuello, A. Cirone, H. S. Chen, Hyun Lee, J. D. Lough, K. Mason, S. A. Bilgili, E. C. Ferreira, Robert L. Byer, J. Calderón Bustillo, Sanjeev Dhurandhar, O. Halim, N. A. Robertson, Stuart Reid, F. J. Hayes, Patrick Godwin, N. Sennett, P. Kumar, Jacob Scheuer, B. R. Hall, J. Hanks, R. M. Martin, David A. Nichols, Edward K. Porter, J. G. Bartlett, Márton Tápai, K. W. Tsang, C. Horst, W. A. Campbell, Andreas Freise, C. V. Kalaghatgi, M. Rakhmanov, G. Pagano, Paul D. Lasky, J. W. Westhouse, M. C. Araya, Srishti Tiwari, C. Lazzaro, Patricia Schmidt, V. Brisson, Bernard F. Schutz, Li Ju, Matthew Pitkin, D. Cohen, Kiran Prasai, P. J. Veitch, S. A. Usman, C. Messenger, Liam Cunningham, E. A. M. Muniz, Daniel A. Shaddock, P. Gruning, Brittany Kamai, Riccardo Ciolfi, Alberto Vecchio, Geoffrey Mo, J. M. Fishner, Roman Schnabel, J. Hanson, M. Wade, M. Montani, P. Sharma, Héctor Estellés, N. Letendre, F. Ricci, A. Lenon, J. E. Brau, A. A. van Veggel, Richard Gray, Efim A. Khazanov, Peter T. H. Pang, C. Affeldt, G. Ballardin, Moritz Mehmet, A. A. Ciobanu, M. Granata, Minchuan Zhou, F. Marion, P. Brockill, Nancy Aggarwal, Hang Yu, P. G. Murray, Fabien Kéfélian, J. H. Hough, P. W. F. Forsyth, S. R. Thondapu, J. R. Palamos, Michele Zanolin, S. Mukherjee, T. J. Massinger, T. Vo, V. Kalogera, N. Leroy, G. D. Hammond, Javed Rana, H. Fong, G. Greco, M. Haney, T. A. Callister, Alec Mishkin, R. Cavalieri, S. R. P. Mohapatra, G. Giordano, K. Toland, A. K. Srivastava, A. E. Pace, H. Ohta, Vuk Mandic, B. Bécsy, M. Kasprzack, I. Dave, B. D. Lackey, R. L. Ward, Scott Coughlin, A.J. Weinstein, K. H. Lai, M. Phelps, H. S. Cho, L. Kuo, H. Yamamoto, E. Capocasa, M. Chan, S. Walsh, D. J. McManus, A. Schönbeck, B. Rajbhandari, Andrew Mehta, S. D. Linker, R. Robie, M. Fletcher, B. Hughey, R. D. Kennedy, José A. Font, Gregorio Carullo, S. Kumar, J. Prasad, H. K. Gulati, V. Raymond, Steven Bloemen, H. J. Bulten, Shiuh Chao, P. J. Sutton, N. Singh, C. Buy, Samuele Cortese, J. McIver, Vivishek Sudhir, P. A. Altin, A. Basti, N. A. Lockerbie, E. Schreiber, Charalampos Markakis, P. Grassia, Kipp Cannon, M. Steinke, P.H. Nguyen, Ryan N. Lang, Z. Doctor, Alyssa Garcia, J. H. Romie, Carlos O. Lousto, S. Sitmukhambetov, Alejandro Torres-Forné, A. Samajdar, D. M. Wysocki, T. Mistry, Mark A. Scheel, Charlie Hoy, F. Clara, M. A. Aloy, T. M. Evans, C. North, Thomas Dent, P. Corban, P. Ajith, B. Mours, Mandar Patil, Abhirup Ghosh, J. Neilson, Bala R. Iyer, Y. K. Lecoeuche, M. Muratore, Karsten Danzmann, Fabrizio Barone, N. Mukund, P. B. Covas, M. C. Edwards, T. Hinderer, Marta Colleoni, J. A. Giaime, Michael Pürrer, R. Pedurand, Benno Willke, A. Grado, D. C. Vander-Hyde, S. S. Y. Chua, J. Eichholz, J.-P. Coulon, Hua Wang, E. A. Chase, J. Betzwieser, G. Kang, L. R. Cominsky, O. A. Hannuksela, Z. Frei, A. Pal-Singh, S. Caride, Kevin Barkett, N. Bode, S. E. Gossan, Tristan Briant, R. Gustafson, Antoine Heidmann, Rana X. Adhikari, S. McCormick, C. Casentini, Slawomir Gras, D. Töyrä, H. Overmier, S. W. S. Ng, G. Wang, M. C. Heintze, J. S. Areeda, I. Belahcene, B. B. Lane, N. Mazumder, Maher Yazback, F. Donovan, J. Bosveld, N. A. Holland, N. V. Keerthana, M.L. Walker, C. Cahillane, L. Sun, M. C. Milovich-Goff, Dániel Barta, J. D. E. Creighton, V. Gayathri, P. Puppo, J.-D. Fournier, S. J. Kapadia, A. L. Stuver, A. S. Sengupta, H. W. Lee, I. Di Palma, S. T. Countryman, Francesco Pannarale, E. A. Huerta, J. L. Wright, Alessandra Corsi, B. W. Schulte, A. Rocchi, J. P. Zendri, R. Kashyap, Chandra Kant Mishra, R. Bhandare, Sylvain Marsat, Lee McCuller, T. Bulik, T. D. Abbott, O. Puncken, J. M. Gonzalez Castro, Philip F. Hopkins, C. Cocchieri, B. Goncharov, R. Birney, M. Kinley-Hanlon, I. Fiori, Shawn Rosofsky, Jun Liu, S. Raja, S. E. Strigin, D. Sellers, J. Meidam, Jeff R. Powell, Riccardo Sturani, D. Hoak, Stefan L. Danilishin, Patrick Brady, L. Matone, Haocun Yu, M. Landry, R. M. S. Schofield, Surabhi Sachdev, Christopher J. Moore, V. Avendano, R. Mittleman, Nelson Christensen, Geoffrey Lovelace, Soichiro Morisaki, John Worden, P. Couvares, Carl-Johan Haster, O. J. Piccinni, L. Rolland, C. L. Romel, Miriam Cabero, Alessandra Buonanno, L. Wallace, S. Biscoveanu, M. B. Shaner, Benjamin J. Owen, Alexander Urban, Antoni Ramos-Buades, V. V. Frolov, A. Singhal, F. Carbognani, Jordan Camp, R. L. Savage, A. S. Bell, M. Laxen, Anchal Gupta, A. Królak, B. D. Cheeseboro, G. Cerretani, P. J. Easter, J. F. J. van den Brand, M. J. Szczepańczyk, L. Di Fiore, E. Bonilla, S. Sunil, M. Tacca, Jessica Steinlechner, A. Neunzert, P.-F. Cohadon, M. Heurs, Irina Kowalska, E. Katsavounidis, Xiuling Li, C. I. Torrie, Jan Harms, Kazuhiro Agatsuma, Kin Sing Stephen Lee, Frank Ohme, M. Tonelli, R. De Rosa, Kwan-Lok Li, I. Nardecchia, Reed Essick, Martin Hendry, Cecilio García-Quirós, S. Kandhasamy, M. Fishbach, B. Sorazu, Christopher Wipf, Archisman Ghosh, A. P. Lundgren, Gabrielle Allen, E. J. Daw, M. Punturo, F. Garufi, Antonio Marquina, Surendra Nadh Somala, I. Dorrington, Robert J. McCarthy, T. A. Ferreira, R. Frey, Joseph Smith, S. Brunett, J. Zweizig, A. W. Heptonstall, E. L. Merilh, D. Barker, K. D. Giardina, Denis Martynov, Marco Bazzan, C. Ingram, L. Pinard, L. Naticchioni, Salvatore Vitale, R. Kirchhoff, B. L. Pearlstone, N. Man, Antonios Kontos, D. Moffa, J. J. McCann, J.-M. Isac, D. Hofman, Linqing Wen, A. Bisht, A. Kutynia, M. A. Page, Tyson Littenberg, Z. Tornasi, Junwei Cao, Sebastian Steinlechner, T. J. Slaven-Blair, S. ShyamSundar, C. Stachie, Hongyu Shen, O. de Varona, J. B. Kanner, Federico Ferrini, Lijing Shao, G. Vajente, S. M. Gaebel, Christopher P. L. Berry, S. H. Huttner, G. M. Harry, Andrea Chincarini, K. Venkateswara, Yuri Levin, C. Austin, C.D. Booth, M. Barsuglia, S. Appert, A. Giazotto, P. Shawhan, I. Ferrante, T. Z. Summerscales, A. Viceré, T. Huynh-Dinh, Fabio Hernandez, H. Cao, Ashok Kumar, D. J. Vine, W. Katzman, Alena Ananyeva, D. C. Coyne, Stanislav Babak, Rico K. L. Lo, Kendall Ackley, R. K. Nayak, F. Y. Khalili, Ken K. Y. Ng, A. Hreibi, M. Thomas, D. Fiorucci, Manuela Rizzo, H. Radkins, A. Bozzi, A. K. Prajapati, A. R. Wade, M. Agathos, M. Brinkmann, R. Quitzow-James, N. N. Janthalur, B. Sassolas, K. Izumi, L. Xiao, J. S. Lange, H. Y. Chia, M. C. Díaz, W. S. Kim, M. H. Wimmer, K. Haughian, S. Hochheim, M. Yvert, M. Nery, Marc Favata, L. E. Wade, Roger Jones, V. J. Roma, A. P. Spencer, G. Kuehn, C. M. Mow-Lowry, Sergey P. Vyatchanin, Andrew Melatos, M. Lorenzini, A. Masserot, M. Khursheed, Ettore Majorana, Robert Stone, Alessandro Nagar, D. D. Brown, Anthony A. Amato, N. van Bakel, Sebastien Biscans, P. Fulda, P. Charlton, F. Magaña-Sandoval, L. Aiello, M. Gosselin, A. R. Williamson, D. Huet, R. Green, M. Was, M. C. Tringali, A. K. Zadrożny, E. E. Cowan, V. Boschi, L. Zhang, J. H. Klika, M. Bawaj, J. Junker, M. van Beuzekom, K. W. Chung, David Coward, T. Hardwick, D. Steinmeyer, F. Travasso, M. Constancio, A. Allocca, Sascha Husa, G. Venugopalan, D.B. DeBra, Mikhail L. Gorodetsky, C. Whittle, Z. Khan, P. Ehrens, Paul M. Ricker, Y. Setyawati, H. Khan, S. E. Barclay, B. F. Whiting, F. Brighenti, C. Talbot, J. H. Briggs, J. Casanueva Diaz, D. H. Reitze, A. F. Brooks, P. J. Quinonez, V. Kringel, J. L. Willis, Ofek Birnholtz, M. F. Carney, P. Schale, R. Bonnand, Mariana Fazio, H. Vocca, C. Van Den Broeck, E. Sowell, Albrecht Rüdiger, Xing-Jiang Zhu, Jochen Kissel, Felice Sorrentino, V. Srivastava, D. Talukder, Michał Bejger, M. Standke, M. Croquette, David A. Williams, A. Effler, I. W. Harry, D. Mukherjee, Y. R. Chen, J. Jiang, Alessandro Bertolini, M. Fays, D. Moraru, J. C. Driggers, Matthew Evans, M. Bitossi, G. Bergmann, K. Wette, M. M. Hanke, Leo Singer, E. Cesarini, M. Hulko, T. D. Creighton, Eugeniy E. Mikhailov, Jörg Hennig, Eric Howell, A. Strunk, G. Vedovato, L. E. H. Datrier, D. B. Kozak, D. Stocks, C. Vorvick, P. Thomas, M. Arène, S. B. Anderson, Tim Dietrich, A. Perreca, G. Gemme, A. Di Lieto, R. A. Eisenstein, S. J. Chamberlin, Jishnu Suresh, G. D. Meadors, Z. A. Warden, R. Gouaty, T. Zelenova, Riccardo Bassiri, John J. Oh, M. Vasúth, Jonathan Cripe, N. Kijbunchoo, E. Cuoco, Sheelu Abraham, K. Kawabe, S. M. Aston, Michael W. Coughlin, G. D. O'Dea, Bruno Giacomazzo, Giuseppe Intini, M. Drago, Guenakh Mitselmakher, B. A. Boom, A. M. Sergeev, T. Etzel, J.-G. Ducoin, M. Eisenmann, A. Dmitriev, S. Leavey, Hai-Ping Cheng, A. Iess, L. K. Nuttall, D. Wilken, S. Katsanevas, R. Goetz, C. Adams, R. M. Blair, D. Sigg, S. W. Ballmer, D. M. Shoemaker, Binlei Ding, V. Bossilkov, Lindsay DeMarchi, I. Khan, K. Siellez, D. Sentenac, R. Macas, G. Billingsley, S. Macfoy, Sergio Gaudio, D. B. Tanner, A. Trovato, Olivier Minazzoli, Magnus Manske, M. Razzano, C. C. Yancey, F. Vetrano, Zachariah B. Etienne, Jennifer Watchi, E. Maros, R. C. Walet, V. P. Mitrofanov, R. Colgan, C. S. Unnikrishnan, G. Moreno, V. Kondrashov, P. Leaci, S. Meshkov, Seog Oh, S. P. Stevenson, Achamveedu Gopakumar, R. Inta, C. J. Richardson, S. Klimenko, M. J. Yap, C. Palomba, W. G. Anderson, G. Cella, F.L. Linde, P. Booker, L. Milano, S. C. Tait, N. V. Krishnendu, A. Pasqualetti, W. Del Pozzo, W. M. Farr, A. C. Green, Fausto Acernese, M. Korobko, B. C. Pant, C. Messick, J. Derby, J. Healy, K. A. Thorne, A. Cumming, M. Denys, M. Tse, S. Ascenzi, S. E. Dwyer, R. M. Magee, David Keitel, V. Germain, S. J. Cooper, Giacomo Ciani, K. Rao, Yongjung Kim, Peter Weßels, I. A. Bilenko, L. Haegel, David J. Ottaway, B. P. Abbott, H. Vahlbruch, J. C. Mills, E. K. Gustafson, K. Riles, J. Y. Vinet, H. Middleton, S. Doravari, H. Heitmann, Piotr Jaranowski, M. S. Shahriar, P. Ruggi, M. Weinert, H. A. G. Gabbard, D. M. Macleod, Karan Jani, B. L. Swinkels, Arunava Mukherjee, S. Privitera, L. Glover, Imre Bartos, Isabel Cordero-Carrión, H. Qi, E. Genin, J. Zhang, F. Baldaccini, B. U. Gadre, A. Lartaux-Vollard, B. Irwin, R. Shink, L. Rei, Huang-Wei Pan, Gijs Nelemans, S. Vass, Kenneth A. Strain, Jimin George, R. Coyne, C. Gray, G. H. Ogin, T. J. Shaffer, M. Sieniawska, Fabrice Matichard, A. Paoli, K. A. Santiago, F. Fidecaro, G. M. Guidi, G. Cagnoli, Arnold Miller, H. N. Isa, Suvadeep Bose, V. Tiwari, V. Quetschke, Yann Bouffanais, Martin M. Fejer, L. F. Ortega, D. Lumaca, M. Pedraza, R. Bork, S. Ghonge, Y. Minenkov, P. Bacon, K. AultONeal, K. Chakravarti, E. D. Hall, L. Sammut, Lionel London, D. George, R. K. Lanza, Y. Boetzel, Alexander C. Jenkins, P. Dupej, Eric B. Flynn, Z. Márka, M. Mantovani, T. Prestegard, D. W. Yeeles, Xie Chen, A. Markowitz, Fabio Marchesoni, P. Hello, Samuel Deléglise, M. Merzougui, A. Fernandez-Galiana, S. M. Scott, M. Obergaulinger, Turlough P. Downes, F. Cavalier, A. Ain, R. J. Trudeau, K. Holt, Chunglee Kim, L. van der Schaaf, S. A. Pai, C. De Rossi, W. Parker, A. Gennai, Rahul Kumar, Harald P. Pfeiffer, Milan Gupta, G. Dálya, B. Gateley, G. Cho, J. C. Bayley, Aaron Buikema, V. Sandberg, E. J. King, M. J. Cowart, S. Koley, M. Boer, G. Mendell, S. J. Jadhav, B. Idzkowski, V. Loriette, V. Skliris, J. K. Blackburn, E. Chassande-Mottin, Shubhanshu Tiwari, G. Koekoek, L. Trozzo, C. Pankow, P. M. Meyers, Koh Ueno, Christian Pedersen, Albert Lazzarini, Kyungmin Kim, N. Koper, H. Wittel, M. Deenadayalan, B. O'Reilly, A. W. Jones, Sheila Rowan, S. G. Schwalbe, D. Pascucci, R. De Pietri, S. Mitra, T. Sadecki, W. Ren, Rocco Romano, John D. Scott, J. Z. Wang, S. Grunewald, R. Prasanna, R. Cotesta, R. G. Ormiston, S. Kaufer, Rainer Weiss, David E. McClelland, Paul J. Groot, M. Zevin, R. A. Mercer, S. Ossokine, Jinsook Kim, Rebecca Fisher, J. Li, A. M. Holgado, H. Fair, Samaya Nissanke, X. Liu, M. A. Bizouard, K. Bossie, John Veitch, J. Lehmann, Al Imran Malik, K. G. Arun, J. D. Tasson, C. K. Cheong, J. R. Gair, M. Fitz-Axen, B. K. Berger, S. D'Antonio, N. Arnaud, K. E. Ramirez, W. Z. Korth, Daniel E. Holz, F. Di Renzo, Torrey Cullen, B. J. J. Slagmolen, Archana Pai, F. Paoletti, Vijay Varma, M. MacInnis, Marco Romanelli, M. Fyffe, F. Cipriano, David Blair, C. Fee, Gabriela Gonzalez, F. Aubin, G. Stratta, Jesper Munch, K. R. Corley, A. Mullavey, T. J. N. Nelson, J. Birch, S. Bae, P. Rapagnani, F. J. Raab, D. Tuyenbayev, B. Patricelli, D. S. Wu, Margaret Millhouse, S. Barnum, D. Buskulic, S. G. Gaonkar, E. Coccia, M. E. Zucker, C. Graef, B. A. Weaver, Xiaohui Fan, J. G. Rollins, Richard O'Shaughnessy, B. Barr, M. De Laurentis, D. Ugolini, P. Clearwater, G. Valdes, David Jones, M. R. Ganija, L.-W. Wei, Haixing Miao, G. Bogaert, R. Taylor, P. Popolizio, Koji Arai, Ryan Lynch, A. D. Viets, D. Meacher, E. J. Fauchon-Jones, E. J. Sanchez, S. Ponrathnam, G. A. Prodi, K. L. Dooley, Fangchen Feng, Lisa Barsotti, Kris Ryan, E. A. Quintero, Marco Cavaglia, J.J. Bero, Leo Tsukada, David H. Shoemaker, M. Lormand, D. J. Stops, S. Karki, Anirban Dasgupta, E. Z. Hamilton, R. J. G. Jonker, J. S. H. Lee, T. Dal Canton, J. Warner, R. Passaquieti, D. Verkindt, Mairi Sakellariadou, G. Pillant, S. H. R. Yuen, Keith Rose, K. S. Karvinen, F. Martelli, C. Rajan, Pablo Cerdá-Durán, Peter R. Saulson, V. Sequino, Tenglin Li, R. DeSalvo, D. Estevez, B. Pang, Paul T. Baker, O. V. Palashov, Sean T. McWilliams, D. Rosińska, J. C. Barayoga, V. Fafone, R. Tso, Jonathan Richardson, F. Piergiovanni, Chang-Hwan Lee, N. Sanchis-Gual, N. Radulescu, L. Mereni, Terry G. McRae, S. Mastrogiovanni, Richard J. Abbott, L. G. Prokhorov, Patrick M. Koch, S. Antier, S. Banagiri, A. Grant, D. Chatterjee, T. L. Lam, A. Pele, A. Chiummo, Nergis Mavalvala, Alessandro Longo, Richard J. Oram, M. Davier, Jerome Degallaix, François Bondu, F. Badaracco, Sebastian Khan, B. C. Barish, Hartmut Grote, R. J. E. Smith, John A. Clark, Ben Farr, Christophe Collette, Ho-Gyu Lee, G. Losurdo, Luca Gammaitoni, R. Metzdorff, C. J. Perez, B. D. O'Brien, M. K. M. Bader, O. Chaibi, Devon S. Johnson, C. Bradaschia, P. Oppermann, Neil J. Cornish, S. Frasca, M. Di Giovanni, Ik Siong Heng, Kai Staats, F-L. Lin, L. Conti, M. Chaturvedi, S. Márka, Stephen Fairhurst, Carl Blair, Peter Aufmuth, T. Di Girolamo, V. Mangano, A. L. Miller, S. Ghosh, László Á. Gergely, A. Macquet, P. Astone, B. Lantz, Daichi Tsuna, K. Mogushi, P. J. King, J. T. Whelan, S. G. Crowder, J. Feicht, Joey Shapiro Key, J. R. Sanders, António Alves da Silva, Q. Chu, S. V. Angelova, L. Magaña Zertuche, Lili Yang, Laura Cadonati, D. A. Steer, M. Branchesi, Zefeng Zhou, D. Y. T. Pong, L. Kleybolte, E. Massera, F. Wellmann, Edward Seidel, O. E. S. Sauter, J. Woehler, S. Chung, K. S. Phukon, A. Avila-Alvarez, Chad Hanna, A. Bramley, C. Kimball, J. Oberling, M. Pirello, K. Gill, Walter Winkler, A. S. Markosyan, Harald Lück, J. Bidler, M. Cho, G. Gaur, S. C. McGuire, J. F. Read, F. Nocera, C. Zhao, Alicia M. Sintes, S. Di Pace, K. Haris, T. Zhang, N. Demos, Thibaut Jacqmin, T. Regimbau, I. Maksimovic, G. Hemming, S. M. Koehlenbeck, M. Saleem, M. Oliver, Douglas Davis, Geraint Pratten, E. Goetz, Tarun Souradeep, Andrea Taracchini, D. Bersanetti, G. Ashton, S. Penn, J. V. van Heijningen, Yu Wang, F. Thies, G. L. Mansell, V. Dattilo, Edwin J. Son, Eric Thrane, Stefan Hild, Y. Ma, A. Brillet, C. Michel, M. Vardaro, Sarah Caudill, T. D. Knowles, F. Robinet, V. B. Adya, J. K. Wofford, F. Cleva, M. P. Ross, T. B. Edo, M. Pichot, Maximiliano Isi, E. M. Gretarsson, Ying Guo, D. Beniwal, Peter Fritschel, Wenxiao Wang, M. Masso-Reid, S. Kwang, L. E. Sanchez, Enrico Calloni, G. Traylor, Thomas Corbitt, L. Salconi, C. A. Costa, Zhihui Du, Laboratoire des matériaux avancés (LMA), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Laboratoire de l'Accélérateur Linéaire (LAL), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Sud - Paris 11 (UP11), AstroParticule et Cosmologie (APC (UMR_7164)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Laboratoire d'Annecy de Physique des Particules (LAPP), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), (Astro)-Particles Physics, Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), and Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)
Subjects: Physics, [PHYS]Physics [physics], 010504 meteorology & atmospheric sciences, Gravitational wave, Astronomy, Astronomy and Astrophysics, 01 natural sciences, LIGO, Supernova, Fomalhaut, Space and Planetary Science, 0103 physical sciences, [PHYS.ASTR]Physics [physics]/Astrophysics [astro-ph], 010303 astronomy & astrophysics, ComputingMilieux_MISCELLANEOUS, 0105 earth and related environmental sciences
Abstract: Equation (5) of the published article?(Abbott et al. 2019) is in error; it should read (Formula Presented) The upper limits on ò presented in the published article are unaffected by this error.
Published: 2021

8. [A possible relationship between anti-SARS-CoV-2 vaccination and glomerular diseases: food for thought for the nephrologist]

Author: Manuela, Rizzo, Antonella, Marino, Anna, Sannino, Valentina, Urciuoli, Ivana, Capuano, and Antonio, Pisani
Subjects: Male, Nephrologists, COVID-19 Vaccines, SARS-CoV-2, Nephrosis, Lipoid, Vaccination, COVID-19, Humans, Female, Glomerulonephritis, IGA
Abstract: In order to fight the SARS-CoV-2 pandemic, mass-vaccination programs have been launched globally starting December 2020. The pace of COVID-19 vaccines development was impressive and although data from clinical trials and post-authorization studies showed acceptable safety profile, additional studies and long-term population-level surveillance are needed. A possible link between all type of vaccination and immunological diseases is perhaps one of the hottest topics in literature; correspondingly, there is growing concern over the small but growing number of case reports linking COVID-19 vaccines with the development of glomerular disease. Our group conducted a systematic review of such cases. Results showed that IgA nephropathy (IgAN) and Minimal Change Disease (MCD) are the most frequently associated glomerulopathies. Interestingly, IgAN cases are mostly flares occurring few hours after the second dose of RNA vaccines and have a good clinical outcome, while both de novo and recurring MCD can occur up to 28 days after the first or second dose of vaccines. RNA vaccines are the most common vaccine type to be associated with glomerulopathy. Of course, this may simply reflect the more widespread use of these vaccines. However, compared to traditional vaccines, they do seem produce a higher antibody response and a stronger CD8+ T- and CD4+ T-cell response, including higher production of chemokines and cytokines.
Published: 2022

9. Adherence, persistence and efficacy of dasatinib and nilotinib in the treatment of patients resistant or intolerant to imatinib with chronic myeloid leukemia in chronic phase: an Italian multicenter study over two years in real life

Author: Maria Monteverde, Caterina de Rosa, Felice Musicco, Francesca Federici, Giancarlo Torquati, Arianna Pasquazi, Anna Rita Scortechini, Alberto Costantini, Maria Cantonetti, Luca Franceschini, Antonietta Vozza, Angela Frazzetto, M Scaldaferri, Fabrizio Pane, Katiuscia Di Biagio, Chiara Rossi, Maria Grazia Celeste, Gaetano La Barba, Luigia Luciano, Irene Colasanto, Manuela Rizzo, Rosaria Lanzillo, Fiorenzo Santoleri, Francesco Cattel, and Elena Ranucci
Subjects: Oncology, medicine.medical_specialty, Dasatinib, Medication adherence, Antineoplastic Agents, 030204 cardiovascular system & hematology, Persistence (computer science), 03 medical and health sciences, 0302 clinical medicine, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, hemic and lymphatic diseases, Internal medicine, medicine, Humans, In real life, 030212 general & internal medicine, Protein Kinase Inhibitors, business.industry, Myeloid leukemia, Imatinib, General Medicine, Thiazoles, Pyrimidines, Treatment Outcome, Italy, Nilotinib, Multicenter study, Imatinib Mesylate, business, medicine.drug
Abstract: The use of dasatinib and nilotinib in the treatment of patients with chronic myeloid leukemia represents a valid therapeutic option for patients resistant or intolerant to imatinib. In this multicentre study, adherence, persistence and efficacy in real life over two years of treatment were evaluated.Adherence to treatment was calculated as the ratio between the dose received and the prescribed dose. The dose received was calculated using pharmacy refill data. The persistence with treatment was calculated as the difference between the end and the beginning of the treatment. Efficacy was assigned as Progression-Free Survival (PFS) and Events-Free Survival (EFS) and represented through the Kaplan-Meier curve.The number of patients analysed was 117, 70 treated with dasatinib and 47 with nilotinib. Adherence to treatment for dasatinib and nilotinib at two years was 0.91 and 0.82 respectively. Persistence at two years was 77% while the PFS was 92% for both drugs in the study.Adherence to the treatment calculated over two years showed a superiority of dasatinib over nilotinib. Nevertheless, the efficacy in terms of PFS and EFS is superimposable between the two drugs in the study.
Published: 2021

10. Tolvaptan vs. somatostatin in the treatment of ADPKD: A review of the literature

Author: Ivana Capuano, Manuela Rizzo, Eleonora Riccio, Pasquale Buonanno, Antonio Pisani, Capuano, Ivana, Buonanno, Pasquale, Riccio, Eleonora, Rizzo, Manuela, and Pisani, Antonio
Subjects: business.industry, Polycystic liver disease, Autosomal dominant polycystic kidney disease, Tolvaptan, Octreotide, General Medicine, Disease, urologic and male genital diseases, medicine.disease, Bioinformatics, Polycystic Kidney, Autosomal Dominant, Clinical trial, Somatostatin, Tolerability, Nephrology, medicine, Humans, business, Antidiuretic Hormone Receptor Antagonists, medicine.drug, Glomerular Filtration Rate
Abstract: Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic disorder with an estimated prevalence between 1 : 1,000 and 1 : 2,500. Until a few decades ago, ADPKD was considered an untreatable disease, relentlessly progressing towards end-stage renal disease because of the lack of specific interventions. In the last decade, some aberrant molecular pathways involved in ADPKD development have been identified, and controlled clinical trials have been conducted to investigate the potential role of active drugs on these pathophysiological mechanisms such somatostatin and tolvaptan. Somatostatin analogues have been shown to be effective not only in ADPKD, but also in polycystic liver disease (PLD) with beneficial effect on cardiac function and a better cost/benefit profile; the only somatostatin analogue currently available for clinical use is octreotide long-acting release (octreotide-LAR), and it is approved only in Italy. On the contrary, tolvaptan is authorized worldwide and has received more attention in the last years, even if its clinical use is widely limited by aquaresis tolerability. The aim of this review is to investigate the advantages and drawbacks of somatostatin analogues and tolvaptan in the treatment of ADPKD.
Published: 2022

11. Impact of COVID-19 pandemic on CKD outpatient management

Author: Manuela Rizzo, Eleonora Riccio, Roberta Rossano, and Antonio Pisani
Subjects: medicine.medical_specialty, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), MEDLINE, covid, General Medicine, Nephrology, Pandemic, Emergency medicine, medicine, business, Outpatient management
Abstract: Patients with chronic disorders, like chronic kidney disease (CKD), are considered at greater risk of COVID-19 infection, with higher morbidity and mortality. To date, specific instructions have been developed for managing COVID-19 outbreaks for patients on haemodialysis and peritoneal dialysis, and with kidney transplants; however, the proper management of patients with non-dialysis CKD is still being evaluated. The rapid spread of COVID-19 and the consequent lockdown, required many changes in our CKD center organization to avoid unnecessary exposure of staff and patients to infection, while still continuing to provide care and support to our patients. Therefore, elective treatments and procedures, routine laboratory testing and non-urgent outpatient clinics were deferred, and patients were divided in 2 main priority groups: 1)Non urgent, deferrable patients, for whom we adopted telemedicine follow-up; 2)Urgent, undeferrable outpatients, for whom an effort has been made to arrange for specific appointment times for blood drawing and for ambulatory visits. Specific recommendations have been provided to our staff office to respond to patient questions about a possible COVID-19 exposure. Elective procedures, as kidney biopsies and access creation for dialysis, have been defereed in most cases, except for urgent patients. For patients receiving intravenous treatments, we organized home therapy services; new enrolment into clinical trials has been paused during the COVID-19 crisis, but CKD patients enrolled in therapeutic clinical trials should continue the study drug.
Published: 2021

12. New insight into the catalytic -dependent and -independent roles of METTL3 in sustaining aberrant translation in chronic myeloid leukemia

Author: Marcella Marchioni, Melissa Sorci, Mattia Pelizzola, Silvia Masciarelli, Francesco Fazi, Lavinia Ceci Ginistrelli, Cristina Attrotto, Alessandro Fatica, Alessia Iaiza, Ernestina Capuano, Claudia Tito, Manuela Rizzo, Zaira Ianniello, Tiziana Ottone, Luca Franceschini, Maria Teresa Voso, and Stefano de Pretis
Subjects: Cancer Research, Adenosine, Messenger, Drug Resistance, Ribosome biogenesis, translation, Models, hemic and lymphatic diseases, Chronic, Tumor, leukemia, Myeloid leukemia, RNA-Binding Proteins, Translation (biology), Ribosome, Up-Regulation, Gene Knockdown Techniques, Imatinib Mesylate, Settore BIO/17 - ISTOLOGIA, Tyrosine kinase, medicine.drug, RNA modification, Cell Survival, Immunology, Biology, Models, Biological, Article, Catalysis, Cell Line, Proto-Oncogene Proteins c-myc, Cellular and Molecular Neuroscience, Cell Line, Tumor, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, medicine, Humans, RNA, Messenger, Myeloproliferative neoplasm, Chronic myeloid leukaemia, Cell Proliferation, Cell Nucleus, QH573-671, Methyltransferase complex, Imatinib, Cell Biology, Methyltransferases, medicine.disease, Biological, Settore MED/15, Fusion protein, Drug Resistance, Neoplasm, Protein Biosynthesis, Cancer research, Neoplasm, RNA, BCR-ABL Positive, Cytology, Myelogenous
Abstract: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by the presence of tyrosine kinase BCR-ABL1 fusion protein, which deregulate transcription and mRNA translation. Tyrosine kinase inhibitors (TKIs) are the first-choice treatment. However, resistance to TKIs remains a challenge to cure CML patients. Here, we reveal that the m6A methyltransferase complex METTL3/METTL14 is upregulated in CML patients and that is required for proliferation of primary CML cells and CML cell lines sensitive and resistant to the TKI imatinib. We demonstrate that depletion of METTL3 strongly impairs global translation efficiency. In particular, our data show that METTL3 is crucial for the expression of genes involved in ribosome biogenesis and translation. Specifically, we found that METTL3 directly regulates the level of PES1 protein identified as an oncogene in several tumors. We propose a model in which nuclear METTL3/METTL14 methyltransferase complex modified nascent transcripts whose translation is enhanced by cytoplasmic localization of METTL3, independently from its catalytic activity. In conclusion, our results point to METTL3 as a novel relevant oncogene in CML and as a promising therapeutic target for TKI resistant CML.
Published: 2021

13. Erratum: Search for gravitational waves from Scorpius X-1 in the second Advanced LIGO observing run with an improved hidden Markov model [Phys. Rev. D 100, 122002 (2019)]

Author: S. J. Jadhav, Samuele Cortese, Charlie Hoy, V. Srivastava, M. Fays, Rebecca Fisher, J. Li, Chris A. Collins, T. Hinderer, A. Di Lieto, Rana X. Adhikari, Al Imran Malik, S. J. Chamberlin, M. Vasúth, Nikhil Sarin, Jonathan Cripe, M. Fyffe, Gabriela Gonzalez, K. R. Corley, F. Donovan, C. F. Da Silva Costa, V. Bossilkov, D. Lumaca, M. A. Okada, K. Mason, S. A. Bilgili, J. D. E. Creighton, Soichiro Morisaki, Jun Liu, E. C. Ferreira, Sanjeev Dhurandhar, D. B. Tanner, Sebastiano Bernuzzi, O. Halim, K. W. Tsang, W. Katzman, M. Yvert, R. M. S. Schofield, M. Nery, L. Naticchioni, R. M. Martin, David A. Nichols, M. Korobko, P. J. Veitch, W. A. Campbell, Ettore Majorana, Benjamin J. Owen, J. F. J. van den Brand, J. Junker, S. Sunil, M. Tacca, S. Hochheim, Martin Hendry, Cecilio García-Quirós, P. Ehrens, Paul M. Ricker, H. Khan, T. Prestegard, G. Cho, H. Fong, G. Greco, M. Bitossi, G. Bergmann, P. A. Altin, Antonios Kontos, S. Walsh, J. G. Bartlett, Márton Tápai, P.H. Nguyen, Junwei Cao, Y. Boetzel, A. Samajdar, K. Wette, F. Thies, John J. Oh, E. A. M. Muniz, Riccardo Ciolfi, Peter T. H. Pang, B. W. Schulte, L. Xiao, F. Ricci, C. Affeldt, R. Goetz, D. C. Vander-Hyde, C. Adams, A. A. Ciobanu, B. Mours, Mandar Patil, Abhirup Ghosh, Liam Cunningham, Archana Pai, F. Paoletti, Z. B. Etienne, Tristan Briant, P. Ruggi, P. Fulda, S. H. Huttner, A. Mullavey, T. J. N. Nelson, Peter Aufmuth, Gregorio Carullo, R. M. Blair, D. Sigg, T. Di Girolamo, S. W. Ballmer, D. M. Shoemaker, Hua Wang, L. Sun, S. R. P. Mohapatra, J. D. Lough, G. Giordano, K. Toland, D. J. Hofman, M. Punturo, Slawomir Gras, S. W. S. Ng, G. Moreno, S. Kumar, C. Buy, Callum Dale Booth, A. M. Sintes, Andrew Melatos, M. Lorenzini, A. Masserot, S. E. Barclay, J. L. Willis, J. McIver, J. H. Briggs, Mark Hannam, Ofek Birnholtz, S. Ghosh, László Á. Gergely, D. M. Wysocki, A. Macquet, B. Lantz, Daichi Tsuna, R. D. Kennedy, José A. Font, N. Singh, Eric Howell, S. Leavey, Chandra Kant Mishra, R. Bhandare, Piotr Jaranowski, K. Mogushi, N. Bode, D. George, Dániel Barta, R. K. Lanza, P. Dupej, Eric B. Flynn, B. Gateley, Aaron Buikema, R. W. L. Jones, C. C. Wipf, E. J. King, A. Strunk, N. Kijbunchoo, Sheelu Abraham, M. J. Cowart, Hai-Ping Cheng, A. Iess, L. K. Nuttall, S. T. Countryman, Surabhi Sachdev, Christopher J. Moore, S. Biscoveanu, Antoni Ramos-Buades, V. V. Frolov, S. Mitra, Xiaohui Fan, Richard O'Shaughnessy, B. Barr, A. D. Viets, D. Meacher, D. Tuyenbayev, Kevin Barkett, I. Dorrington, I. Di Palma, R. Kirchhoff, B. L. Pearlstone, Kendall Ackley, R. K. Nayak, H. Y. Chia, F. Magaña-Sandoval, A. Allocca, M. F. Carney, Ajay Kumar, Jörg Hennig, Charalampos Markakis, R. Pedurand, Benno Willke, A. Grado, T. Sadecki, W. Ren, S. Grunewald, R. Prasanna, R. L. Ward, P. J. Sutton, Alyssa Garcia, J. H. Romie, P. J. King, J. T. Whelan, K. H. Lai, S. G. Crowder, J. Feicht, Joey Shapiro Key, J. R. Sanders, M. Bawaj, M. M. Hanke, S. B. Anderson, M. R. Ganija, S. Ponrathnam, S. Karki, D. Verkindt, O. Puncken, M. B. Shaner, S. B. Coughlin, A. Neunzert, P.-F. Cohadon, M. Heurs, Reed Essick, Kazuhiro Agatsuma, F. Frasconi, T. Hardwick, D. Steinmeyer, F. Travasso, Michał Bejger, M. Standke, M. Croquette, A. Effler, J. Jiang, A. Perreca, G. Gemme, M. Drago, Guenakh Mitselmakher, Zhihui Du, A. Parida, S. S. Eikenberry, K. E. Ramirez, S. Barnum, Ryan Lynch, D. C. Williams, Sung-Po Chao, R. De Rosa, Kwan-Lok Li, D. Passuello, I. Nardecchia, A. Cirone, Hiroyuki Ohta, Robert J. McCarthy, Tim Dietrich, Jennifer Watchi, Sergio Gaudio, C. J. Richardson, J. Healy, V. Kringel, A. M. Holgado, R. Macas, G. Billingsley, S. Macfoy, N. Mukund, L. R. Cominsky, R. Gustafson, Linqing Wen, R. Flaminio, B. A. Boom, A. M. Sergeev, B. Pang, Z. Tornasi, P. Kumar, S. Kandhasamy, M. Fishbach, B. Sorazu, A. Kutynia, Paul T. Baker, A. K. Lenon, S. Mastrogiovanni, M. Pedraza, F. Cavalier, M. Fitz-Axen, Marcus E. Lower, J. S. Kissel, Hartmut Grote, S. Doravari, A. Singhal, Alena Ananyeva, Odylio D. Aguiar, I. W. Martin, Andrea Chincarini, A. K. Zadrożny, T. Z. Summerscales, Leo Tsukada, E. Z. Hamilton, S. A. Usman, Roman Schnabel, J. E. Brau, V. Boschi, M. van Beuzekom, R. Tso, Jonathan Richardson, L. Mereni, G. Losurdo, R. Metzdorff, M. C. Milovich-Goff, J. L. Wright, Patrick M. Koch, S. Antier, S. Banagiri, Alessandra Corsi, S. Raja, S. E. Strigin, H. S. Chen, S. Husa, S. Bose, J. Zweizig, V. Germain, J. Steinlechner, C. Cahillane, V. Gayathri, H. Fair, D. H. Shoemaker, P. Brockill, R. L. Savage, A. S. Bell, Hyun Lee, J. Calderón Bustillo, Edward K. Porter, C. Messenger, M. J. Yap, C. Palomba, S. Ascenzi, S. Privitera, M. S. Shahriar, Lee McCuller, T. Bulik, T. D. Abbott, G. Cagnoli, Devon S. Johnson, C. Horst, Alberto Vecchio, Geoffrey Mo, J. M. Fishner, M. Montani, H. J. Bulten, Geoffrey Lovelace, T. Mistry, G. Rutins, Graham Woan, M. H. Wimmer, M. Constancio, D. Rosińska, A. A. van Veggel, Richard Gray, Efim A. Khazanov, G. Ballardin, Moritz Mehmet, Kiran Prasai, Alessandra Buonanno, C.-J. Haster, Gabrielle Allen, J.-M. Isac, F. Marion, N. Leroy, Nancy Aggarwal, Zahoor Ali Khan, M. Phelps, S. Babak, Alexander C. Jenkins, Xie Chen, A. Markowitz, S. Vitale, G. Dálya, M. Laxen, Anchal Gupta, F. Y. Khalili, Robert L. Byer, Stuart Reid, F. J. Hayes, Jacob Scheuer, B. Bécsy, M. Kasprzack, Bala R. Iyer, S. S. Y. Chua, S. McCormick, C. Casentini, G. Wang, L. Matone, Vuk Mandic, Neil J. Cornish, M. J. Szczepańczyk, Denis Martynov, Marco Bazzan, F-L. Lin, D. J. McManus, C. Ingram, L. Pinard, B. R. Hall, Héctor Estellés, N. Letendre, Alec Mishkin, R. Cavalieri, I. Dave, C. Talbot, E. J. Daw, Maurizio Canepa, Antonio Marquina, Rosa Poggiani, V. Frey, A. K. Mehta, E. K. Wessel, S. Farinon, P. Raffai, T. L. Lam, Alessandro Longo, Richard J. Oram, François Bondu, F. Badaracco, Daniel E. Holz, B. J. J. Slagmolen, B. Patricelli, D. S. Wu, Margaret Millhouse, N. Sennett, Patrick Godwin, K. L. Dooley, Marta Colleoni, J. A. Giaime, L. Wallace, A. Królak, R. Frey, Joseph Smith, S. Brunett, D. Barker, A. Bisht, Maher Yazback, Y. K. Lecoeuche, G. M. Harry, K. Venkateswara, R. Cotesta, T. Etzel, J. B. Kanner, Robert Stone, Alessandro Nagar, J. C. Barayoga, A. Dmitriev, A. R. Williamson, Albrecht Rüdiger, Xing-Jiang Zhu, R. A. Eisenstein, Jishnu Suresh, Federico Ferrini, E. L. Merilh, N. Koper, Sebastian Steinlechner, A. Pasqualetti, M. Tse, D. M. Macleod, B. L. Swinkels, L. Glover, Vivishek Sudhir, V. Tiwari, Yann Bouffanais, Lijing Shao, G. Vajente, S. M. Gaebel, A. K. Srivastava, A. E. Pace, E. Schreiber, A. Basti, Ryan N. Lang, M. Rakhmanov, G. Pagano, G. D. Meadors, J. Eichholz, Li Ju, J.-P. Coulon, E. A. Chase, Z. Frei, Sofia Suvorova, T. Zelenova, D. H. Reitze, S. Caride, A. F. Brooks, P. J. Quinonez, J.-D. Fournier, Riccardo Bassiri, Magnus Manske, M. C. Araya, Srishti Tiwari, C. Lazzaro, Philip F. Hopkins, Leo Singer, Patricia Schmidt, V. Brisson, M. Obergaulinger, E. Maros, L. Trozzo, S. Katsanevas, I. Fiori, T. A. Ferreira, K. D. Giardina, J. K. Wofford, P. Leaci, P. Booker, K. W. Chung, S. Kaufer, Shawn Rosofsky, Haocun Yu, Archisman Ghosh, A. P. Lundgren, M. A. Page, Hongyu Shen, D. C. Coyne, K. Izumi, E. Cesarini, S. D. Linker, R. Robie, Mark A. Scheel, M. Fletcher, B. Hughey, Albert Lazzarini, S. G. Gaonkar, Jimin George, M. Sieniawska, K. Chakravarti, Fabio Marchesoni, P. Hello, Haixing Miao, Y. R. Chen, Samaya Nissanke, M. A. Bizouard, B. K. Berger, Ken K. Y. Ng, A. Hreibi, F. Clara, Alessandro Bertolini, Achamveedu Gopakumar, S. L. Danilishin, G. Bogaert, J. J. Bero, Manuela Rizzo, R. Taylor, Daniel A. Shaddock, Brittany Kamai, Rainer Weiss, G. Venugopalan, J. C. Driggers, D.B. DeBra, C. V. Kalaghatgi, J. Hanson, C. Whittle, Kyungmin Kim, B. O'Reilly, P. Gruning, K. Siellez, B. F. Schutz, N. V. Krishnendu, J. Derby, K. A. Thorne, M. Was, Isabel Cordero-Carrión, J. S. Lange, B. Irwin, M. C. Tringali, A. C. Green, Andrew Matas, J. Hanks, Fausto Acernese, C. Gray, G. H. Ogin, T. J. Shaffer, A. Ain, C. Fee, R. J. Trudeau, J. Birch, S. Bae, E. Coccia, C. S. Unnikrishnan, B. U. Gadre, W. M. Farr, B. C. Pant, J.-G. Ducoin, M. Eisenmann, R. C. Walet, Fangchen Feng, S. E. Gossan, M. Boer, Shubhanshu Tiwari, M. E. Zucker, C. Graef, B. A. Weaver, J. G. Rollins, Lindsay DeMarchi, L.-W. Wei, V. P. Mitrofanov, Lisa Barsotti, Anirban Dasgupta, L. Milano, W. Del Pozzo, Hang Yu, R. J. G. Jonker, H. Heitmann, M. A. Aloy, J. S. Areeda, K. A. Santiago, A. Gennai, Rahul Kumar, Harald P. Pfeiffer, Kris Ryan, E. A. Quintero, I. Belahcene, John Worden, A. S. Sengupta, H. W. Lee, P. Couvares, H. Vocca, Eugeniy E. Mikhailov, G. Vedovato, L. E. H. Datrier, D. B. Kozak, C. Messick, Imre Bartos, D. Stocks, M. Mantovani, Francesco Pannarale, C. Vorvick, L. Sammut, David Blair, S. Koley, Jan Harms, David E. McClelland, Lionel London, B. Idzkowski, V. Loriette, V. Skliris, G. Kang, A. Pal-Singh, A. Rocchi, B. B. Lane, C. Cocchieri, M. Khursheed, N. V. Keerthana, M.L. Walker, B. Goncharov, R. Birney, M. Kinley-Hanlon, G. Koekoek, F. Brighenti, D. Ugolini, P. Clearwater, E. J. Fauchon-Jones, M. Lormand, V. Quetschke, Martin M. Fejer, R. Bork, S. Ghonge, K. AultONeal, M. Hulko, G. D. O'Dea, E. Cuoco, Bruno Giacomazzo, V. Avendano, P. G. Murray, D. J. Stops, Fabien Kéfélian, J. S. H. Lee, T. Dal Canton, Felix Wellmann, J. Warner, R. Passaquieti, X. Liu, R. Mittleman, S. D'Antonio, Binlei Ding, D. Pascucci, C. C. Yancey, Nelson Christensen, K. Bossie, C. Rajan, M. Agathos, S. Meshkov, Seog Oh, A. Cumming, G. A. Prodi, S. M. Scott, L. van der Schaaf, S. A. Pai, E. Genin, J. Zhang, Jay D. Tasson, M. Landry, R. DeSalvo, L. Di Fiore, F. Baldaccini, L. F. Ortega, Felice Sorrentino, A. Chiummo, W. G. Anderson, J. H. Hough, P. W. F. Forsyth, S. R. Thondapu, J. R. Palamos, D. Moraru, O. V. Palashov, Sean T. McWilliams, F. Piergiovanni, G. Cella, F.L. Linde, N. Sanchis-Gual, N. Radulescu, N. A. Robertson, Giuseppe Intini, D. Moffa, Giacomo Ciani, K. Rao, J. J. McCann, B. P. Abbott, Michele Zanolin, D. W. Yeeles, D. Chatterjee, T. J. Slaven-Blair, S. ShyamSundar, C. Stachie, T. J. Massinger, T. Vo, E. K. Gustafson, V. Kalogera, C. De Rossi, C. Austin, J. Bosveld, M. Barsuglia, Y. Levin, R. J. E. Smith, Luca Gammaitoni, Sebastien Biscans, A. Trovato, M. Davier, Jordan Camp, F. Vetrano, S. Vass, J. K. Blackburn, E. Chassande-Mottin, Sylvain Marsat, Sheila Rowan, R. Coyne, Fabrice Matichard, G. D. Hammond, Javed Rana, S. E. Dwyer, R. M. Magee, David Keitel, L. Zhang, J. H. Klika, L. Rolland, Christopher P. L. Berry, K. S. Phukon, S. J. Cooper, A. Lartaux-Vollard, N. Man, Z. Márka, K. A. Strain, M. K. M. Bader, O. Chaibi, P. Thomas, M. Arène, M. Pürrer, M. Merzougui, Matthew Evans, T. D. Creighton, R. Inta, K. Haughian, L. Kuo, H. Yamamoto, E. Capocasa, M. Chan, A. Schönbeck, B. Rajbhandari, S. Fairhurst, J. Prasad, S. Frasca, S. Klimenko, Kai Staats, L. Conti, M. Chaturvedi, Carl Blair, M. Thomas, H. Vahlbruch, J. C. Mills, K. Riles, J. Y. Vinet, H. Middleton, D. Talukder, Rob Evans, I. W. Harry, Z. A. Warden, R. Gouaty, V. Raymond, M. Weinert, H. A. G. Gabbard, F. Fidecaro, G. M. Guidi, Steven Bloemen, N. A. Lockerbie, Michael Steinke, Arnold Miller, H. N. Isa, Carlos O. Lousto, S. Sitmukhambetov, C. North, Thomas Dent, P. Corban, P. Ajith, A. J.R. Weinstein, M. Muratore, M. C. Heintze, F. Carbognani, E. Katsavounidis, Xiuling Li, H. Radkins, A. Bozzi, M. Brinkmann, M. C. Díaz, D. Huet, David Coward, Mikhail L. Gorodetsky, R. Bonnand, Mariana Fazio, Olivier Minazzoli, M. Razzano, R. Colgan, F. Martelli, Karan Jani, R. Shink, Pradeep Kumar Sharma, L. Rei, Huang-Wei Pan, Gijs Nelemans, E. D. Hall, Turlough P. Downes, K. Holt, Chunglee Kim, V. Sandberg, Karsten Danzmann, Koh Ueno, A. W. Jones, R. De Pietri, Rocco Romano, John D. Scott, R. A. Mercer, S. Ossokine, Jinsook Kim, C. K. Cheong, S. Stevenson, F. Aubin, G. Stratta, Jesper Munch, D. Buskulic, M. De Laurentis, C-H. Lee, Andreas Freise, Paul D. Lasky, J. W. Westhouse, Matthew Pitkin, D. Cohen, M. Wade, M. Granata, Minchuan Zhou, K. S. Karvinen, S. Mukherjee, T. M. Evans, P. B. Covas, V. Kondrashov, Arunava Mukherjee, M. C. Edwards, J. M. Gonzalez Castro, Alexander Urban, B. D. Cheeseboro, G. Cerretani, P. J. Easter, Christian Pedersen, Y. Minenkov, P. Bacon, A. Viceré, T. Huynh-Dinh, M. Cabero, H. Cao, D. J. Vine, W. Z. Korth, J. C. Bayley, Marc Favata, L. E. Wade, V. J. Roma, H. Wittel, M. Deenadayalan, A. P. Spencer, D. D. Brown, F. Di Renzo, Torrey Cullen, Anthony A. Amato, N. van Bakel, G. Valdes, David Jones, Marco Cavaglia, K. Kawabe, S. G. Schwalbe, J. Z. Wang, R. G. Ormiston, S. M. Aston, Michael W. Coughlin, A. W. Heptonstall, Pablo Cerdá-Durán, Peter R. Saulson, V. Sequino, I. Khan, R. Abbott, Terry G. McRae, L. G. Prokhorov, J. R. Gair, Samuel Deléglise, A. Fernandez-Galiana, A. L. Stuver, J. P. Zendri, C. Pankow, P. M. Meyers, F. Cipriano, Paul J. Groot, M. Zevin, S. Appert, Y. Setyawati, A. Giazotto, P. Shawhan, I. Ferrante, F. J. Raab, Rico K. L. Lo, P. Charlton, Kejia Lee, S. C. Tait, Yongjung Kim, Peter Weßels, I. A. Bilenko, L. Haegel, John Veitch, J. Lehmann, N. Arnaud, Vijay Varma, M. MacInnis, S. Caudill, Marco Romanelli, P. Rapagnani, David J. Ottaway, A. Paoli, W. Parker, P. Popolizio, E. J. Sanchez, John A. Clark, Ben Farr, W. S. Kim, Christophe Collette, Ho-Gyu Lee, C. J. Perez, B. D. O'Brien, C. Bradaschia, P. Oppermann, M. Di Giovanni, Ik Siong Heng, S. Márka, V. Mangano, A. L. Miller, P. Astone, Mairi Sakellariadou, G. Pillant, S. H. R. Yuen, O. de Varona, Keith Rose, Tenglin Li, D. Estevez, V. Fafone, D. Mukherjee, A. Grant, A. Pele, Nergis Mavalvala, Jerome Degallaix, Sebastian Khan, B. C. Barish, O. J. Piccinni, E. Bonilla, Irina Kowalska, M. Tonelli, Koya Arai, R. Quitzow-James, N. N. Janthalur, B. Sassolas, Fabrizio Barone, J. Betzwieser, E. Goetz, Tarun Souradeep, S. Penn, V. B. Adya, G. L. Mansell, V. Dattilo, Edwin J. Son, Stefan Hild, Y. Ma, A. Brillet, M. Vardaro, F. Robinet, Antoine Heidmann, António Alves da Silva, Q. Chu, D. Töyrä, H. Overmier, H. Qi, S. V. Angelova, L. Magaña Zertuche, Lili Yang, M. Branchesi, Zefeng Zhou, D. Y. T. Pong, E. Massera, Edward Seidel, O. E. S. Sauter, J. Woehler, S. Chung, N. Mazumder, A. Avila-Alvarez, K. Gill, Liam Dunn, Walter Winkler, A. S. Markosyan, Harald Lück, M. Cho, N. A. Holland, G. Gaur, S. C. McGuire, J. F. Read, S. Di Pace, K. Haris, D. Sellers, N. Demos, I. Maksimovic, G. Hemming, J. Meidam, Jeff R. Powell, S. M. Koehlenbeck, Riccardo Sturani, D. Hoak, D. Sentenac, Patrick Brady, M. Haney, T. A. Callister, H. S. Cho, William Moran, H. K. Gulati, Rahul Kashyap, Alejandro Torres-Forné, J. Neilson, B. D. Lackey, P. Grassia, Z. Doctor, D. M. Wilken, O. A. Hannuksela, Andrea Taracchini, P. Puppo, S. J. Kapadia, E. A. Huerta, C. L. Romel, F. Garufi, Surendra Nadh Somala, Tyson Littenberg, D. Fiorucci, A. K. Prajapati, A. R. Wade, G. Kuehn, C. M. Mow-Lowry, Sergey P. Vyatchanin, L. Aiello, M. Gosselin, R. Green, E. E. Cowan, B. F. Whiting, J. Casanueva Diaz, P. Schale, C. Van Den Broeck, E. Sowell, T. Zhang, Thibaut Jacqmin, T. Regimbau, C. I. Torrie, M. Saleem, M. Oliver, Douglas Davis, Geraint Pratten, D. Bersanetti, G. Ashton, J. V. van Heijningen, Yu Wang, Francisco Hernandez Vivanco, Eric Thrane, C. Michel, T. D. Knowles, F. Ohme, F. Cleva, M. P. Ross, T. B. Edo, M. Pichot, Maximiliano Isi, E. M. Gretarsson, Ying Guo, D. Beniwal, Peter Fritschel, Wenxiao Wang, M. Masso-Reid, K. C. Cannon, S. Kwang, L. E. Sanchez, Enrico Calloni, G. Traylor, Thomas Corbitt, L. Salconi, C. A. Costa, Laura Cadonati, D. A. Steer, L. Kleybolte, Chad Hanna, A. Bramley, C. Kimball, J. Oberling, M. Pirello, J. Bidler, F. Nocera, C. Zhao, Milan Gupta, G. Mendell, Laboratoire des matériaux avancés (LMA), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Laboratoire de l'Accélérateur Linéaire (LAL), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Sud - Paris 11 (UP11), AstroParticule et Cosmologie (APC (UMR_7164)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Laboratoire d'Annecy de Physique des Particules (LAPP), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), Astrophysique Relativiste Théories Expériences Métrologie Instrumentation Signaux (ARTEMIS), Centre National de la Recherche Scientifique (CNRS)-Observatoire de la Côte d'Azur, Université Côte d'Azur (UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), Institut des Fonctions Optiques pour les Technologies de l'informatiON (Institut FOTON), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-École Nationale Supérieure des Sciences Appliquées et de Technologie (ENSSAT)-Centre National de la Recherche Scientifique (CNRS)-IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT), Laboratoire Kastler Brossel (LKB [Collège de France]), École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Fédération de recherche du Département de physique de l'Ecole Normale Supérieure - ENS Paris (FRDPENS), Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Sorbonne Université (SU)-Collège de France (CdF (institution)), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL), Institut des Hautes Etudes Scientifiques (IHES), IHES, LIGO Scientific, VIRGO, Abbott, B. P., Abbott, R., Abbott, T. D., Abraham, S., Acernese, F., Ackley, K., Adams, C., Adhikari, R. X., Adya, V. B., Affeldt, C., Agathos, M., Agatsuma, K., Aggarwal, N., Aguiar, O. D., Aiello, L., Ain, A., Ajith, P., Allen, G., Allocca, A., Aloy, M. A., Altin, P. A., Amato, A., Ananyeva, A., Anderson, S. B., Anderson, W. G., Angelova, S. V., Antier, S., Appert, S., Arai, K., Araya, M. C., Areeda, J. S., Arene, M., Arnaud, N., Ascenzi, S., Ashton, G., Aston, S. M., Astone, P., Aubin, F., Aufmuth, P., Aultoneal, K., Austin, C., Avendano, V., Avila-Alvarez, A., Babak, S., Bacon, P., Badaracco, F., Bader, M. K. M., Bae, S., Baker, P. T., Baldaccini, F., Ballardin, G., Ballmer, S. W., Banagiri, S., Barayoga, J. C., Barclay, S. E., Barish, B. C., Barker, D., Barkett, K., Barnum, S., Barone, F., Barr, B., Barsotti, L., Barsuglia, M., Barta, D., Bartlett, J., Bartos, I., Bassiri, R., Basti, A., Bawaj, M., Bayley, J. C., Bazzan, M., Becsy, B., Bejger, M., Belahcene, I., Bell, A. S., Beniwal, D., Berger, B. K., Bergmann, G., Bernuzzi, S., Bero, J. J., Berry, C. P. L., Bersanetti, D., Bertolini, A., Betzwieser, J., Bhandare, R., Bidler, J., Bilenko, I. A., Bilgili, S. A., Billingsley, G., Birch, J., Birney, R., Birnholtz, O., Biscans, S., Biscoveanu, S., Bisht, A., Bitossi, M., Bizouard, M. A., Blackburn, J. K., Blair, C. D., Blair, D. G., Blair, R. M., Bloemen, S., Bode, N., Boer, M., Boetzel, Y., Bogaert, G., Bondu, F., Bonilla, E., Bonnand, R., Booker, P., Boom, B. A., Booth, C. D., Bork, R., Boschi, V., Bose, S., Bossie, K., Bossilkov, V., Bosveld, J., Bouffanais, Y., Bozzi, A., Bradaschia, C., Brady, P. R., Bramley, A., Branchesi, M., Brau, J. E., Briant, T., Briggs, J. H., Brighenti, F., Brillet, A., Brinkmann, M., Brisson, V., Brockill, P., Brooks, A. F., Brown, D. D., Brunett, S., Buikema, A., Bulik, T., Bulten, H. J., Buonanno, A., Buskulic, D., Buy, C., Byer, R. L., Cabero, M., Cadonati, L., Cagnoli, G., Cahillane, C., Calderon Bustillo, J., Callister, T. A., Calloni, E., Camp, J. B., Campbell, W. A., Canepa, M., Cannon, K. C., Cao, H., Cao, J., Capocasa, E., Carbognani, F., Caride, S., Carney, M. F., Carullo, G., Casanueva Diaz, J., Casentini, C., Caudill, S., Cavaglia, M., Cavalier, F., Cavalieri, R., Cella, G., Cerda-Duran, P., Cerretani, G., Cesarini, E., Chaibi, O., Chakravarti, K., Chamberlin, S. J., Chan, M., Chao, S., Charlton, P., Chase, E. A., Chassande-Mottin, E., Chatterjee, D., Chaturvedi, M., Cheeseboro, B. D., Chen, H. Y., Chen, X., Chen, Y., Cheng, H. -P., Cheong, C. K., Chia, H. Y., Chincarini, A., Chiummo, A., Cho, G., Cho, H. S., Cho, M., Christensen, N., Chu, Q., Chua, S., Chung, K. W., Chung, S., Ciani, G., Ciobanu, A. A., Ciolfi, R., Cipriano, F., Cirone, A., Clara, F., Clark, J. A., Clearwater, P., Cleva, F., Cocchieri, C., Coccia, E., Cohadon, P. -F., Cohen, D., Colgan, R., Colleoni, M., Collette, C. G., Collins, C., Cominsky, L. R., Constancio, M., Conti, L., Cooper, S. J., Corban, P., Corbitt, T. R., Cordero-Carrion, I., Corley, K. R., Cornish, N., Corsi, A., Cortese, S., Costa, C. A., Cotesta, R., Coughlin, M. W., Coughlin, S. B., Coulon, J. -P., Countryman, S. T., Couvares, P., Covas, P. B., Cowan, E. E., Coward, D. M., Cowart, M. J., Coyne, D. C., Coyne, R., Creighton, J. D. E., Creighton, T. D., Cripe, J., Croquette, M., Crowder, S. G., Cullen, T. J., Cumming, A., Cunningham, L., Cuoco, E., Dal Canton, T., Dalya, G., Danilishin, S. L., D'Antonio, S., Danzmann, K., Dasgupta, A., Da Silva Costa, C. F., Datrier, L. E. H., Dattilo, V., Dave, I., Davier, M., Davis, D., Daw, E. J., Debra, D., Deenadayalan, M., Degallaix, J., De Laurentis, M., Deleglise, S., Del Pozzo, W., Demarchi, L. M., Demos, N., Dent, T., De Pietri, R., Derby, J., De Rosa, R., De Rossi, C., Desalvo, R., De Varona, O., Dhurandhar, S., Diaz, M. C., Dietrich, T., Di Fiore, L., Di Giovanni, M., Di Girolamo, T., Di Lieto, A., Ding, B., Di Pace, S., Di Palma, I., Di Renzo, F., Dmitriev, A., Doctor, Z., Donovan, F., Dooley, K. L., Doravari, S., Dorrington, I., Downes, T. P., Drago, M., Driggers, J. C., Du, Z., Ducoin, J. -G., Dupej, P., Dwyer, S. E., Easter, P. J., Edo, T. B., Edwards, M. C., Effler, A., Ehrens, P., Eichholz, J., Eikenberry, S. S., Eisenmann, M., Eisenstein, R. A., Essick, R. C., Estelles, H., Estevez, D., Etienne, Z. B., Etzel, T., Evans, M., Evans, T. M., Fafone, V., Fair, H., Fairhurst, S., Fan, X., Farinon, S., Farr, B., Farr, W. M., Fauchon-Jones, E. J., Favata, M., Fays, M., Fazio, M., Fee, C., Feicht, J., Fejer, M. M., Feng, F., Fernandez-Galiana, A., Ferrante, I., Ferreira, E. C., Ferreira, T. A., Ferrini, F., Fidecaro, F., Fiori, I., Fiorucci, D., Fishbach, M., Fisher, R. P., Fishner, J. M., Fitz-Axen, M., Flaminio, R., Fletcher, M., Flynn, E., Fong, H., Font, J. A., Forsyth, P. W. F., Fournier, J. -D., Frasca, S., Frasconi, F., Frei, Z., Freise, A., Frey, R., Frey, V., Fritschel, P., Frolov, V. V., Fulda, P., Fyffe, M., Gabbard, H. A., Gadre, B. U., Gaebel, S. M., Gair, J. R., Gammaitoni, L., Ganija, M. R., Gaonkar, S. G., Garcia, A., Garcia-Quiros, C., Garufi, F., Gateley, B., Gaudio, S., Gaur, G., Gayathri, V., Gemme, G., Genin, E., Gennai, A., George, D., George, J., Gergely, L., Germain, V., Ghonge, S., Ghosh, A., Ghosh, S., Giacomazzo, B., Giaime, J. A., Giardina, K. D., Giazotto, A., Gill, K., Giordano, G., Glover, L., Godwin, P., Goetz, E., Goetz, R., Goncharov, B., Gonzalez, G., Gonzalez Castro, J. M., Gopakumar, A., Gorodetsky, M. L., Gossan, S. E., Gosselin, M., Gouaty, R., Grado, A., Graef, C., Granata, M., Grant, A., Gras, S., Grassia, P., Gray, C., Gray, R., Greco, G., Green, A. C., Green, R., Gretarsson, E. M., Groot, P., Grote, H., Grunewald, S., Gruning, P., Guidi, G. M., Gulati, H. K., Guo, Y., Gupta, A., Gupta, M. K., Gustafson, E. K., Gustafson, R., Haegel, L., Halim, O., Hall, B. R., Hall, E. D., Hamilton, E. Z., Hammond, G., Haney, M., Hanke, M. M., Hanks, J., Hanna, C., Hannam, M. D., Hannuksela, O. A., Hanson, J., Hardwick, T., Haris, K., Harms, J., Harry, G. M., Harry, I. W., Haster, C. -J., Haughian, K., Hayes, F. J., Healy, J., Heidmann, A., Heintze, M. C., Heitmann, H., Hello, P., Hemming, G., Hendry, M., Heng, I. S., Hennig, J., Heptonstall, A. W., Hernandez Vivanco, F., Heurs, M., Hild, S., Hinderer, T., Hoak, D., Hochheim, S., Hofman, D., Holgado, A. M., Holland, N. A., Holt, K., Holz, D. E., Hopkins, P., Horst, C., Hough, J., Howell, E. J., Hoy, C. G., Hreibi, A., Huerta, E. A., Huet, D., Hughey, B., Hulko, M., Husa, S., Huttner, S. H., Huynh-Dinh, T., Idzkowski, B., Iess, A., Ingram, C., Inta, R., Intini, G., Irwin, B., Isa, H. N., Isac, J. -M., Isi, M., Iyer, B. R., Izumi, K., Jacqmin, T., Jadhav, S. J., Jani, K., Janthalur, N. N., Jaranowski, P., Jenkins, A. C., Jiang, J., Johnson, D. S., Jones, A. W., Jones, D. I., Jones, R., Jonker, R. J. G., Ju, L., Junker, J., Kalaghatgi, C. V., Kalogera, V., Kamai, B., Kandhasamy, S., Kang, G., Kanner, J. B., Kapadia, S. J., Karki, S., Karvinen, K. S., Kashyap, R., Kasprzack, M., Katsanevas, S., Katsavounidis, E., Katzman, W., Kaufer, S., Kawabe, K., Keerthana, N. V., Kefelian, F., Keitel, D., Kennedy, R., Key, J. S., Khalili, F. Y., Khan, H., Khan, I., Khan, S., Khan, Z., Khazanov, E. A., Khursheed, M., Kijbunchoo, N., Kim, C., Kim, J. C., Kim, K., Kim, W., Kim, W. S., Kim, Y. -M., Kimball, C., King, E. J., King, P. J., Kinley-Hanlon, M., Kirchhoff, R., Kissel, J. S., Kleybolte, L., Klika, J. H., Klimenko, S., Knowles, T. D., Koch, P., Koehlenbeck, S. M., Koekoek, G., Koley, S., Kondrashov, V., Kontos, A., Koper, N., Korobko, M., Korth, W. Z., Kowalska, I., Kozak, D. B., Kringel, V., Krishnendu, N., Krolak, A., Kuehn, G., Kumar, A., Kumar, P., Kumar, R., Kumar, S., Kuo, L., Kutynia, A., Kwang, S., Lackey, B. D., Lai, K. H., Lam, T. L., Landry, M., Lane, B. B., Lang, R. N., Lange, J., Lantz, B., Lanza, R. K., Lartaux-Vollard, A., Lasky, P. D., Laxen, M., Lazzarini, A., Lazzaro, C., Leaci, P., Leavey, S., Lecoeuche, Y. K., Lee, C. H., Lee, H. K., Lee, H. M., Lee, H. W., Lee, J., Lee, K., Lehmann, J., Lenon, A., Leroy, N., Letendre, N., Levin, Y., Li, J., Li, K. J. L., Li, T. G. F., Li, X., Lin, F., Linde, F., Linker, S. D., Littenberg, T. B., Liu, J., Liu, X., Lo, R. K. L., Lockerbie, N. A., London, L. T., Longo, A., Lorenzini, M., Loriette, V., Lormand, M., Losurdo, G., Lough, J. D., Lousto, C. O., Lovelace, G., Lower, M. E., Luck, H., Lumaca, D., Lundgren, A. P., Lynch, R., Ma, Y., Macas, R., Macfoy, S., Macinnis, M., Macleod, D. M., Macquet, A., Magana-Sandoval, F., Magana Zertuche, L., Magee, R. M., Majorana, E., Maksimovic, I., Malik, A., Man, N., Mandic, V., Mangano, V., Mansell, G. L., Manske, M., Mantovani, M., Marchesoni, F., Marion, F., Marka, S., Marka, Z., Markakis, C., Markosyan, A. S., Markowitz, A., Maros, E., Marquina, A., Marsat, S., Martelli, F., Martin, I. W., Martin, R. M., Martynov, D. V., Mason, K., Massera, E., Masserot, A., Massinger, T. J., Masso-Reid, M., Mastrogiovanni, S., Matas, A., Matichard, F., Matone, L., Mavalvala, N., Mazumder, N., Mccann, J. J., Mccarthy, R., Mcclelland, D. E., Mccormick, S., Mcculler, L., Mcguire, S. C., Mciver, J., Mcmanus, D. J., Mcrae, T., Mcwilliams, S. T., Meacher, D., Meadors, G. D., Mehmet, M., Mehta, A. K., Meidam, J., Melatos, A., Mendell, G., Mercer, R. A., Mereni, L., Merilh, E. L., Merzougui, M., Meshkov, S., Messenger, C., Messick, C., Metzdorff, R., Meyers, P. M., Miao, H., Michel, C., Middleton, H., Mikhailov, E. E., Milano, L., Miller, A. L., Miller, A., Millhouse, M., Mills, J. C., Milovich-Goff, M. C., Minazzoli, O., Minenkov, Y., Mishkin, A., Mishra, C., Mistry, T., Mitra, S., Mitrofanov, V. P., Mitselmakher, G., Mittleman, R., Mo, G., Moffa, D., Mogushi, K., Mohapatra, S. R. P., Montani, M., Moore, C. J., Moraru, D., Moreno, G., Morisaki, S., Mours, B., Mow-Lowry, C. M., Mukherjee, A., Mukherjee, D., Mukherjee, S., Mukund, N., Mullavey, A., Munch, J., Muniz, E. A., Muratore, M., Murray, P. G., Nagar, A., Nardecchia, I., Naticchioni, L., Nayak, R. K., Neilson, J., Nelemans, G., Nelson, T. J. N., Nery, M., Neunzert, A., Ng, K. Y., Ng, S., Nguyen, P., Nichols, D., Nissanke, S., Nocera, F., North, C., Nuttall, L. K., Obergaulinger, M., Oberling, J., O'Brien, B. D., O'Dea, G. D., Ogin, G. H., Oh, J. J., Oh, S. H., Ohme, F., Ohta, H., Okada, M. A., Oliver, M., Oppermann, P., Oram, R. J., O'Reilly, B., Ormiston, R. G., Ortega, L. F., O'Shaughnessy, R., Ossokine, S., Ottaway, D. J., Overmier, H., Owen, B. J., Pace, A. E., Pagano, G., Page, M. A., Pai, A., Pai, S. A., Palamos, J. R., Palashov, O., Palomba, C., Pal-Singh, A., Pan, H. -W., Pang, B., Pang, P. T. H., Pankow, C., Pannarale, F., Pant, B. C., Paoletti, F., Paoli, A., Parida, A., Parker, W., Pascucci, D., Pasqualetti, A., Passaquieti, R., Passuello, D., Patil, M., Patricelli, B., Pearlstone, B. L., Pedersen, C., Pedraza, M., Pedurand, R., Pele, A., Penn, S., Perez, C. J., Perreca, A., Pfeiffer, H. P., Phelps, M., Phukon, K. S., Piccinni, O. J., Pichot, M., Piergiovanni, F., Pillant, G., Pinard, L., Pirello, M., Pitkin, M., Poggiani, R., Pong, D. Y. T., Ponrathnam, S., Popolizio, P., Porter, E. K., Powell, J., Prajapati, A. K., Prasad, J., Prasai, K., Prasanna, R., Pratten, G., Prestegard, T., Privitera, S., Prodi, G. A., Prokhorov, L. G., Puncken, O., Punturo, M., Puppo, P., Purrer, M., Qi, H., Quetschke, V., Quinonez, P. J., Quintero, E. A., Quitzow-James, R., Raab, F. J., Radkins, H., Radulescu, N., Raffai, P., Raja, S., Rajan, C., Rajbhandari, B., Rakhmanov, M., Ramirez, K. E., Ramos-Buades, A., Rana, J., Rao, K., Rapagnani, P., Raymond, V., Razzano, M., Read, J., Regimbau, T., Rei, L., Reid, S., Reitze, D. H., Ren, W., Ricci, F., Richardson, C. J., Richardson, J. W., Ricker, P. M., Riles, K., Rizzo, M., Robertson, N. A., Robie, R., Robinet, F., Rocchi, A., Rolland, L., Rollins, J. G., Roma, V. J., Romanelli, M., Romano, R., Romel, C. L., Romie, J. H., Rose, K., Rosinska, D., Rosofsky, S. G., Ross, M. P., Rowan, S., Rudiger, A., Ruggi, P., Rutins, G., Ryan, K., Sachdev, S., Sadecki, T., Sakellariadou, M., Salconi, L., Saleem, M., Samajdar, A., Sammut, L., Sanchez, E. J., Sanchez, L. E., Sanchis-Gual, N., Sandberg, V., Sanders, J. R., Santiago, K. A., Sarin, N., Sassolas, B., Saulson, P. R., Sauter, O., Savage, R. L., Schale, P., Scheel, M., Scheuer, J., Schmidt, P., Schnabel, R., Schofield, R. M. S., Schonbeck, A., Schreiber, E., Schulte, B. W., Schutz, B. F., Schwalbe, S. G., Scott, J., Scott, S. M., Seidel, E., Sellers, D., Sengupta, A. S., Sennett, N., Sentenac, D., Sequino, V., Sergeev, A., Setyawati, Y., Shaddock, D. A., Shaffer, T., Shahriar, M. S., Shaner, M. B., Shao, L., Sharma, P., Shawhan, P., Shen, H., Shink, R., Shoemaker, D. H., Shoemaker, D. M., Shyamsundar, S., Siellez, K., Sieniawska, M., Sigg, D., Silva, A. D., Singer, L. P., Singh, N., Singhal, A., Sintes, A. M., Sitmukhambetov, S., Skliris, V., Slagmolen, B. J. J., Slaven-Blair, T. J., Smith, J. R., Smith, R. J. E., Somala, S., Son, E. J., Sorazu, B., Sorrentino, F., Souradeep, T., Sowell, E., Spencer, A. P., Srivastava, A. K., Srivastava, V., Staats, K., Stachie, C., Standke, M., Steer, D. A., Steinke, M., Steinlechner, J., Steinlechner, S., Steinmeyer, D., Stevenson, S. P., Stocks, D., Stone, R., Stops, D. J., Strain, K. A., Stratta, G., Strigin, S. E., Strunk, A., Sturani, R., Stuver, A. L., Sudhir, V., Summerscales, T. Z., Sun, L., Sunil, S., Suresh, J., Sutton, P. J., Swinkels, B. L., Szczepanczyk, M. J., Tacca, M., Tait, S. C., Talbot, C., Talukder, D., Tanner, D. B., Tapai, M., Taracchini, A., Tasson, J. D., Taylor, R., Thies, F., Thomas, M., Thomas, P., Thondapu, S. R., Thorne, K. A., Thrane, E., Tiwari, S., Tiwari, V., Toland, K., Tonelli, M., Tornasi, Z., Torres-Forne, A., Torrie, C. I., Toyra, D., Travasso, F., Traylor, G., Tringali, M. C., Trovato, A., Trozzo, L., Trudeau, R., Tsang, K. W., Tse, M., Tso, R., Tsukada, L., Tsuna, D., Tuyenbayev, D., Ueno, K., Ugolini, D., Unnikrishnan, C. S., Urban, A. L., Usman, S. A., Vahlbruch, H., Vajente, G., Valdes, G., Van Bakel, N., Van Beuzekom, M., Van Den Brand, J. F. J., Van Den Broeck, C., Vander-Hyde, D. C., Van Heijningen, J. V., Van Der Schaaf, L., Van Veggel, A. A., Vardaro, M., Varma, V., Vass, S., Vasuth, M., Vecchio, A., Vedovato, G., Veitch, J., Veitch, P. J., Venkateswara, K., Venugopalan, G., Verkindt, D., Vetrano, F., Vicere, A., Viets, A. D., Vine, D. J., Vinet, J. -Y., Vitale, S., Vo, T., Vocca, H., Vorvick, C., Vyatchanin, S. P., Wade, A. R., Wade, L. E., Wade, M., Walet, R., Walker, M., Wallace, L., Walsh, S., Wang, G., Wang, H., Wang, J. Z., Wang, W. H., Wang, Y. F., Ward, R. L., Warden, Z. A., Warner, J., Was, M., Watchi, J., Weaver, B., Wei, L. -W., Weinert, M., Weinstein, A. J., Weiss, R., Wellmann, F., Wen, L., Wessel, E. K., Wessels, P., Westhouse, J. W., Wette, K., Whelan, J. T., Whiting, B. F., Whittle, C., Wilken, D. M., Williams, D., Williamson, A. R., Willis, J. L., Willke, B., Wimmer, M. H., Winkler, W., Wipf, C. C., Wittel, H., Woan, G., Woehler, J., Wofford, J. K., Worden, J., Wright, J. L., Wu, D. S., Wysocki, D. M., Xiao, L., Yamamoto, H., Yancey, C. C., Yang, L., Yap, M. J., Yazback, M., Yeeles, D. W., Yu, H., Yuen, S. H. R., Yvert, M., Zadrozny, A. K., Zanolin, M., Zelenova, T., Zendri, J. -P., Zevin, M., Zhang, J., Zhang, L., Zhang, T., Zhao, C., Zhou, M., Zhou, Z., Zhu, X. J., Zucker, M. E., Zweizig, J., Dunn, L. M., Suvorova, S., Evans, R. J., and Moran, W.
Subjects: Physics, data analysis method, erratum, 010308 nuclear & particles physics, Gravitational wave, Scorpius X-1, LIGO, gravitational radiation, gravitational radiation: direct detection, 01 natural sciences, gravitational radiation detector, Theoretical physics, cosmic rays, binary: spin, gravitational radiation: emission, 0103 physical sciences, [PHYS.GRQC]Physics [physics]/General Relativity and Quantum Cosmology [gr-qc], Experiments in gravity, X-ray: binary, Hidden Markov model, numerical calculations, 010303 astronomy & astrophysics, cosmology
Abstract: International audience; We present results from a semicoherent search for continuous gravitational waves from the low-mass x-ray binary Scorpius X-1, using a hidden Markov model (HMM) to track spin wandering. This search improves on previous HMM-based searches of LIGO data by using an improved frequency domain matched filter, the J-statistic, and by analyzing data from Advanced LIGO’s second observing run. In the frequency range searched, from 60 to 650 Hz, we find no evidence of gravitational radiation. At 194.6 Hz, the most sensitive search frequency, we report an upper limit on gravitational wave strain (at 95% confidence) of h095%=3.47×10-25 when marginalizing over source inclination angle. This is the most sensitive search for Scorpius X-1, to date, that is specifically designed to be robust in the presence of spin wandering.
Published: 2021

14. Early detection of IgH monoclonal rearrangement in follicular spicules of the nose preceding multiple myeloma diagnosis

Author: Alessandro Giunta, Luca Franceschini, Luca Bianchi, Maria Cantonetti, Mauro Mazzeo, Manuela Rizzo, Cosimo Di Raimondo, Marilena Minieri, Carmelo Gurnari, Sergio Bernardini, Ida Provenzano, and Maria Cristina Rapanotti
Subjects: Pathology, medicine.medical_specialty, business.industry, Early detection, Dermatology, medicine.disease, Sponge spicule, medicine.anatomical_structure, Monoclonal, Follicular phase, medicine, business, Multiple myeloma, Nose
Published: 2020

15. Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group

Author: Tommaso Za, Agostina Siniscalchi, M.T. Petrucci, Maria Cantonetti, L. De Rosa, Alessandro Andriani, Giusy Antolino, T. Caravita di Toritto, Ombretta Annibali, Alfonso Piciocchi, G. La Verde, U Coppetelli, Federico Vozella, Manuela Rizzo, V. De Stefano, and Giuseppe Cimino
Subjects: Oncology, Adult, Male, medicine.medical_specialty, Kaplan-Meier Estimate, Disease-Free Survival, Bortezomib, 03 medical and health sciences, 0302 clinical medicine, Antineoplastic Agents, Immunological, Clinical Trials, Phase II as Topic, Refractory, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Medicine, Humans, Multicenter Studies as Topic, Lenalidomide, Multiple myeloma, Dexamethasone, Aged, Aged, 80 and over, Hematology, business.industry, Hematopoietic Stem Cell Transplantation, Daratumumab, Antibodies, Monoclonal, General Medicine, Middle Aged, medicine.disease, Progression-Free Survival, Thalidomide, Myeloma Proteins, Tolerability, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Female, business, Multiple Myeloma, Oligopeptides, 030215 immunology, medicine.drug
Abstract: Daratumumab (DARA) is a human IgG-K monoclonal antibody (MoAb) targeting CD38 that is approved alone or in combination with bortezomib and dexamethasone or lenalidomide and dexamethasone for relapsed or refractory MM (RRMM) in patients previously exposed or double refractory to proteasome inhibitors (PI) and immunomodulatory drugs (IMiDs). However, there are limited data on its clinical activity and tolerability in real-world patients. Therefore, in the present study, we aim to determine the efficacy and toxicity profile of daratumumab in a real-life setting. In this study, we report the experience of the multiple myeloma GIMEMA Lazio Group in 62 relapsed/refractory MM patients treated with daratumumab as monotherapy who had previously received at least two treatment lines including a PI and an IMiDs or had been double refractory. Patients received DARA 16 mg/kg intravenously weekly for 8 weeks, every 2 weeks for 16 weeks, and every 4 weeks until disease progression or unacceptable toxicity. The overall response rate to daratumumab was 46%. Median progression-free survival (PFS) and overall survival reached 2.7 and 22.4 months, respectively. DARA was generally well tolerated; however, 2 patients interrupted their therapy due to adverse events. Present real-life experience confirms that DARA monotherapy is an effective strategy for heavily pre-treated and refractory patients with multiple myeloma, with a favorable safety profile.
Published: 2020

16. Therapy regimens including Daratumumab for relapsed/refractory multiple myeloma patients: Report from the Multiple Myeloma GIMEMA Lazio Group

Author: Fazio, Francesca, Md1, Germana, Sfara2, Federico, Vozella, Manuela, Rizzo, Md3, Valeria, Tomarchio, Md4, Laura De Padua, Md5, Angela, Rago, Md6, Vanessa, Velotta2, Gianfranco, Lapietra, Luca, Franceschini, Md7, Ombretta, Annibali, Svitlana, Gumenyuk, Md8, Giusy, Antolino, Md9, Mariagrazia, Garzia, Md10, Velia, Borganzoni, Md11, Alfonso, Piciocchi12, Tommaso Caravita di Toritto6, Alessandro, Andriani, Paolo De Fabritiis, Md2, Maria Teresa Petrucci, and Md13
Published: 2020

17. COVID-19 Experience in Hemodialysis Patients: A Cue for Therapeutic Heparin-Based Strategies

Author: Manuela Rizzo, Eleonora Riccio, Valentina Angelucci, and Antonio Pisani
Subjects: Coronavirus disease 2019 (COVID-19), medicine.drug_class, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), medicine.medical_treatment, Pneumonia, Viral, 030232 urology & nephrology, 030204 cardiovascular system & hematology, Bioinformatics, 03 medical and health sciences, 0302 clinical medicine, Renal Dialysis, Pandemic, medicine, Humans, Pandemics, Heparin, business.industry, Anticoagulant, Clinical course, Anticoagulants, COVID-19, covid, Entry into host, Hemodialysis, Coronavirus Infections, business, medicine.drug
Abstract: In our opinion, the use of heparin could play a crucial role in these patients. In fact, recent studies have shown that heparin, the most commonly used anticoagulant during HD procedures, had anti-inflammatory properties and a direct antiviral action, due to its ability to prevent SARS-CoV-2 pseudovirus entry into host cells. These activities, together with its anticoagulant action, could explain the ability of heparin to ameliorate COVID-19 clinical course.
Published: 2020

18. Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy

Author: Tiziana Ottone, Daniela Diverio, Robin Foà, Maria Teresa Voso, Valentina Alfonso, Massimo Breccia, Laura Cicconi, Roberto Latagliata, Luca Franceschini, Matteo Molica, Manuela Rizzo, Licia Iaccarino, Francesco Lo-Coco, and Mariadomenica Divona
Subjects: Male, medicine.medical_treatment, ATO, ATRA, Acute promyelocytic leukemia, Molecular relapse, Stem cell transplant, Salvage therapy, Kaplan-Meier Estimate, Hematopoietic stem cell transplantation, Gastroenterology, Arsenicals, chemistry.chemical_compound, 0302 clinical medicine, Arsenic Trioxide, Leukemia, Promyelocytic, Acute, Recurrence, Antineoplastic Combined Chemotherapy Protocols, Arsenic trioxide, Aged, 80 and over, Remission Induction, Hematopoietic Stem Cell Transplantation, Oxides, Hematology, General Medicine, Middle Aged, Combined Modality Therapy, Treatment Outcome, 030220 oncology & carcinogenesis, Female, medicine.drug, Adult, medicine.medical_specialty, Tretinoin, Disease-Free Survival, Drug Administration Schedule, Young Adult, 03 medical and health sciences, Internal medicine, medicine, Humans, neoplasms, Aged, Proportional Hazards Models, Retrospective Studies, Salvage Therapy, Chemotherapy, business.industry, medicine.disease, Regimen, chemistry, Drug Evaluation, business, Settore MED/15 - Malattie del Sangue, Progressive disease, Follow-Up Studies, 030215 immunology
Abstract: Prolonged therapy with all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) is highly effective in newly diagnosed acute promyelocytic leukemia (APL) but there is limited data on the efficacy of this regimen in the relapse setting. We report here on 22 APL patients treated with prolonged ATRA-ATO therapy at the time of disease relapse. Twenty patients obtained molecular complete remission (CRm) after 2 cycles (90%). Of these, two patients underwent hematopoietic stem cell transplant (HSCT) while the remaining proceeded to receive additional cycles (up to a total of 5) of ATRA-ATO. With a median follow-up of 58 months from the time of relapse (range: 21-128 months), the 4-year OS probability was 0.85 (95% CI 0.61-0.94), DFS was 0.74 (95% CI 0.49-0.88), and EFS 0.68 (95% CI 0.45-0.83). Two patients were resistant to ATRA-ATO salvage and five relapsed at a median of 19 months. Of these, four died due to progressive disease while three relapsed achieved a new CRm after further salvage therapy. This experience confirms the potentially curative effect of prolonged ATRA-ATO therapy in relapsed APL, especially in patients with long first complete remission.
Published: 2018

19. Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial

Author: Fortunato Morabito, Angelo Vacca, Enrica Antonia Martino, Giovanna Leonardi, Mariella Grasso, Maria Teresa Petrucci, Alessandra Larocca, Paola Omedè, Vittorio Montefusco, Antonietta Falcone, Giulia Benevolo, Carolina Terragna, Ilaria Saltarella, Pellegrino Musto, Roberto Ria, Lorenzo De Paoli, Francesca Patriarca, Sara Bringhen, Chiara Nozzoli, Daniela Gottardi, Vincenzo Callea, Nicola Giuliani, Manuela Rizzo, Massimo Offidani, Antonio Palumbo, Luca Baldini, Mario Boccadoro, Tommasina Guglielmelli, and Franco Dammacco
Subjects: 0301 basic medicine, Oncology, Male, Vascular Endothelial Growth Factor A, Response rate, Cancer Research, Becaplermin, law.invention, 0302 clinical medicine, Randomized controlled trial, law, Bone Marrow, Multiple myeloma, Blood plasma, Antineoplastic Combined Chemotherapy Protocols, Overall survival, Aged, 80 and over, Hematology, Bortezomib, Hepatocyte Growth Factor, Progression-free survival, lcsh:Diseases of the blood and blood-forming organs, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Prognosis, medicine.anatomical_structure, Angiogenic factors, 030220 oncology & carcinogenesis, Female, Fibroblast Growth Factor 2, medicine.drug, medicine.medical_specialty, lcsh:RC254-282, 03 medical and health sciences, Internal medicine, medicine, Biomarkers, Tumor, Humans, Molecular Biology, Aged, lcsh:RC633-647.5, business.industry, Research, medicine.disease, Clinical trial, 030104 developmental biology, Logistic Models, ROC Curve, Bone marrow, business, Follow-Up Studies
Abstract: Background Several new drugs are approved for treatment of patients with multiple myeloma (MM), but no validated biomarkers are available for the prediction of a clinical outcome. We aimed to establish whether pretreatment blood and bone marrow plasma concentrations of major cytokines and angiogenic factors (CAFs) of patients from a phase 3 trial of a MM treatment could have a prognostic and predictive value in terms of response to therapy and progression-free and overall survival and whether these patients could be stratified for their prognosis. Methods Blood and bone marrow plasma levels of Ang-2, FGF-2, HGF, VEGF, PDGF-β, IL-8, TNF-α, TIMP-1, and TIMP-2 were determined at diagnosis in MM patients enrolled in the GIMEMA MM0305 randomized controlled trial by an enzyme-linked immunosorbent assay (ELISA). These levels were correlated both reciprocally and with the type of therapy and patients’ characteristics and with a group of non-MM patients as controls. Results No significant differences were detected between the blood and bone marrow plasma levels of angiogenic cytokines. A cutoff for each CAF was established. The therapeutic response of patients with blood plasma levels of CAFs lower than the cutoff was better than the response of those with higher levels in terms of percentage of responding patients and quality of response. Conclusion FGF-2, HGF, VEGF, and PDGF-β plasma levels at diagnosis have predictive significance for response to treatment. The stratification of patients based on the levels of CAFs at diagnosis and their variations after therapy is useful to characterize different risk groups concerning outcome and response to therapy. Trial registration Clinical trial information can be found at the following link: NCT01063179 Electronic supplementary material The online version of this article (10.1186/s13045-018-0691-4) contains supplementary material, which is available to authorized users.
Published: 2019

20. Recurrent Sweet's syndrome in a patient with multiple myeloma

Author: Maria Cantonetti, Ida Provenzano, Francesca Passarelli, Livio Pupo, Daniela Nasso, Carmelo Gurnari, Sara Vaccarini, Luca Franceschini, Lucia Anemona, and Manuela Rizzo
Subjects: Oncology, medicine.medical_specialty, Sweet's syndrome, Case Report, Case Reports, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, stomatognathic system, immune system diseases, Internal medicine, hemic and lymphatic diseases, medicine, multiple myeloma, Multiple myeloma, business.industry, digestive, oral, and skin physiology, food and beverages, General Medicine, medicine.disease, Settore MED/15, 030220 oncology & carcinogenesis, business, DISEASE RELAPSE
Abstract: Key Clinical Message We report on a case of Sweet's syndrome associated with multiple myeloma, as harbinger for disease relapse.
Published: 2018

21. Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia

Author: Luca Franceschini, Emiliano Fabiani, Eleonora De Bellis, Carmelo Gurnari, Vito Mario Rapisarda, Manuela Rizzo, Maria Teresa Voso, Francesco Lo Coco, Diana Postorivo, Paola Panetta, Anna Maria Nardone, and Giulia Falconi
Subjects: 0301 basic medicine, Cancer Research, Pathology, medicine.medical_specialty, Myeloid, Isochromosome, Philadelphia chromosome, 03 medical and health sciences, hemic and lymphatic diseases, medicine, Secondary Acute Myeloid Leukemia, business.industry, 030111 toxicology, Myelodysplastic syndromes, Myeloid leukemia, Articles, medicine.disease, atypical chronic myeloid leukemia, isochromosome(X)(p10), secondary acute myeloid leukemia, Basophilia, medicine.anatomical_structure, Oncology, Atypical chronic myeloid leukemia, business, Settore MED/15 - Malattie del Sangue
Abstract: The World Health Organization classifies atypical chronic myeloid leukemia (aCML) as a myeloproliferative/myelodisplastic hematological disorder. The primary manifestations are leukocytosis with disgranulopoiesis, absence of basophilia and/or monocytosis, splenomegaly and absence of Philadelphia chromosome or BCR/ABL fusion. Overall 50-65% of patients demonstrate karyotypic abnormalities, although no specific cytogenetic alterations have been associated with this disease. X chromosome alterations have been rarely reported in myeloid malignancies. Although Isodicentric X, idic(X)(q13) is well known in females with myelodysplastic syndromes (MDS), little data are available on X isochromosome and its pathogenetic potential in these disorders. i(X)(p10) is observed in a variety of hematologic malignancies, both myeloid and lymphoid, as a unique abnormality, as well as part of a more complex karyotype, in females and less frequently in male patients. The present report describes the first patient with aCML, with documented isolated i(X)(p10), who developed a secondary acute myeloid leukemia (sAML).
Published: 2017

22. First narrow-band search for continuous gravitational waves from known pulsars in advanced detector data

Author: G. M. Harry, K. Venkateswara, T. Zhang, Robert Stone, Thibaut Jacqmin, John A. Clark, Ben Farr, W. S. Kim, Christophe Collette, Joseph Ashley Taylor, Ho-Gyu Lee, C. J. Perez, A. R. Williamson, Albrecht Rüdiger, C. I. Torrie, Olivier Minazzoli, G. Kang, A. Pal-Singh, Xing-Jiang Zhu, N. Gehrels, M. Razzano, M. Saleem, A. Nitz, R. A. Eisenstein, B. J. J. Slagmolen, M. Oliver, Douglas Davis, Geraint Pratten, Hee-Suk Cho, S. A. Usman, Jishnu Suresh, Roman Schnabel, J. M. Gonzalez Castro, J. V. van Heijningen, P. Oppermann, M. Di Giovanni, Ik Siong Heng, F. Martelli, Karan Jani, S. Vinciguerra, A. Lenon, J. E. Brau, G. D. Meadors, M. Pedraza, Alexander Urban, A. A. van Veggel, B. D. Cheeseboro, G. Cerretani, T. Zelenova, Riccardo Bassiri, Magnus Manske, L. Rei, Huang-Wei Pan, Gijs Nelemans, Eric Thrane, Efim A. Khazanov, G. Ballardin, Moritz Mehmet, S. Márka, V. Mangano, E. Maros, M. Phelps, Michael E Zucker, B. D. Lackey, S. Appert, E. D. Hall, Jolien D. E. Creighton, A. L. Miller, G. Vedovato, D. B. Kozak, C. Vorvick, L. Pinard, A. Viceré, T. Huynh-Dinh, C. Michel, D. J. McManus, R. Mittleman, V. Dattilo, Nelson Christensen, D. C. Coyne, D. Finstad, Sarah Caudill, G. D. O'Dea, T. D. Knowles, S. D. Linker, R. Robie, P. Astone, D. Barta, C. C. Yancey, A. Ain, Kipp Cannon, T. Hinderer, W. G. Anderson, F. Ohme, V. B. Adya, Turlough P. Downes, Giacomo Ciani, K. Holt, B. P. Abbott, E. K. Gustafson, W. Z. Korth, Rana X. Adhikari, Mark A. Scheel, H. Cao, D. J. Vine, F. Clara, T. Hardwick, D. Steinmeyer, S. Vass, A. Chiummo, Fabrice Matichard, F. Travasso, Chunglee Kim, V. Sandberg, Rosemary Frey, A. A. Shah, Y. Levin, D. M. Wilken, T. Sadecki, W. Ren, S. Grunewald, Marc Favata, Roger Jones, V. J. Roma, B. Machenschalk, F. Donovan, Laura Sampson, D. Moffa, James G. Bartlett, K. Bossie, H. Fair, D. H. Shoemaker, P. Brockill, F. Ricci, A. P. Spencer, D. Buskulic, O. A. Hannuksela, M. Poe, L. Pekowsky, R. L. Savage, M. J. Yap, F. Salemi, Koh Ueno, Roy Williams, A. S. Bell, M. Laxen, Anchal Gupta, F. Y. Khalili, F. Di Renzo, K. Siellez, G. Valdes, Luca Gammaitoni, D. D. Brown, M. Fyffe, Ken K. Y. Ng, A. Effler, A. Perreca, M. Constancio, Sebastien Biscans, A. Hreibi, Manuela Rizzo, Anthony A. Amato, N. van Bakel, Andrea Taracchini, Mairi Sakellariadou, G. Pillant, P. Puppo, O. de Varona, C. Affeldt, Q. Chu, Charalampos Markakis, P. J. Sutton, P. T. Baker, J. H. Romie, David Jones, Laura Cadonati, Marco Cavaglia, M. Was, H. Vocca, Eugeniy E. Mikhailov, A. Masserot, S. J. Kapadia, L. M. Perri, G. Gemme, M. Drago, M. J. Szczepańczyk, Denis Martynov, Marco Bazzan, Tenglin Li, C. Palomba, S. Privitera, Guenakh Mitselmakher, L. Kleybolte, I. Kowalska, D. Estevez, K. Kawabe, S. N. Tiwari, S. M. Aston, J. Cripe, M. Muratore, Heinz-Bernd Eggenstein, E. A. Huerta, M. K. M. Bader, R. Pedurand, Benno Willke, A. Grado, L. Naticchioni, Salvatore Vitale, A. Kutynia, L. Trozzo, Priscilla Canizares, C. Cahillane, Albert Lazzarini, Jochen Schmidt, R. Goetz, Tarun Souradeep, B. A. Boom, A. M. Sergeev, A. J. Weinstein, L. Cunningham, M. S. Shahriar, C. L. Romel, A. Brillet, R. T. DeRosa, C. Buy, Piotr Jaranowski, Susan M. Scott, G. McIntyre, V. Fafone, A. B. Nielsen, J. B. Kanner, R. Douglas, M. C. Heintze, N. Mukund, Leo Singer, Pablo Cerdá-Durán, Peter R. Saulson, M. A. Bizouard, C. E. Cirelli, Chad Hanna, I. Khan, Federico Ferrini, A. Dasgupta, Lijing Shao, E. Cuoco, G. Vajente, S. M. Gaebel, Achamveedu Gopakumar, T. Dal Canton, D. Mukherjee, Christopher M. Biwer, J. Oberling, M. Pirello, Jay D. Tasson, M. Landry, V. Gayathri, J. McIver, F. Carbognani, S. Walsh, Miriam Cabero, S. Frasca, L. Di Fiore, B. Mours, F. Frasconi, A. Grant, Alessandra Buonanno, C.-J. Haster, C. Austin, Gabrielle Allen, P. Kumar, A. K. W. Chung, M. Barsuglia, D. George, L. R. Cominsky, R. K. Lanza, Fiodor Sorrentino, P. Dupej, A. Pele, Sumit Kumar, R. Flaminio, J.-P. Coulon, K. V. Tokmakov, B. R. Hall, R. Gustafson, J. W. W. Pratt, Terry G. McRae, B. U. Gadre, L. G. Prokhorov, J. Westerweck, Samaya Nissanke, S. Ascenzi, S. Doravari, J.-M. Isac, F. Garufi, M. Bejger, Surendra Nadh Somala, D. Bersanetti, F. Marion, F. Nocera, Colm Talbot, Andreas Freise, Vincenzo Pierro, L. Zhang, T. Theeg, Paul D. Lasky, M. P. Ross, P. Thomas, J. S. Kissel, T. B. Edo, E. Thomas, Maximiliano Isi, Nergis Mavalvala, Innocenzo M. Pinto, H. Qi, S. V. Angelova, A. Gennai, Rahul Kumar, Harald P. Pfeiffer, A. Sheperd, V. Predoi, I. W. Martin, David Cohen, David E. McClelland, Jerome Degallaix, C. Casentini, Sebastian Khan, L. Magaña Zertuche, Lili Yang, Erik Katsavounidis, O. J. Piccinni, N. Bode, B. Gateley, Xie Chen, A. Markowitz, K. W. K. Wong, Howard Pan, Aaron Buikema, C. C. Wipf, E. J. King, Lionel Martellini, E. M. Gretarsson, J. A. Sonnenberg, R. Cavalieri, Peter Fritschel, Wenxiao Wang, M. Branchesi, V. Kondrashov, Arunava Mukherjee, Y. Minenkov, Alessandro Bertolini, J. C. Driggers, L. Conti, C. Fee, S. Bae, E. Coccia, C. Graef, B. A. Weaver, M. Masso-Reid, C. Kent, G. Mendell, D. Passuello, H. Radkins, A. Bozzi, A. Cirone, A. L. Stuver, J. P. Zendri, A. K. Srivastava, A. E. Pace, M. Thomas, Hyun Lee, E. Bonilla, J. Calderón Bustillo, J. C. Batch, Zefeng Zhou, H. Vahlbruch, K. Riles, W. Parker, Odylio D. Aguiar, P. Couvares, Matthew Pitkin, M. Wade, H. Middleton, S. Mitra, M. Brinkmann, S. Kaufer, M. Weinert, H. A. G. Gabbard, F. Fidecaro, S. Raja, S. E. Strigin, C. Lazzaro, Patricia Schmidt, A. Avila-Alvarez, V. Brisson, D. H. Reitze, A. W. Muir, E. Cesarini, Laleh Sadeghian, R. C. Walet, V. P. Mitrofanov, L. E. Sanchez, S. J. Cooper, M. C. Araya, J. Trinastic, Edward K. Porter, E. Massera, L. Milano, W. Del Pozzo, P. F. Cohadon, Kevin Barkett, A. Giazotto, M. C. Díaz, T. J. Cullen, Kazuhiro Agatsuma, A. Basti, Ryan N. Lang, G. M. Guidi, Kenneth A. Strain, Jimin George, J. C. Bayley, H. Wittel, S. G. Schwalbe, C. Messenger, Rainer Weiss, L. Glover, M. Tonelli, H. N. Isa, Tyson Littenberg, R. De Rosa, Badri Krishnan, L. Rolland, P. Leaci, A. Colla, J. G. Rollins, L.-W. Wei, J. Eichholz, Jens Birch, E. A. Chase, M. Leonardi, Enrico Calloni, G. Traylor, L. Salconi, I. Nardecchia, A. R. Wade, G. Kuehn, C. M. Mow-Lowry, D. Huet, R. G. Ormiston, J. Zweizig, H. Heitmann, M. K. Gupta, P. Shawhan, I. Ferrante, Rico K. L. Lo, B. Day, J. R. Gair, David Coward, P. Charlton, Kai Staats, Stephen Fairhurst, Carl Blair, A. F. Brooks, M. Sieniawska, Sergey P. Vyatchanin, Gregory Ashton, S. J. Kimbrell, N. Leroy, Kejia Lee, R. Quitzow-James, Fabio Marchesoni, P. Hello, D. Nolting, Carlos Cepeda, Robert J. McCarthy, D. V. Atallah, A. W. Heptonstall, M. Ducrot, Z. Frei, P. A. Altin, Alvin J. K. Chua, Rebecca Fisher, V. Sequino, S. Caride, J.-D. Fournier, M. Gosselin, Sheon Chua, R. Bonnand, Fabrizio Barone, S. S. Forsyth, M. Mohan, Linqing Wen, B. Agarwal, Edward Seidel, O. E. S. Sauter, O. Halim, D. S. Rabeling, K. W. Tsang, N. Man, W. W. Johnson, D. Barker, A. Samajdar, B. Sassolas, J. Woehler, Kris Ryan, E. A. Quintero, M. Granata, Minchuan Zhou, J. Devenson, K. S. Karvinen, S. Mukherjee, D. C. Vander-Hyde, Aviral Singh, Sebastian Steinlechner, I. Dorrington, S. C. Tait, Yongjung Kim, Z. Tornasi, Peter Weßels, Andrew Lundgren, Kyungmin Kim, Debarati Chatterjee, B. O'Reilly, P. Gruning, B. F. Whiting, J. Casanueva Diaz, Philip F. Hopkins, S. Xiao, T. R. Corbitt, F. J. Raab, K. E. Gushwa, P. Schale, G. P. Newton, G. Cella, B. Bécsy, M. Kasprzack, Shiuh Chao, R. De Pietri, C. C. Buchanan, Tristan Briant, M. Haney, E. Schreiber, O. Bock, C. Van Den Broeck, I. Di Palma, E. Mejuto-Villa, Soumi De, K. Haughian, L. Sun, T. A. Callister, I. Fiori, Gabriela Gonzalez, Archisman Ghosh, E. M. Fries, Rocco Romano, I. A. Bilenko, David J. Ottaway, John D. Scott, S. Chung, P. Popolizio, Koji Arai, R. A. Mercer, Jade Powell, S. Ossokine, Jinsook Kim, J. D. Lough, K. E. Ramirez, A. M. Sintes, P. Aufmuth, M. Boer, H. Fong, G. Greco, N. Letendre, Chandra Kant Mishra, E. J. Sanchez, M. J. Cowart, R. Bhandare, Lee McCuller, A. Paoli, A. K. Zadrożny, V. Boschi, T. D. Abbott, David Blair, T. M. Evans, Carsten Kramer, V. Dolique, Michael L. Gorodetsky, M. van Beuzekom, Collin D. Capano, Zoheyr Doctor, D. Lumaca, P. B. Covas, T. Westphal, M. A. Okada, K. Mason, L. McNeill, L. Wallace, G. Bogaert, Yi-Ming Hu, Alejandro Torres-Forné, H. Fehrmann, Ryan Lynch, A. Moggi, J. Ming, A. Królak, Vuk Mandic, S. Penn, D. Schuette, A. Ananyeva, S. L. Danilishin, M. Fays, S. Brunett, D. Ugolini, P. Clearwater, K. G. Arun, A. Di Lieto, E. C. Ferreira, Sanjeev Dhurandhar, M. W. Coughlin, B. Shapiro, E. J. Fauchon-Jones, J. A. Giaime, M. Lormand, Sascha Husa, G. Venugopalan, L. Sammut, D.B. DeBra, C. Whittle, Benjamin William Allen, Lionel London, Mandar Patil, Abhirup Ghosh, Karsten Danzmann, Hua Wang, G. Stratta, Jesper Munch, M. C. Edwards, S. J. Chamberlin, M. Vasúth, E. L. Merilh, A. Bisht, G. L. Mansell, R. M. Martin, C. Beer, D. Talukder, D. J. Stops, M. Prijatelj, David A. Williams, J. Warner, R. Passaquieti, M. Fitz-Axen, M. Punturo, J. Neilson, B. Pang, Slawomir Gras, Simon Stevenson, David A. Nichols, M. De Laurentis, Hsiao-Wen Chen, K. Izumi, D. B. Tanner, O. Puncken, Xavier Siemens, Kevin Napier, Edwin J. Son, C. Rajan, V. Loriette, Maher Yazback, X. Guo, P. Bacon, Daniel E. Holz, I. W. Harry, G. A. Prodi, K. A. Thorne, M. Korobko, S. Mastrogiovanni, Stefan Hild, Y. Ma, C-H. Lee, M. Factourovich, R. DeSalvo, Isabel Cordero-Carrión, O. V. Palashov, Sean T. McWilliams, F. Piergiovanni, Riccardo Ciolfi, Yi Chen, Peter T. H. Pang, R. Kirchhoff, B. L. Pearlstone, G. Mueller, B. Patricelli, J. Betzwieser, E. A. Muñiz, P. J. Veitch, J. Page, Antoine Heidmann, Kendall Ackley, R. K. Nayak, N. Sanchis-Gual, Athol J. Kemball, B. W. Schulte, J. Junker, John Miller, D. S. Wu, Margaret Millhouse, T. Prestegard, C. A. Costa, M. Vardaro, S. G. Gaonkar, M. B. Shaner, Steven Reyes, F. Robinet, Hartmut Grote, K. Gill, L. E. Wade, H. Y. Chia, F. Magaña-Sandoval, Haixing Miao, M. Davier, Jordan Camp, A. C. Green, G. Losurdo, Walter Winkler, A. S. Markosyan, Jörg Hennig, D. Töyrä, H. Overmier, Harald Lück, S. Rieger, L. Nevin, N. Mazumder, D. Verkindt, Archana Pai, F. Paoletti, R. Metzdorff, Fausto Acernese, M. Cho, J. J. Bero, Samuel Deléglise, P. Ruggi, G. Gaur, S. C. McGuire, J. F. Read, S. Di Pace, A. Mullavey, T. J. N. Nelson, R. Taylor, K. L. Dooley, V. Germain, J. E. Broida, A. Fernandez-Galiana, Mi Zhang, C. Gray, G. H. Ogin, T. J. Shaffer, Xiaohui Fan, Richard O'Shaughnessy, B. Barr, M. Bawaj, Lisa Barsotti, I. Maksimovic, A. Neunzert, T. Chmiel, M. Heurs, M. Mantovani, R. L. Ward, G. Hemming, M. Pichot, S. Gomes, J. Steinlechner, A. D. Viets, D. Meacher, Sylvia J. Zhu, Leo Tsukada, S. Koley, E. Z. Hamilton, S. M. Koehlenbeck, Neil J. Cornish, D. Pascucci, D. Sellers, J. Meidam, C. Bradaschia, T. Denker, Riccardo Sturani, Christopher P. L. Berry, A. D. Silva, C. Pankow, P. M. Meyers, R. J. G. Jonker, Barry C. Barish, Swetha Bhagwat, D. Rosińska, Richard J. Abbott, M. F. Carney, John Worden, D. Tuyenbayev, M. R. Ganija, Chunnong Zhao, A. Staley, S. Karki, S. Jawahar, T. Di Girolamo, Paul J. Groot, M. Zevin, John Veitch, V. Kringel, R. Tso, J-Y. Vinet, Patrick M. Koch, Reed Essick, Tomasz Bulik, D. Fiorucci, Richard J. Oram, J. Lehmann, François Bondu, J. C. Barayoga, Jan Harms, Jing Wang, N. Arnaud, Maggie Tse, Matthew Evans, T. D. Creighton, D. Hoak, D. Sentenac, Patrick Brady, J. S. Areeda, S. Kandhasamy, B. Sorazu, Vijay Varma, M. MacInnis, Satyanarayan Ray Pitambar Mohapatra, P. Rapagnani, S. Ghosh, László Á. Gergely, M. Yvert, Daichi Tsuna, S. Banagiri, R. Inta, S. Klimenko, Z. Márka, Evan Goetz, T. T. Nguyen, Andrea Chincarini, B. B. Miller, E. A. Houston, A. Post, S. Meshkov, Seog Oh, A. Cumming, T. Z. Summerscales, Jong H. Chow, A. Pasqualetti, G. Dálya, K. Mogushi, M. Ast, R. Coyne, E. Genin, P. J. King, F. Baldaccini, L. F. Ortega, D. M. Macleod, B. L. Swinkels, M. J. Hart, K. H. Lai, M. Katolik, G. Bergmann, C. De Rossi, J. Feicht, L. Kuo, H. Yamamoto, E. Capocasa, A. Schönbeck, J. K. Blackburn, A. Sawadsky, E. Chassande-Mottin, Sheila Rowan, B. Rajbhandari, V. Tiwari, Daniel Wysocki, Yann Bouffanais, Joey Shapiro Key, J. R. Sanders, J. Prasad, M. Pürrer, S. Kwang, Todd Adams, V. Raymond, Steven Bloemen, N. A. Lockerbie, Michael Steinke, C. North, Thomas Dent, Vladimir Dergachev, P. Corban, James Whelan, M. Nery, Ettore Majorana, Zhihui Du, A. Parida, P. Ehrens, Paul M. Ricker, S. S. Eikenberry, Yanxi Zhang, M. Bitossi, K. Wette, F. Thies, John J. Oh, Rory Smith, C. Adams, R. M. Blair, D. Sigg, Rosa Poggiani, S. W. Ballmer, D. M. Shoemaker, V. Frey, E. K. Wessel, S. Farinon, Michelle E. Walker, G. Moreno, P. Raffai, S. D’Antonio, Y. F. Wang, J. Hanks, D. A. Brown, Nicholas Demos, P. G. Murray, I. Belahcene, A. S. Sengupta, H. W. Lee, Francesco Pannarale, K. R. Corley, A. Rocchi, Sumanta Tewari, B. K. Berger, Fabien Kéfélian, C. Cocchieri, B. Goncharov, R. Birney, J. H. Hough, P. W. F. Forsyth, M. Kinley-Hanlon, Maria Ilaria Del Principe, M. Agathos, S. R. Morriss, J. R. Palamos, D. Moraru, Gianpietro Cagnoli, S. B. Coughlin, Michele Zanolin, I. Magaña Hernandez, Giuseppe Intini, A. Allocca, F. Vetrano, S. Antier, M. Dovale Álvarez, S. E. Dwyer, R. M. Magee, David Keitel, A. Lartaux-Vollard, T. J. Massinger, T. Vo, Suvadeep Bose, R. Gouaty, V. Kalogera, M. Merzougui, C. Horst, Alberto Vecchio, Will M. Farr, M. Montani, Nancy Aggarwal, Zahoor Ali Khan, G. D. Hammond, I. Dave, M. Fletcher, B. Hughey, C. F. Da Silva Costa, Wynn C. G. Ho, S. E. Gossan, S. H. Huttner, P. Fulda, F. Cleva, Andrew Melatos, M. Lorenzini, S. E. Barclay, J. L. Willis, Ofek Birnholtz, S. G. Crowder, Eric Howell, S. Leavey, Hai-Ping Cheng, L. K. Nuttall, R. Macas, G. Billingsley, S. Macfoy, G. Rutins, Graham Woan, Robert L. Byer, Stuart Reid, Mark Hannam, Jacob Scheuer, M. Rakhmanov, C. R. Billman, Bernard F. Schutz, Li Ju, Daniel A. Shaddock, Brittany Kamai, C. V. Kalaghatgi, J. Hanson, A. Strunk, N. Kijbunchoo, Hang Yu, Sergio Gaudio, B. Lantz, Jun Liu, J. Healy, R. M. S. Schofield, Jonathan Newport, H. J. Bulten, Geoffrey Lovelace, Bala R. Iyer, S. McCormick, G. Wang, C. Aulbert, Benjamin J. Owen, J. F. J. van den Brand, S. Sunil, M. Tacca, Martin Hendry, Cecilio García-Quirós, L. Matone, Haocun Yu, E. E. Cowan, Antonios Kontos, Junwei Cao, M. C. Milovich-Goff, J. L. Wright, Alessandra Corsi, J. E. Lord, E. J. Daw, Antonio Marquina, Paolo Addesso, K. D. Giardina, C. Dreissigacker, J. K. Wofford, M. A. Page, J. S. Lange, M. C. Tringali, N. A. Robertson, Márton Tápai, David Jonathan Hofman, Beverly J. Smith, Z. B. Etienne, Jonathan Blackman, M. Chan, K. Toland, R. D. Kennedy, José A. Font, Maya Fishbach, Tania Regimbau, M. M. Hanke, S. B. Anderson, A. Bohe, F. Jiménez-Forteza, Jennifer Watchi, Maria Alessandra Papa, F. Cavalier, T. Etzel, C. S. Unnikrishnan, Lloyd Paul Aiello, B. C. Pant, C. Messick, N. Indik, M. Afrough, Imre Bartos, V. Quetschke, Bangalore Suryanarayana Sathyaprakash, Martin M. Fejer, S. Cortese, J. R. Smith, R. Bork, S. Ghonge, K. AultONeal, W. Katzman, L. van der Schaaf, S. A. Pai, S. T. Countryman, Andrew Matas, Surabhi Sachdev, Christopher J. Moore, S. Biscoveanu, Antoni Ramos-Buades, V. V. Frolov, A. Singhal, Stanislav Babak, M. H. Wimmer, A. Noack, Laboratoire d'Annecy de Physique des Particules (LAPP), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), Laboratoire des matériaux avancés (LMA), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Laboratoire de l'Accélérateur Linéaire (LAL), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Sud - Paris 11 (UP11), AstroParticule et Cosmologie (APC (UMR_7164)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Astrophysique Relativiste Théories Expériences Métrologie Instrumentation Signaux (ARTEMIS), Centre National de la Recherche Scientifique (CNRS)-Observatoire de la Côte d'Azur, Université Côte d'Azur (UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), Institut des Fonctions Optiques pour les Technologies de l'informatiON (Institut FOTON), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-École Nationale Supérieure des Sciences Appliquées et de Technologie (ENSSAT)-Centre National de la Recherche Scientifique (CNRS)-IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT), Laboratoire Kastler Brossel (LKB [Collège de France]), École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Fédération de recherche du Département de physique de l'Ecole Normale Supérieure - ENS Paris (FRDPENS), Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Sorbonne Université (SU)-Collège de France (CdF (institution)), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL), LIGO Scientific, Virgo, The LIGO Scientific Collaboration, The Virgo Collaboration, (Astro)-Particles Physics, Laboratoire d'Annecy de Physique des Particules (LAPP/Laboratoire d'Annecy-le-Vieux de Physique des Particules), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Observatoire de Paris, PSL Research University (PSL)-PSL Research University (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Université Nice Sophia Antipolis (... - 2019) (UNS), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire de la Côte d'Azur, Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-École Nationale Supérieure des Sciences Appliquées et de Technologie (ENSSAT)-Centre National de la Recherche Scientifique (CNRS)-Université Bretagne Loire (UBL)-IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique), Fédération de recherche du Département de physique de l'Ecole Normale Supérieure - ENS Paris (FRDPENS), Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS Paris)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS Paris)-Collège de France (CdF)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), ESPCI ParisTech, Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire de la Côte d'Azur, COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Université de Rennes (UR)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-École Nationale Supérieure des Sciences Appliquées et de Technologie (ENSSAT)-Centre National de la Recherche Scientifique (CNRS), École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Collège de France (CdF (institution))-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Abbott, B. P., Abbott, R., Abbott, T. D., Acernese, F., Ackley, K., Adams, C., Adams, T., Addesso, P., Adhikari, R. X., Adya, V. B., Affeldt, C., Afrough, M., Agarwal, B., Agathos, M., Agatsuma, K., Aggarwal, N., Aguiar, O. D., Aiello, L., Ain, A., Allen, B., Allen, G., Allocca, A., Altin, P. A., Amato, A., Ananyeva, A., Anderson, S. B., Anderson, W. G., Angelova, S. V., Antier, S., Appert, S., Arai, K., Araya, M. C., Areeda, J. S., Arnaud, N., Arun, K. G., Ascenzi, S., Ashton, G., Ast, M., Aston, S. M., Astone, P., Atallah, D. V., Aufmuth, P., Aulbert, C., Aultoneal, K., Austin, C., Avila-Alvarez, A., Babak, S., Bacon, P., Bader, M. K. M., Bae, S., Baker, P. T., Baldaccini, F., Ballardin, G., Ballmer, S. W., Banagiri, S., Barayoga, J. C., Barclay, S. E., Barish, B. C., Barker, D., Barkett, K., Barone, F., Barr, B., Barsotti, L., Barsuglia, M., Barta, D., Bartlett, J., Bartos, I., Bassiri, R., Basti, A., Batch, J. C., Bawaj, M., Bayley, J. C., Bazzan, M., Bã©csy, B., Beer, C., Bejger, M., Belahcene, I., Bell, A. S., Berger, B. K., Bergmann, G., Bero, J. J., Berry, C. P. L., Bersanetti, D., Bertolini, A., Betzwieser, J., Bhagwat, S., Bhandare, R., Bilenko, I. A., Billingsley, G., Billman, C. R., Birch, J., Birney, R., Birnholtz, O., Biscans, S., Biscoveanu, S., Bisht, A., Bitossi, M., Biwer, C., Bizouard, M. A., Blackburn, J. K., Blackman, J., Blair, C. D., Blair, D. G., Blair, R. M., Bloemen, S., Bock, O., Bode, N., Boer, M., Bogaert, G., Bohe, A., Bondu, F., Bonilla, E., Bonnand, R., Boom, B. A., Bork, R., Boschi, V., Bose, S., Bossie, K., Bouffanais, Y., Bozzi, A., Bradaschia, C., Brady, P. R., Branchesi, M., Brau, J. E., Briant, T., Brillet, A., Brinkmann, M., Brisson, V., Brockill, P., Broida, J. E., Brooks, A. F., Brown, D. A., Brown, D. D., Brunett, S., Buchanan, C. C., Buikema, A., Bulik, T., Bulten, H. J., Buonanno, A., Buskulic, D., Buy, C., Byer, R. L., Cabero, M., Cadonati, L., Cagnoli, G., Cahillane, C., CalderÃ³n Bustillo, J., Callister, T. A., Calloni, E., Camp, J. B., Canizares, P., Cannon, K. C., Cao, H., Cao, J., Capano, C. D., Capocasa, E., Carbognani, F., Caride, S., Carney, M. F., Casanueva Diaz, J., Casentini, C., Caudill, S., Cavagliã , M., Cavalier, F., Cavalieri, R., Cella, G., Cepeda, C. B., CerdÃ¡-DurÃ¡n, P., Cerretani, G., Cesarini, E., Chamberlin, S. J., Chan, M., Chao, S., Charlton, P., Chase, E., Chassande-Mottin, E., Chatterjee, D., Cheeseboro, B. D., Chen, H. Y., Chen, X., Chen, Y., Cheng, H. -. P., Chia, H., Chincarini, A., Chiummo, A., Chmiel, T., Cho, H. S., Cho, M., Chow, J. H., Christensen, N., Chu, Q., Chua, A. J. K., Chua, S., Chung, A. K. W., Chung, S., Ciani, G., Ciolfi, R., Cirelli, C. E., Cirone, A., Clara, F., Clark, J. A., Clearwater, P., Cleva, F., Cocchieri, C., Coccia, E., Cohadon, P. -. F., Cohen, D., Colla, A., Collette, C. G., Cominsky, L. R., Constancio, M., Conti, L., Cooper, S. J., Corban, P., Corbitt, T. R., Cordero-CarriÃ³n, I., Corley, K. R., Cornish, N., Corsi, A., Cortese, S., Costa, C. A., Coughlin, M. W., Coughlin, S. B., Coulon, J. -. P., Countryman, S. T., Couvares, P., Covas, P. B., Cowan, E. E., Coward, D. M., Cowart, M. J., Coyne, D. C., Coyne, R., Creighton, J. D. E., Creighton, T. D., Cripe, J., Crowder, S. G., Cullen, T. J., Cumming, A., Cunningham, L., Cuoco, E., Dal Canton, T., Dã¡lya, G., Danilishin, S. L., D'Antonio, S., Danzmann, K., Dasgupta, A., Da Silva Costa, C. F., Dattilo, V., Dave, I., Davier, M., Davis, D., Daw, E. J., Day, B., De, S., Debra, D., Degallaix, J., De Laurentis, M., Delã©glise, S., Del Pozzo, W., Demos, N., Denker, T., Dent, T., De Pietri, R., Dergachev, V., De Rosa, Rosario, Derosa, R. T., De Rossi, C., Desalvo, R., De Varona, O., Devenson, J., Dhurandhar, S., Dãaz, M. C., Di Fiore, L., Di Giovanni, M., Di Girolamo, T., Di Lieto, A., Di Pace, S., Di Palma, I., Di Renzo, F., Doctor, Z., Dolique, V., Donovan, F., Dooley, K. L., Doravari, S., Dorrington, I., Douglas, R., Dovale Ã lvarez, M., Downes, T. P., Drago, M., Dreissigacker, C., Driggers, J. C., Du, Z., Ducrot, M., Dupej, P., Dwyer, S. E., Edo, T. B., Edwards, M. C., Effler, A., Eggenstein, H. -. B., Ehrens, P., Eichholz, J., Eikenberry, S. S., Eisenstein, R. A., Essick, R. C., Estevez, D., Etienne, Z. B., Etzel, T., Evans, M., Evans, T. M., Factourovich, M., Fafone, V., Fair, H., Fairhurst, S., Fan, X., Farinon, S., Farr, B., Farr, W. M., Fauchon-Jones, E. J., Favata, M., Fays, M., Fee, C., Fehrmann, H., Feicht, J., Fejer, M. M., Fernandez-Galiana, A., Ferrante, I., Ferreira, E. C., Ferrini, F., Fidecaro, F., Finstad, D., Fiori, I., Fiorucci, D., Fishbach, M., Fisher, R. P., Fitz-Axen, M., Flaminio, R., Fletcher, M., Fong, H., Font, J. A., Forsyth, P. W. F., Forsyth, S. S., Fournier, J. -. D., Frasca, S., Frasconi, F., Frei, Z., Freise, A., Frey, R., Frey, V., Fries, E. M., Fritschel, P., Frolov, V. V., Fulda, P., Fyffe, M., Gabbard, H., Gadre, B. U., Gaebel, S. M., Gair, J. R., Gammaitoni, L., Ganija, M. R., Gaonkar, S. G., Garcia-Quiros, C., Garufi, F., Gateley, B., Gaudio, S., Gaur, G., Gayathri, V., Gehrels, N., Gemme, G., Genin, E., Gennai, A., George, D., George, J., Gergely, L., Germain, V., Ghonge, S., Ghosh, Abhirup, Ghosh, Archisman, Ghosh, S., Giaime, J. A., Giardina, K. D., Giazotto, A., Gill, K., Glover, L., Goetz, E., Goetz, R., Gomes, S., Goncharov, B., Gonzã¡lez, G., Gonzalez Castro, J. M., Gopakumar, A., Gorodetsky, M. L., Gossan, S. E., Gosselin, M., Gouaty, R., Grado, A., Graef, C., Granata, M., Grant, A., Gras, S., Gray, C., Greco, G., Green, A. C., Gretarsson, E. M., Groot, P., Grote, H., Grunewald, S., Gruning, P., Guidi, G. M., Guo, X., Gupta, A., Gupta, M. K., Gushwa, K. E., Gustafson, E. K., Gustafson, R., Halim, O., Hall, B. R., Hall, E. D., Hamilton, E. Z., Hammond, G., Haney, M., Hanke, M. M., Hanks, J., Hanna, C., Hannam, M. D., Hannuksela, O. A., Hanson, J., Hardwick, T., Harms, J., Harry, G. M., Harry, I. W., Hart, M. J., Haster, C. -. J., Haughian, K., Healy, J., Heidmann, A., Heintze, M. C., Heitmann, H., Hello, P., Hemming, G., Hendry, M., Heng, I. S., Hennig, J., Heptonstall, A. W., Heurs, M., Hild, S., Hinderer, T., Ho, W. C. G., Hoak, D., Hofman, D., Holt, K., Holz, D. E., Hopkins, P., Horst, C., Hough, J., Houston, E. A., Howell, E. J., Hreibi, A., Hu, Y. M., Huerta, E. A., Huet, D., Hughey, B., Husa, S., Huttner, S. H., Huynh-Dinh, T., Indik, N., Inta, R., Intini, G., Isa, H. N., Isac, J. -. M., Isi, M., Iyer, B. R., Izumi, K., Jacqmin, T., Jani, K., Jaranowski, P., Jawahar, S., JimÃ©nez-Forteza, F., Johnson, W. W., Jones, D. I., Jones, R., Jonker, R. J. G., Ju, L., Junker, J., Kalaghatgi, C. V., Kalogera, V., Kamai, B., Kandhasamy, S., Kang, G., Kanner, J. B., Kapadia, S. J., Karki, S., Karvinen, K. S., Kasprzack, M., Katolik, M., Katsavounidis, E., Katzman, W., Kaufer, S., Kawabe, K., Kã©fã©lian, F., Keitel, D., Kemball, A. J., Kennedy, R., Kent, C., Key, J. S., Khalili, F. Y., Khan, I., Khan, S., Khan, Z., Khazanov, E. A., Kijbunchoo, N., Kim, Chunglee, Kim, J. C., Kim, K., Kim, W., Kim, W. S., Kim, Y. -. M., Kimbrell, S. J., King, E. J., King, P. J., Kinley-Hanlon, M., Kirchhoff, R., Kissel, J. S., Kleybolte, L., Klimenko, S., Knowles, T. D., Koch, P., Koehlenbeck, S. M., Koley, S., Kondrashov, V., Kontos, A., Korobko, M., Korth, W. Z., Kowalska, I., Kozak, D. B., Krã¤mer, C., Kringel, V., Krishnan, B., Krã³lak, A., Kuehn, G., Kumar, P., Kumar, R., Kumar, S., Kuo, L., Kutynia, A., Kwang, S., Lackey, B. D., Lai, K. H., Landry, M., Lang, R. N., Lange, J., Lantz, B., Lanza, R. K., Lartaux-Vollard, A., Lasky, P. D., Laxen, M., Lazzarini, A., Lazzaro, C., Leaci, P., Leavey, S., Lee, C. H., Lee, H. K., Lee, H. M., Lee, H. W., Lee, K., Lehmann, J., Lenon, A., Leonardi, M., Leroy, N., Letendre, N., Levin, Y., Li, T. G. F., Linker, S. D., Littenberg, T. B., Liu, J., Lo, R. K. L., Lockerbie, N. A., London, L. T., Lord, J. E., Lorenzini, M., Loriette, V., Lormand, M., Losurdo, G., Lough, J. D., Lovelace, G., Lã¼ck, H., Lumaca, D., Lundgren, A. P., Lynch, R., Ma, Y., Macas, R., Macfoy, S., Machenschalk, B., Macinnis, M., Macleod, D. M., MagaÃ±a Hernandez, I., MagaÃ±a-Sandoval, F., MagaÃ±a Zertuche, L., Magee, R. M., Majorana, E., Maksimovic, I., Man, N., Mandic, V., Mangano, V., Mansell, G. L., Manske, M., Mantovani, M., Marchesoni, F., Marion, F., Mã¡rka, S., Mã¡rka, Z., Markakis, C., Markosyan, A. S., Markowitz, A., Maros, E., Marquina, A., Martelli, F., Martellini, L., Martin, I. W., Martin, R. M., Martynov, D. V., Mason, K., Massera, E., Masserot, A., Massinger, T. J., Masso-Reid, M., Mastrogiovanni, S., Matas, A., Matichard, F., Matone, L., Mavalvala, N., Mazumder, N., Mccarthy, R., Mcclelland, D. E., Mccormick, S., Mcculler, L., Mcguire, S. C., Mcintyre, G., Mciver, J., Mcmanus, D. J., Mcneill, L., Mcrae, T., Mcwilliams, S. T., Meacher, D., Meadors, G. D., Mehmet, M., Meidam, J., Mejuto-Villa, E., Melatos, A., Mendell, G., Mercer, R. A., Merilh, E. L., Merzougui, M., Meshkov, S., Messenger, C., Messick, C., Metzdorff, R., Meyers, P. M., Miao, H., Michel, C., Middleton, H., Mikhailov, E. E., Milano, L., Miller, A. L., Miller, B. B., Miller, J., Millhouse, M., Milovich-Goff, M. C., Minazzoli, O., Minenkov, Y., Ming, J., Mishra, C., Mitra, S., Mitrofanov, V. P., Mitselmakher, G., Mittleman, R., Moffa, D., Moggi, A., Mogushi, K., Mohan, M., Mohapatra, S. R. P., Montani, M., Moore, C. J., Moraru, D., Moreno, G., Morriss, S. R., Mours, B., Mow-Lowry, C. M., Mueller, G., Muir, A. W., Mukherjee, Arunava, Mukherjee, D., Mukherjee, S., Mukund, N., Mullavey, A., Munch, J., Muã±iz, E. A., Muratore, M., Murray, P. G., Napier, K., Nardecchia, I., Naticchioni, L., Nayak, R. K., Neilson, J., Nelemans, G., Nelson, T. J. N., Nery, M., Neunzert, A., Nevin, L., Newport, J. M., Newton, G., Ng, K. K. Y., Nguyen, T. T., Nichols, D., Nielsen, A. B., Nissanke, S., Nitz, A., Noack, A., Nocera, F., Nolting, D., North, C., Nuttall, L. K., Oberling, J., O'Dea, G. D., Ogin, G. H., Oh, J. J., Oh, S. H., Ohme, F., Okada, M. A., Oliver, M., Oppermann, P., Oram, Richard J., O'Reilly, B., Ormiston, R., Ortega, L. F., O'Shaughnessy, R., Ossokine, S., Ottaway, D. J., Overmier, H., Owen, B. J., Pace, A. E., Page, J., Page, M. A., Pai, A., Pai, S. A., Palamos, J. R., Palashov, O., Palomba, C., Pal-Singh, A., Pan, Howard, Pan, Huang-Wei, Pang, B., Pang, P. T. H., Pankow, C., Pannarale, F., Pant, B. C., Paoletti, F., Paoli, A., Papa, M. A., Parida, A., Parker, W., Pascucci, D., Pasqualetti, A., Passaquieti, R., Passuello, D., Patil, M., Patricelli, B., Pearlstone, B. L., Pedraza, M., Pedurand, R., Pekowsky, L., Pele, A., Penn, S., Perez, C. J., Perreca, A., Perri, L. M., Pfeiffer, H. P., Phelps, M., Piccinni, O. J., Pichot, M., Piergiovanni, F., Pierro, V., Pillant, G., Pinard, L., Pinto, I. M., Pirello, M., Pitkin, M., Poe, M., Poggiani, R., Popolizio, P., Porter, E. K., Post, A., Powell, J., Prasad, J., Pratt, J. W. W., Pratten, G., Predoi, V., Prestegard, T., Prijatelj, M., Principe, M., Privitera, S., Prodi, G. A., Prokhorov, L. G., Puncken, O., Punturo, M., Puppo, P., Pã¼rrer, M., Qi, H., Quetschke, V., Quintero, E. A., Quitzow-James, R., Raab, F. J., Rabeling, D. S., Radkins, H., Raffai, P., Raja, S., Rajan, C., Rajbhandari, B., Rakhmanov, M., Ramirez, K. E., Ramos-Buades, A., Rapagnani, P., Raymond, V., Razzano, M., Read, J., Regimbau, T., Rei, L., Reid, S., Reitze, D. H., Ren, W., Reyes, S. D., Ricci, F., Ricker, P. M., Rieger, S., Riles, K., Rizzo, M., Robertson, N. A., Robie, R., Robinet, F., Rocchi, A., Rolland, L., Rollins, J. G., Roma, V. J., Romano, R., Romel, C. L., Romie, J. H., RosiÅ„ska, D., Ross, M. P., Rowan, S., Rã¼diger, A., Ruggi, P., Rutins, G., Ryan, K., Sachdev, S., Sadecki, T., Sadeghian, L., Sakellariadou, M., Salconi, L., Saleem, M., Salemi, F., Samajdar, A., Sammut, L., Sampson, L. M., Sanchez, E. J., Sanchez, L. E., Sanchis-Gual, N., Sandberg, V., Sanders, J. R., Sassolas, B., Sathyaprakash, B. S., Saulson, P. R., Sauter, O., Savage, R. L., Sawadsky, A., Schale, P., Scheel, M., Scheuer, J., Schmidt, J., Schmidt, P., Schnabel, R., Schofield, R. M. S., Schã¶nbeck, A., Schreiber, E., Schuette, D., Schulte, B. W., Schutz, B. F., Schwalbe, S. G., Scott, J., Scott, S. M., Seidel, E., Sellers, D., Sengupta, A. S., Sentenac, D., Sequino, V., Sergeev, A., Shaddock, D. A., Shaffer, T. J., Shah, A. A., Shahriar, M. S., Shaner, M. B., Shao, L., Shapiro, B., Shawhan, P., Sheperd, A., Shoemaker, D. H., Shoemaker, D. M., Siellez, K., Siemens, X., Sieniawska, M., Sigg, D., Silva, A. D., Singer, L. P., Singh, A., Singhal, A., Sintes, A. M., Slagmolen, B. J. J., Smith, B., Smith, J. R., Smith, R. J. E., Somala, S., Son, E. J., Sonnenberg, J. A., Sorazu, B., Sorrentino, F., Souradeep, T., Spencer, A. P., Srivastava, A. K., Staats, K., Staley, A., Steinke, M., Steinlechner, J., Steinlechner, S., Steinmeyer, D., Stevenson, S. P., Stone, R., Stops, D. J., Strain, K. A., Stratta, G., Strigin, S. E., Strunk, A., Sturani, R., Stuver, A. L., Summerscales, T. Z., Sun, L., Sunil, S., Suresh, J., Sutton, P. J., Swinkels, B. L., SzczepaÅ„czyk, M. J., Tacca, M., Tait, S. C., Talbot, C., Talukder, D., Tanner, D. B., Tã¡pai, M., Taracchini, A., Tasson, J. D., Taylor, J. A., Taylor, R., Tewari, S. V., Theeg, T., Thies, F., Thomas, E. G., Thomas, M., Thomas, P., Thorne, K. A., Thrane, E., Tiwari, S., Tiwari, V., Tokmakov, K. V., Toland, K., Tonelli, M., Tornasi, Z., Torres-FornÃ©, A., Torrie, C. I., Tã¶yrã¤, D., Travasso, F., Traylor, G., Trinastic, J., Tringali, M. C., Trozzo, L., Tsang, K. W., Tse, M., Tso, R., Tsukada, L., Tsuna, D., Tuyenbayev, D., Ueno, K., Ugolini, D., Unnikrishnan, C. S., Urban, A. L., Usman, S. A., Vahlbruch, H., Vajente, G., Valdes, G., Van Bakel, N., Van Beuzekom, M., Van Den Brand, J. F. J., Van Den Broeck, C., Vander-Hyde, D. C., Van Der Schaaf, L., Van Heijningen, J. V., Van Veggel, A. A., Vardaro, M., Varma, V., Vass, S., Vasãºth, M., Vecchio, A., Vedovato, G., Veitch, J., Veitch, P. J., Venkateswara, K., Venugopalan, G., Verkindt, D., Vetrano, F., Vicerã©, A., Viets, A. D., Vinciguerra, S., Vine, D. J., Vinet, J. -. Y., Vitale, S., Vo, T., Vocca, H., Vorvick, C., Vyatchanin, S. P., Wade, A. R., Wade, L. E., Wade, M., Walet, R., Walker, M., Wallace, L., Walsh, S., Wang, G., Wang, H., Wang, J. Z., Wang, W. H., Wang, Y. F., Ward, R. L., Warner, J., Was, M., Watchi, J., Weaver, B., Wei, L. -. W., Weinert, M., Weinstein, A. J., Weiss, R., Wen, L., Wessel, E. K., Weãÿels, P., Westerweck, J., Westphal, T., Wette, K., Whelan, J. T., Whiting, B. F., Whittle, C., Wilken, D., Williams, D., Williams, R. D., Williamson, A. R., Willis, J. L., Willke, B., Wimmer, M. H., Winkler, W., Wipf, C. C., Wittel, H., Woan, G., Woehler, J., Wofford, J., Wong, K. W. K., Worden, J., Wright, J. L., Wu, D. S., Wysocki, D. M., Xiao, S., Yamamoto, H., Yancey, C. C., Yang, L., Yap, M. J., Yazback, M., Yu, Hang, Yu, Haocun, Yvert, M., Zadroå¼ny, A., Zanolin, M., Zelenova, T., Zendri, J. -. P., Zevin, M., Zhang, L., Zhang, M., Zhang, T., Zhang, Y. -. H., Zhao, C., Zhou, M., Zhou, Z., Zhu, S. J., Zhu, X. J., Zucker, M. E., Zweizig, J., École Nationale Supérieure des Sciences Appliquées et de Technologie (ENSSAT)-IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Observatoire de Paris, and PSL Research University (PSL)-PSL Research University (PSL)-Université Paris Diderot - Paris 7 (UPD7)
Subjects: Gravitational-wave observatory, Physics and Astronomy (miscellaneous), Astronomy, 01 natural sciences, rotation, neutron stars, General Relativity and Quantum Cosmology, gravitational waves, LIGO, stochastic gravitational-wave, neutron star, 010303 astronomy & astrophysics, GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries), QC, pulsar, QB, Physics, High Energy Astrophysical Phenomena (astro-ph.HE), Gravitational Waves, neutron stars, advanced detectors, narrow-band search, Detector, Amplitude, [PHYS.GRQC]Physics [physics]/General Relativity and Quantum Cosmology [gr-qc], Astrophysics - High Energy Astrophysical Phenomena, asymmetry, Coherence (physics), young pulsar, interferometer, neutron star: spin, FOS: Physical sciences, General Relativity and Quantum Cosmology (gr-qc), proper motion, advanced detectors, Gravitational waves, Pulsar, 0103 physical sciences, ddc:530, Gravitational Waves, 010308 nuclear & particles physics, Gravitational wave, gravitational radiation, 530 Physik, gravitational radiation detector, Computational physics, coherence, detector: sensitivity, Neutron star, electromagnetic, Physics and Astronomy, narrow-band search, Dewey Decimal Classification::500 | Naturwissenschaften::530 | Physik, [PHYS.ASTR]Physics [physics]/Astrophysics [astro-ph], discovery
Abstract: Spinning neutron stars asymmetric with respect to their rotation axis are potential sources of continuous gravitational waves for ground-based interferometric detectors. In the case of known pulsars a fully coherent search, based on matched filtering, which uses the position and rotational parameters obtained from electromagnetic observations, can be carried out. Matched filtering maximizes the signal-to-noise (SNR) ratio, but a large sensitivity loss is expected in case of even a very small mismatch between the assumed and the true signal parameters. For this reason, {\it narrow-band} analyses methods have been developed, allowing a fully coherent search for gravitational waves from known pulsars over a fraction of a hertz and several spin-down values. In this paper we describe a narrow-band search of eleven pulsars using data from Advanced LIGO's first observing run. Although we have found several initial outliers, further studies show no significant evidence for the presence of a gravitational wave signal. Finally, we have placed upper limits on the signal strain amplitude lower than the spin-down limit for 5 of the 11 targets over the bands searched: in the case of J1813-1749 the spin-down limit has been beaten for the first time. For an additional 3 targets, the median upper limit across the search bands is below the spin-down limit. This is the most sensitive narrow-band search for continuous gravitational waves carried out so far., 9 Figures, 7 tables, submitted to PRD
Published: 2017

23. Immunotherapy in Multiple Myeloma: Experience of the Multiple Myeloma Gimema Lazio Group

Author: Federico Vozella, Giusy Antolino, Giacinto La Verde, Luca De Rosa, Agostina Siniscalchi, Tommaso Za, Alessandro Andriani, Maria Cantonetti, Manuela Rizzo, Maria Teresa Petrucci, Valerio De Stefano, U Coppetelli, Giuseppe Cimino, Robin Foà, Ombretta Annibali, Tommaso Caravita di Toritto, and Alfonso Piciocchi
Subjects: medicine.medical_specialty, Combination therapy, business.industry, Bortezomib, medicine.medical_treatment, Immunology, Daratumumab, Cell Biology, Hematology, Hematopoietic stem cell transplantation, medicine.disease, Biochemistry, Discontinuation, Transplantation, Internal medicine, medicine, business, Multiple myeloma, Lenalidomide, medicine.drug
Abstract: Introduction .Treatment of multiple myeloma (MM) patients (pts) has radically changed over the last years following the introduction of next generation proteasome inhibitors (PI) and immunomodulatory derivatives (IMiDs). Despite the improvement of pts' outcome due to these drugs, MM remainsan incurable disease given its propensity for clonal heterogeneity and its complex interaction with the surrounding bone marrow microenvironment. Almost all pts eventually relapse despite their responses to PI, IMiDs or both. Recently, one further therapeutic option for MM patients is represented bydaratumumab, an anti-CD38 monoclonal antibody approved alsofor heavily pre-treated pts who have exhausted all other therapeutic options. Patients and Methods. We report the experience of the Multiple Myeloma GIMEMA Lazio Group in 50 relapsed/refractory MM pts treated with daratumumab as monotherapy. Twenty-nine pts (58%) were men and 21 (32%) women. According to the ISS,24 pts (48%) were ISS I, 11 (22%) ISS II, 7 (14%) ISS III and 8(16%)not evaluable. According toDurie& Salmon, 20 pts (40%) were 1 A, 2 (4%) 1 B, 12 (24%) II A, 1 (2%) II B,7 (14%) III A, 3 (6%) III B and 5 (10%) not evaluable. Isotype IgG-k was found in 21 pts (42%), IgG-λ in 13 (26%), IgA-k in 6 (12%), IgA-λ in 3 (6%), micromolecular k in 5 (10%) andmicromolecular λ in 2 (4%). Median age was 62.3 years (range, 43.1 - 85.7); 32 pts (64%) were refractory to the last line of therapy; 26 (52%) had previously received a stem cell transplant (13 single autologous, 12 tandem autologous and one an autologous followed by an allogeneic transplant). After a median follow-up from diagnosis of 54.5 months (range 1.0 - 203.0) and a median of 3 previous lines of therapy (range 2 - 8), pts received a median of 3 cycles (range 1 - 23) of daratumumab. Results.Forty-seven pts (94%) performed at least one cycle and were evaluable for response. The overall response rate was 74%; in particular, 2 pts obtained a CR (4.2%), 3 pts a VGPR (6.3%), 17 pts a PR (36.2%) and 15 pts a SD (32%), while 10 pts (21.3%) presented a PD. After a median follow-up of 5.3 months (range 1 - 31) ,24 pts(65%) were still in response and alive, one pt (5.8%) died in PR due to post-allograft GVHD and 12 (32%) experienced a PD (1 CR, 1 VGPR, 6 PR and 4 SD). Seven (19%) pts died and 30 (81%) are still alive. With regard to the 3 pts not evaluable for response, 2 died early and 1 has not yet completed the first cycle. The median time to response, duration of response, progression-free survival and overall survival were 1.5 months (range 1.0 - 6.0), 6.7 months (95% CI, 4.14 - 14.21), 5.7 months (95% CI, 3.26 - 13.75) and 22.5 months (95% CI, 11.6 - 36.1), respectively. Daratumumab was well tolerated; the most common adverse events, of any grade, were infections in 20 pts (42.0%) and anaemia in 21 pts (44.0%), which did not lead to treatment discontinuation. Infusion-related reactionswere observed in 7pts (14.8%), grade I-II (4 pts), grade III (3 pts). Conclusions.Daratumumab monotherapy is an effective strategy for heavily pre-treated and refractory pts with multiple myeloma, with a favorable safety profile. This treatment option needs to be considered for pts not eligible for combination therapy of daratumumab with bortezomib or lenalidomide, recently approved also in our country. Disclosures Vozella: Takeda Oncology; Amgen: Honoraria. Annibali:Celgene; Takeda; Amgen, Janssen Cilag: Honoraria. Caravita di Toritto:Johnson & Johnson: Other: Advisory Board, Travel and Accomodation EHA; Amgen: Other: Advisory Board; Bristol-Myers Squibb: Honoraria, Other: Travel and Accomodation EMN; Takeda: Other: Advisory Board; Celgene: Other: Advisory Board, Travel and Accomodation ASH, Research Funding. Foà:NOVARTIS: Speakers Bureau; JANSSEN: Other: ADVISORY BOARD, Speakers Bureau; CELGENE: Other: ADVISORY BOARD, Speakers Bureau; GILEAD: Speakers Bureau; AMGEN: Other: ADVISORY BOARD; INCYTE: Other: ADVISORY BOARD; CELTRION: Other: ADVISORY BOARD; ABBVIE: Other: ADVISORY BOARD, Speakers Bureau; ROCHE: Other: ADVISORY BOARD, Speakers Bureau. Petrucci:Takeda Oncology; Amgen; Celgene; BMS; Janssen Cilag: Honoraria, Other: Advisory Board.
Published: 2018

24. Unravelling Genetic Mechanisms of Erythrocytosis: A Real-Life Experience from a Single Center

Author: Ambra Di Veroli, Maria Cantonetti, Francesco Buccisano, Maria Luigia Randi, Carmelo Gurnari, Anna Maria Lombardi, Luca Franceschini, Giulia Falconi, Ida Provenzano, Daniela Nasso, Elisabetta Cosi, Maria Teresa Voso, Manuela Rizzo, Giacomo Biagetti, Emiliano Fabiani, Luca Maurillo, and Francesco Lo-Coco
Subjects: Evolutionary biology, Immunology, Myeloproliferative disease, Cell Biology, Hematology, Psychology, Single Center, Biochemistry, Genetic pedigree
Abstract: Introduction Erythrocytosis is characterized by persistently raised hemoglobin (HB) and hematocrit (Ht) levels. Differential diagnosis includes Polycythemia Vera (PV), secondary, hereditary (HE) and idiopathic erythrocytosis (IE). Recently, Randi et al. (Br J Haematol, 2018) demonstrated the recurrence of HFE single nucleotide variants (SNVs) in patients with IE, postulating a possible link between Hemochromatosis genes and erythrocytosis. The most frequent HFE SNVs are C282Y and H63D, reported at allele frequencies of about 13% and 4% in Caucasian countries. HE has also been associated with mutations in genes members of the complex pathway of "oxygen sensing" (EPOR, VHL, HIF-2a and PHD2). To date, 30 mutations have been described in the PHD2 gene, all localized in the catalytic domain, which impair binding to HIF-2a. The PHD2p.C127S variant is frequently observed in Tibetans with D4E in cis (overall prevalence of this haplotype is 88.6% at altitudes above 3000m), in linkage disequilibrium with other missense mutations (in particular HIF-2a/EPAS1). Surprisingly, the combination of PHD2/HIF-2a variants result in a gain-of-function effect that blunts the hypoxic response, providing a molecular mechanism for the observed protection of Tibetans from erythrocytosis at high altitude. In normoxic conditions and in low-landers, the PHD2p.C127S variant may lead to increased erythropoiesis as reported in the literature. Patients and Methods Twenty-three patients with erythrocytosis (21 males and 2 females with a median age of 56 years, range 18-76, Table 1) negative for JAK2 mutations (both V617F and exon 12 variants), and with a bone marrow histology not suggestive of a myeloproliferative syndrome were studied for secondary causes of erythrocytosis using an appropriate algorithm (EPO levels, chest and abdomen imaging, spirometry, venous p50 of HB, arterial blood gas analysis). Since all tests were negative, HE genes mutation analysis was carried out, using Sanger sequencing of EPOR exon 8, the VHL coding region, PHD2 exon 1-3 and HIF-2a exon 12. HFE SNVs were studied using allele-specific real-time PCR. Results Sequencing of HE genes identified 4 carriers of PHD2 variants in 23 patients (17%). One patient had a novel missense heterozygous mutation (PHD2p.I269N). The study of his kindred showed that his sister and one daughter have HE and both carried the same heterozygous mutation of the propositus. Furthermore, his father had died with a diagnosis of PV in the pre-JAK2 era. In contrast, the patient's brother and the other daughter, both with normal Hb and Hct, had wild-type PHD2. Of note, the propositus and his two daughters were heterozygous for H63D in the HFE gene. The patient's pedigree is illustrated in Figure 1. Interestingly, three further patients tested positive for the PHD2 missense heterozygous variant (PHD2p.C127S) previously reported in the Tibetan population, and whose role in patients with erythrocytosis is still unclear. HFE SNVs real-time PCR revealed 7 carriers of the H63D, 1 of C282Y and 1 of S65C SNV in the HFE gene (about 40% of our cohort). Interestingly, two H63D heterozygous patients were a father and his son. They were all males with a median age of 48 years (range 18-64). The prevalence of HFE SNVs in our cohort of patients with erythrocytosis is higher than expected for H63D and S65C for Caucasians (30% vs 13% for H63D and 4.35 vs 1.5% for S65C), while the allele frequency of C282Y was similar to that of the general population. Finally, the patient with the S65C SNV also had the "Tibetan" PHD2 polymorphism. Conclusions In addition to previously known PHD2 gene alterations, we report here the occurrence in HE patients of a novel PHD2 mutation with an autosomal-dominant inheritance likely involved in disease pathogenesis. The milder phenotypic features of this patient's daughter and sister in terms of erythocytosis, may be explained by the childbearing age and the absence of H63D SNV, respectively. The increased prevalence of HFE SNVs in patients with IE may indicate an effect of impaired iron metabolism on erythropoiesis. Our data show that the inclusion of HFE SNVs and oxygen pathway mutational analysis in the diagnostic algorithm of erythrocytosis may help to better define the genetic basis of erythrocytosis. Further studies -including the analysis of molecules involved in iron storage pathway- in larger IE patient cohorts are warranted in order to clarify the link between HFE gene and IE. Disclosures Voso: Celgene: Research Funding, Speakers Bureau.
Published: 2018

25. Frontline Dasatinib Treatment in a 'Real-Life' Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia

Author: Raffaele Porrini, Monica Bocchia, Fabio Stagno, Patrizia Pregno, Elisabetta Abruzzese, Attilio Guarini, Agostino Antolino, Mario Tiribelli, Antonella Russo Rossi, Nicola Sgherza, Malgorzata Monika Trawinska, Sabrina Leonetti Crescenzi, Gianantonio Rosti, Fausto Castagnetti, Luigiana Luciano, Massimo Breccia, Monica Crugnola, Isabella Capodanno, Roberto Latagliata, Carmen Fava, Sara Galimberti, Massimiliano Bonifacio, Costanzo Feo, Giuliana Alimena, Manuela Rizzo, Endri Mauro, Federica Sorà, Paolo Vigneri, Alessandra Iurlo, Mario Annunziata, Antonella Gozzini, Latagliata, Roberto, Stagno, Fabio, Annunziata, Mario, Abruzzese, Elisabetta, Iurlo, Alessandra, Guarini, Attilio, Fava, Carmen, Gozzini, Antonella, Bonifacio, Massimiliano, Sorà, Federica, Leonetti Crescenzi, Sabrina, Bocchia, Monica, Crugnola, Monica, Castagnetti, Fausto, Capodanno, Isabella, Galimberti, Sara, Feo, Costanzo, Porrini, Raffaele, Pregno, Patrizia, Rizzo, Manuela, Antolino, Agostino, Mauro, Endri, Sgherza, Nicola, Luciano, Luigiana, Tiribelli, Mario, Russo Rossi, Antonella, Trawinska, Malgorzata, Vigneri, Paolo, Breccia, Massimo, Rosti, Gianantonio, and Alimena, Giuliana
Subjects: Original article, Cancer Research, medicine.medical_specialty, Dasatinib, Fusion Proteins, bcr-abl, Antineoplastic Agents, Kaplan-Meier Estimate, elderly patients, lcsh:RC254-282, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, chronic myeloid leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Internal medicine, medicine, Humans, Intensive care medicine, Protein Kinase Inhibitors, In Situ Hybridization, Fluorescence, Aged, Aged, 80 and over, chronic myeloid leukemia,dsatinib,elderly patients, dsatinib, business.industry, Myeloid leukemia, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Chromosome Banding, Clinical trial, Settore MED/15 - MALATTIE DEL SANGUE, Leukemia, Treatment Outcome, 030220 oncology & carcinogenesis, Concomitant, Toxicity, Cohort, Neoplasm Grading, business, Follow-Up Studies, 030215 immunology, medicine.drug, Cohort study
Abstract: Dasatinib (DAS) has been licensed for the frontline treatment in chronic myeloid leukemia (CML). However, very few data are available regarding its efficacy and toxicity in elderly patients with CML outside clinical trials. To address this issue, we set out a "real-life" cohort of 65 chronic phase CML patients older than 65 years (median age 75.1 years) treated frontline with DAS in 26 Italian centers from June 2012 to June 2015, focusing our attention on toxicity and efficacy data. One third of patients (20/65: 30.7%) had 3 or more comorbidities and required concomitant therapies; according to Sokal classification, 3 patients (4.6%) were low risk, 39 (60.0%) intermediate risk, and 20 (30.8%) high risk, whereas 3 (4.6%) were not classifiable. DAS starting dose was 100 mg once a day in 54 patients (83.0%), whereas 11 patients (17.0%) received less than 100 mg/day. Grade 3/4 hematologic and extrahematologic toxicities were reported in 8 (12.3%) and 12 (18.5%) patients, respectively. Overall, 10 patients (15.4%) permanently discontinued DAS because of toxicities. Pleural effusions (all WHO grades) occurred in 12 patients (18.5%) and in 5 of them occurred during the first 3 months. DAS treatment induced in 60/65 patients (92.3%) a complete cytogenetic response and in 50/65 (76.9%) also a major molecular response. These findings show that DAS might play an important role in the frontline treatment of CML patients >65 years old, proving efficacy and having a favorable safety profile also in elderly subjects with comorbidities.
Published: 2016

26. A case of oral mycosis fungoides successfully treated by combination of alemtuzumab and chemotherapy

Author: Francesco Buccisano, Luca Franceschini, E. Bruno, Massimiliano Postorino, Daniela Nasso, Ida Provenzano, I. Onnis, M. I. Del Principe, S. Mauramati, S. Amadori, Federico Meconi, Manuela Rizzo, Lucia Anemona, Sara Vaccarini, Livio Pupo, Annagiulia Zizzari, and Maria Cantonetti
Subjects: Mouth neoplasm, Oncology, medicine.medical_specialty, Chemotherapy, Mycosis fungoides, Pathology, Vincristine, Cyclophosphamide, business.industry, medicine.medical_treatment, Hematology, General Medicine, medicine.disease, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Prednisolone, Medicine, Alemtuzumab, business, Settore MED/15 - Malattie del Sangue, Etoposide, medicine.drug
Published: 2016

27. Minimal tumour burden in haematological diseases: a step forward with quantitative assessment of Bence-Jones in nephelometry?

Author: Maria Cantonetti, Manuela Rizzo, Mariarita Dessì, Sergio Bernardini, Rossella Zenobi, Massimo Pieri, Luca Franceschini, Fabio Duranti, and Alessandro De Stefano
Subjects: Male, Pathology, medicine.medical_specialty, Tumor burden, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Nephelometry and Turbidimetry, Quantitative assessment, Medicine, Humans, amyloidosis, biology, business.industry, Amyloidosis, Settore BIO/12, Hematology, blood diseases, medicine.disease, Minimal residual disease, Hematologic Diseases, Bence Jones protein, Tumor Burden, myeloma, 030220 oncology & carcinogenesis, biology.protein, minimal residual disease, Female, Antibody, business, immunoglobulin, Bence Jones Protein, Nephelometry
Published: 2016

28. Early Autologous Stem-Cell Transplantation Versus Conventional Chemotherapy as Front-Line Therapy in High-Risk, Aggressive Non-Hodgkin’s Lymphoma: An Italian Multicenter Randomized Trial

Author: Sante Tura, Filippo Gherlinzoni, Amalia De Renzo, Luciano Moretti, Vito Michele Lauta, Giovanna Meloni, Patrizio Mazza, Franco Mandelli, Maria Cantonetti, Antonio De Vivo, Maurizio Martelli, Francesco Lauria, Brunangelo Falini, Manuela Rizzo, Edoardo Pescarmona, Sergio Storti, S. A. Pileri, Anna Lia Molinari, Luciano Guardigni, and Pier Luigi Zinzani
Subjects: Male, Cancer Research, Settore MED/06 - Oncologia Medica, medicine.medical_treatment, COMBINATION CHEMOTHERAPY, Leucovorin, Aggressive lymphoma, M-BACOD, MACOP-B, HIGH-DOSE CHEMOTHERAPY, International Prognostic Index, Autologous stem-cell transplantation, Antineoplastic Combined Chemotherapy Protocols, Medicine, Lymphoma, Non-Hodgkin, BONE-MARROW TRANSPLANTATION, Middle Aged, Treatment Outcome, Oncology, Vincristine, Female, medicine.drug, Adult, medicine.medical_specialty, Adolescent, Transplantation, Autologous, CLASSIFICATION, Disease-Free Survival, Bleomycin, Humans, Cyclophosphamide, PROGNOSTIC INDEX, Chemotherapy, business.industry, STANDARD REGIMEN CHOP, medicine.disease, INTENSIVE CHEMOTHERAPY, Non-Hodgkin's lymphoma, Surgery, Transplantation, Regimen, Methotrexate, Doxorubicin, Prednisone, business, Settore MED/15 - Malattie del Sangue, Follow-Up Studies, Stem Cell Transplantation
Abstract: Purpose: To evaluate the role of early intensification with high-dose therapy (HDT) and autologous stem-cell transplantation (ASCT) as front-line chemotherapy for patients with high-risk, histologically aggressive non-Hodgkin’s lymphoma (NHL). Patients and Methods: We planned a multicenter, randomized trial to compare a conventional chemotherapy regimen of methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin (MACOP-B; arm A) with an abbreviated regimen of MACOP-B (8 weeks) followed by HDT and ASCT (arm B) for intermediate-high-risk/high-risk patients (according to the age-adjusted International Prognostic Index). From September 1994 to April 1998, 150 patients with aggressive lymphoma were enrolled onto the trial. Seventy-five patients were randomly assigned to arm A and 75 patients were randomly assigned to arm B. In both arms, involved-field radiation therapy (36 Gy) was delivered to the site of bulky disease. Results: The rate of complete response was 68% in arm A and 76% in arm B (P = not significant [NS]). Three toxic deaths (4%) occurred in arm B and one (1%) occurred in arm A (P = NS). In arm B, 30 patients (40%) did not undergo HDT and ASCT. According to the intention-to-treat analysis at a median follow-up of 24 months, 5-year overall survival probability in arms A and B was 65% and 64% (P = .95), 5-year progression-free survival was 49% and 61% (P = .21), and 5-year relapse-free survival was 65% and 77% (P = .22), respectively. Conclusion: Abbreviated chemotherapy followed by intensification with HDT-ASCT is not superior to conventional chemotherapy in patients with high-risk, aggressive NHL. Additional randomized trials will clarify whether HDT-ASCT as front-line therapy after a complete course of conventional chemotherapy improves survival in this group of patients.
Published: 2003

29. Bone Marrow Angiogenic Potential and Molecular Expression of Cell-Cell Adhesion Molecules and Matrix-Metallo Proteinases in Multiple Myeloma

Author: Francesco Lo-Coco, Luca Franceschini, Federico Meconi, Massimiliano Postorino, Manuela Rizzo, I. Onnis, Sara Vaccarini, R Cerretti, T.M. Suarez Viguria, Maria Cantonetti, Benedetta Mariotti, Livio Pupo, G De Angelis, L. Cicconi, Cristiano Ialongo, and Maria Cristina Rapanotti
Subjects: Cancer Research, Cell adhesion molecule, business.industry, Cell, Hematology, Matrix (biology), medicine.disease, Cell biology, medicine.anatomical_structure, Oncology, medicine, Bone marrow, business, Multiple myeloma
Published: 2015

30. Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study

Author: Francesco Pisani, Antonietta Falcone, Anna Marina Liberati, Tommaso Caravita, Massimo Massaia, Federica Cavallo, Vincenzo Callea, Roberto Ria, Mariella Grasso, Pellegrino Musto, Manuela Rizzo, Mario Boccadoro, Valerio De Stefano, Clotilde Cangialosi, Maria Teresa Petrucci, Andrea Nozza, Luciana Annino, A. Gabbas, Ileana Baldi, Antonio Palumbo, Benedetto Bruno, Giovanna Meloni, Patrizia Pregno, Sara Bringhen, and Anna Levi
Subjects: Melphalan, Male, Transplantation Conditioning, Adult, Aged, Algorithms, Antigens, CD34, Antineoplastic Agents, Alkylating, Bone Marrow Transplantation, Combined Modality Therapy, Dose-Response Relationship, Drug, Female, Humans, Middle Aged, Multiple Myeloma, Myeloablative Agonists, Neoadjuvant Therapy, Transplantation, Autologous, medicine.medical_treatment, Phases of clinical research, Biochemistry, Gastroenterology, Multiple myeloma, INDUCTION, Hematology, CHEMOTHERAPY, Alkylating, SURVIVAL, Drug, Autologous, medicine.drug, medicine.medical_specialty, Immunology, STEM-CELL TRANSPLANTATION, MULTIPLE-MYELOMA, RANDOMIZED-TRIAL, THALIDOMIDE, BORTEZOMIB, REGIMENS, Antineoplastic Agents, Neutropenia, Dose-Response Relationship, Internal medicine, medicine, Mucositis, Autologous transplantation, Antigens, Chemotherapy, Transplantation, business.industry, Cell Biology, medicine.disease, Surgery, CD34, business
Abstract: High-dose (200 mg/m2, MEL200) and intermediate-dose melphalan (100 mg/m2, MEL100) showed significant activity in myeloma. In a phase 3 study, 298 patients were randomly assigned to receive 2 autologous transplantations after conditioning with MEL200 or MEL100. Ninety-six of 149 (64%) completed MEL200 and 103 of 149 (69%) MEL100. Best response to MEL200 was: complete remission 22 of 149 (15%); partial remission 95 of 149 (64%), for an overall response rate of 79%. Best response to MEL100 was: complete remission 12 of 149 (8%); partial remission 95 of 149 (64%), for an overall response rate of 72%. Overall survival did not differ (P = .13); median progression-free survival (31.4 vs 26.2 months, P = .01), median time to progression (34.4 vs 27.0 months, P = .014) were longer in the MEL200. Treatment-related mortality was 3.1% in the MEL200 and 2.9% in the MEL100 group. Severe neutropenia and infections were marginally superior, whereas severe thrombocytopenia, mucositis, gastrointestinal adverse events, and the overall occurrence of at least 1 nonhematologic grade 3 or 4 adverse event were significantly higher in the MEL200 cohort. We conclude that MEL200 leads to longer remission duration and should be considered the standard conditioning regimen for autologous transplantation. This study was registered at www.clinicaltrials.gov as #NCT00950768.
Published: 2010

31. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial

Author: Antonietta Falcone, Antonio Palumbo, Massimo Offidani, Mariella Grasso, Francesca Patriarca, Luca Baldini, Giovannino Ciccone, Vincenzo Callea, Sara Bringhen, Fortunato Morabito, Maide Cavalli, Giovanna Leonardi, Giulia Benevolo, Roberto Ria, Mario Boccadoro, Davide Rossi, Tommasina Guglielmelli, Manuela Rizzo, Alessandra Larocca, Vittorio Montefusco, Daniela Gottardi, Maria Teresa Petrucci, Pellegrino Musto, and Chiara Nozzoli
Subjects: Oncology, Melphalan, Cancer Research, medicine.medical_specialty, Kaplan-Meier Estimate, Disease-Free Survival, Bortezomib, Prednisone, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Multiple myeloma, Proportional Hazards Models, business.industry, Hazard ratio, medicine.disease, Boronic Acids, Thalidomide, Surgery, Transplantation, Treatment Outcome, Pyrazines, Proteasome inhibitor, Multiple Myeloma, business, medicine.drug
Abstract: Purpose The combination of bortezomib-melphalan-prednisone (VMP) is a new standard of care for newly diagnosed multiple myeloma. This phase III study examined the efficacy of the four-drug combination of bortezomib-melphalan-prednisone-thalidomide (VMPT) followed by maintenance with bortezomib-thalidomide (VMPT-VT) compared with VMP treatment alone in untreated multiple myeloma patients who are ineligible for autologous stem-cell transplantation. Patients and Methods A total of 511 patients were randomly assigned to receive nine cycles of VMPT followed by continuous VT as maintenance, or nine cycles of VMP at the same doses with no additional therapy. The primary end point was progression-free survival. Results The 3-year estimates of progression-free survival were 56% in patients receiving VMPT-VT and 41% in those receiving VMP (hazard ratio [HR], 0.67; 95% CI, 0.50 to 0.90; P = .008). At 3 years, the cumulative proportions of patients who did not go on to the next therapy were 72% with VMPT-VT and 60% with VMP (HR, 0.58; 95% CI, 0.50 to 0.90; P = .007). Complete response rates were 38% in the VMPT-VT group and 24% in the VMP group (P < .001). The 3-year overall survival was 89% with VMPT-VT and 87% with VMP (HR, 0.92; 95% CI, 0.53 to 1.60; P = .77). Grade 3 to 4 neutropenia (38% v 28%; P = .02), cardiologic events (10% v 5%; P = .04), and thromboembolic events (5% v 2%; P = .08) were more frequent among patients assigned to the VMPT-VT group than among those assigned to the VMP group; treatment-related deaths were 4% with VMPT-VT and 3% with VMP. Conclusion VMPT followed by VT as maintenance was superior to VMP alone in patients with multiple myeloma who are ineligible for autologous stem-cell transplantation.
Published: 2010

32. Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Followed by Maintenance with Bortezomib and Thalidomide for Initial Treatment of Elderly Multiple Myeloma Patients

Author: Manuela Rizzo, Francesca Patriarca, Vincenzo Callea, Roberto Marasca, Giuseppe Pietrantuono, Antonio Palumbo, Sara Bringhen, Pellegrino Musto, Mario Boccadoro, Francesco Di Raimondo, Barbara Olivero, Caterina Musolino, Chiara Nozzoli, Tommasina Guglielmelli, Giovannino Ciccone, Giulia Benevolo, Renato Zambello, Maria Teresa Petrucci, Mariella Grasso, Massimo Offidani, Clotilde Cangialosi, Roberto Ria, Fortunato Morabito, Anna Levi, Antonietta Falcone, Daniela Gottardi, Valeria Magarotto, Gianluca Gaidano, Davide Rossi, and Vittorio Montefusco
Subjects: Melphalan, medicine.medical_specialty, Intention-to-treat analysis, business.industry, Bortezomib, Immunology, Cell Biology, Hematology, medicine.disease, Biochemistry, Thalidomide, Regimen, Prednisone, Internal medicine, Medicine, business, Multiple myeloma, medicine.drug, Lenalidomide
Abstract: Abstract 128 Background. In newly diagnosed myeloma patients the combination of bortezomib with melphalan-prednisone (VMP) was superior to MP. In relapsed-refractory patients the 4 drug combination bortezomib-melphalan-prednisone-thalidomide (VMPT) induced a high proportion of complete responses (CR). Aims. This prospective, randomized, phase III trial, compared VMPT with a maintenance regimen including bortezomib and thalidomide with VMP without a maintenance regiment. The primary end point was PFS. Methods. Patients (N=511) older than 65 years were randomly assigned to receive VMPT followed by maintenance with bortezomib and thalidomide (N=254) or VMP (N=257). Initially, patients were treated with nine 6-week cycles of VMPT (induction: bortezomib 1.3 mg/m2 days 1,4,8,11,22,25,29,32 in cycles 1–4 and days 1,8,22,29 in cycles 5–9; melphalan 9 mg/m2 days 1–4; prednisone 60 mg/m2 days 1–4 and thalidomide 50 mg days 1–42; maintenance: bortezomib 1.3 mg/m2 every 15 days and thalidomide 50 mg/day) or VMP (bortezomib, melphalan and prednisone at the same doses and schedules previously described without maintenance). In March 2007, the protocol was amended: both VMPT and VMP induction schedules were changed to nine 5-week cycles and bortezomib schedule was modified to weekly administration (1.3 mg/m2 days 1,8,15,22 in cycles 1–9). Results. All patients have been evaluated in intention-to-treat. Patient characteristics were similar in both groups, median age was 71 years. The response rates were always superior in the VMPT group: at least PR rate (86% vs 79%, p=0.02), at least VGPR rate (55% vs 47%, p=0.07) and CR rate (34% vs 21% p=0.0008), respectively. Maintenance treatment did not increase the best response achieved during VMPT induction. After a median follow-up of 17.8 months, the 2-year PFS was 70.0% in the VMPT group and 58.2% in the VMP group (HR=0.62, 95% CI 0.44–0.88, p=0.008). The achievement of CR significantly prolonged PFS in both VMPT (p Disclosures: Palumbo: Janssen-Cilag: Honoraria; Celgene: Honoraria. Off Label Use: thalidomide, lenalidomide, bortezomib . Bringhen:Celgene: Honoraria; Janssen Cilag: Honoraria. Patriarca:Janssen Cilag: Honoraria; Celgene: Honoraria. Petrucci:Celgene: Honoraria; Janssen-Cilag: Honoraria. Musto:Janssen Cilag: Honoraria; Celgene: Honoraria. Boccadoro:Celgene: Consultant, advisory committee, Research Funding; Janssen Cilag: Consultant, advisory committee, Research Funding; Pharmion: Consultant, advisory committee, Research Funding.
Published: 2009

33. Pegylated Liposomal Doxorubicin, Bleomycin, Vinblastine and Dacarbazine (CBVD) in the treatment of advanced primary cutaneous lymphomas

Author: Maria Cantonetti, Giuseppe Alfonso Lombardo, Manuela Rizzo, Sara Vaccarini, Malgorzata Monika Trawinska, Livio Pupo, Elisabetta Abruzzese, Lucia Anemona, Massimiliano Postorino, Roberta Cannarsa, Micol Quaresima, Alessandra Spagnoli, Tullio Faraggiana, and Daniela Renzi
Subjects: medicine.medical_specialty, Mycosis fungoides, business.industry, Dacarbazine, Immunology, macromolecular substances, Cell Biology, Hematology, medicine.disease, Biochemistry, Gastroenterology, Lymphoma, Vinblastine, Transplantation, Median follow-up, Internal medicine, medicine, Rituximab, business, Progressive disease, medicine.drug
Abstract: Abstract 3717 Poster Board III-653 Introduction Primary cutaneous lymphomas (PCL) present in the majority of histologic variants an indolent behaviour and a good prognosis with a prolonged survival. In a very small number of patients (pts), PCL is aggressive at the onset while in pts who are resistant or have relapsed after repeated topic or systemic therapies an advanced disease is more frequently observed. In these patients no therapy is capable of inducing a stable remission of the disease. The efficacy and low toxicity of Pegylated Liposomal Doxorubicin (PLD) as a single agent in second-line therapy of PCL was recently demonstrated. In our study we tested the safety and efficacy of PLD (Caelyx®) (C) in association with three drugs of proven effectiveness in nodal lymphoprolipherative and other primary cutaneous neoplastic disorders: Bleomycin (B), Vinblastine (B) and Dacarbazine (D) (CBVD). Patients and Methods From February 2003 to December 2008 we observed 37 consecutive pts with advanced PCL: 19 Cutaneous T-Cell Lymphomas (CTCL) and 18 cutaneous B-Cell Lymphomas (CBCL). The CTCL pts were: 15 males and 4 females, with median age 59 (27-86) years, of which 7 pts with Anaplastic Large Cell Lymphoma (ALCL) CD30 positive, 7 pts with transformed Mycosis Fungoides (tMF), 3 pts with CD30 negative ALCL, 1pt with Panniculitis-like (Pl) Lymphoma and 1 pt with transformed Sezary Syndrome (tSS), according to the WHO-EORTC consensus classification. Nine pts presented with a nodal involvement and 10 pts were resistant or relapsed after 1 or more systemic treatments. Among the CBCL pts there were: 8 males and 10 females, with median age 61 (42-84) years, 12 pts had a Follicular Centre Lymphoma (FCL), 3 a Marginal Zone Lymphoma (MZL) and 3 a Diffuse Large B-Cell Lymphoma Leg Type (LT). Five pts presented a nodal involvement and 11 pts had received 1 or more previous systemic therapy. All 37 pts received CBVD therapy at following dosage: C: 20 mg/m2, B: 10 mg/m2, V: 6 mg/m2, D: 325 mg/m2 at days 1 and 15, administered intravenously every 4 weeks for a maximum of 6 cycles. Rituximab (R) at dosage of 375 mg/m2 was administered to CBCL pts at 1st day of each cycle. Before the treatment, pts were submitted to a complete staging of disease including TC-scan, bone marrow biopsy, and immunophenotyping of peripheral blood cells. Results In the CTCL group 4 pts received 4 CBVD cycles, 14 pts received 6 CBVD cycles and 1 pt presented a progressive disease after the 1st cycle. Overall Response Rate (ORR) was 94.7% (18/19 pts). Sixteen out of 18 pts (88.8%) had a Complete Remission (CR) with disappearance of nodal involvement and cutaneous lesions, 2/18 pts obtained a Partial Remission (PR) with disappearance of nodal involvement and 75% of cutaneous lesions. In the CBCL group 3 pts received 2 R-CBVD cycles, 3 pts 4 cycles and 11 pts 6 cycles: ORR was 100% and all pts obtained a CR. The occurrence of palmoplantar erytrodisesthesia in 5 pts and grade 2-3 granulocytopenia in 12 pts did not modify the therapy program. Two CTCL pts (1 tSS, 1Pl) and 1 CBCL (LT) pt in CR after therapy received an allogeneic Hemopoietic Stem Cells (HCS) transplant and 1 CBCL(FCL) pt a syngeneic HCS transplant. In CTCL group 11 (61%) pts maintained their response after a median follow up of 15.5 (9-71) months. Among CBCL pts 14 (77.7%) pts are still in CR after a median follow up of 15 (4-36) months. Conclusions Our experience demonstrates that the CBVD association is an effective and safe therapy for advanced PCL in inducing an important tumour burden reduction with a high CR rate. The assessment of response duration requires a longer observation. A larger number of patients in a multicentric trial are needed to confirm our promising results. Disclosures: Off Label Use: liposomial doxorubicin has a peculiar cutaneous tropism and low cardiac toxicity compared with other anthracyclines.
Published: 2009

34. A Prospective, Randomized, Phase III Study of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Versus Bortezomib, Melphalan and Prednisone (VMP) in Elderly Newly Diagnosed Myeloma Patients

Author: Davide Rossi, Roberto Ria, Giulia Benevolo, Mariella Grasso, Roberto Marasca, Mario Boccadoro, Francesco Di Raimondo, Gianluca Gaidano, Valeria Magarotto, Tommasina Guglielmelli, Sara Bringhen, Manuela Rizzo, Francesca Patriarca, Vincenzo Callea, Antonio Palumbo, Massimo Offidani, Maria Teresa Petrucci, Chiara Nozzoli, and Paola Omedè
Subjects: Melphalan, medicine.medical_specialty, Intention-to-treat analysis, business.industry, Surrogate endpoint, Bortezomib, Immunology, Cell Biology, Hematology, Neutropenia, medicine.disease, Biochemistry, Gastroenterology, Surgery, Thalidomide, Prednisone, Internal medicine, medicine, business, Adverse effect, medicine.drug
Abstract: Background: In newly diagnosed myeloma patients the combination of bortezomib with melphalan-prednisone (VMP) was superior to MP. In relapsed-refractory patients the 4 drug combination of bortezomib-melphalan-prednisone-thalidomide (VMPT) induced a high proportion of complete responses (CR). Methods: Newly diagnosed myeloma patients (N=393) older than 65 years, from 58 centers in Italy, were randomly assigned to receive VMPT (N=193) or VMP (N=200). Initially, patients were treated with nine 6-week cycles of VMPT (bortezomib 1.3 mg/m2 days 1,4,8,11,22,25,29,32 in cycles 1–4 and days 1,8,22,29 in cycles 5–9; melphalan 9 mg/m2 days 1–4; prednisone 60 mg/m2 days 1–4 and thalidomide 50 mg days 1–42, followed by bortezomib 1.3 mg/m2 every 15 days and thalidomide 50 mg/day as maintenance) or VMP (bortezomib, melphalan and prednisone at the same doses and schedules previously described without maintenance). In March 2007, the protocol was amended: both VMPT and VMP schedules were changed to nine 5-week cycles and bortezomib schedule was modified to weekly administration (bortezomib 1.3 mg/m2 days 1,8,15,22 in cycles 1–9). Primary end-point was progression-free survival (PFS). Results: Patient characteristics were similar in both groups: median age was 71 years, 23% of patients were aged > 75 years. Patients who received at least 1 cycle were evaluated: 152 patients for VMPT (62 received bortezomib bi-weekly infusion and 90 weekly infusion) and 152 patients for VMP (62 received bortezomib bi-weekly infusion and 90 weekly infusion). Data were analyzed in intention-to-treat. The very good partial response (VGPR) rate was higher in the VMPT group (55% versus 42%, p=0.02), including a CR rate of 31% in the VMPT group and 16% in the VMP group (p=0.003). In the subgroup treated with weekly infusion of bortezomib, VGPR was 59% for VMPT and 37% for VMP (p=0.004), including 28% CR for VMPT and 10% for VMP (p=0.004). Subgroup analyses did not show any statistical difference between responses and either age, B2-microglobulin or chromosomal abnormalities, such as del13, t(4;14), t(14;16) and del17. After a median follow-up of 13.6 months, the 2-year PFS was 83.9% in the VMPT group and 75.7% in the VMP group (HR=0.73, 95% CI 0.38–1.42, p=0.35). In patients who received weekly infusion of bortezomib, the 2-year PFS was 86.8% in the VMPT group and 78.1% in the VMP group (HR=0.65, 95% CI 0.24–1.8, p=0.41). In patients who achieved CR after induction, the 2-year PFS was 100% for VMPT and 79% for VMP (p=0.02). The 3-year overall survival (OS) was 89.5% in the VMPT group and 88.7% in the VMP group (HR=1.02, 95% CI 0.43–2.46, p=0.96). The incidence of grade 3–4 adverse events (AEs) was similar in both groups. In the VMPT patients and in the VMP patients, the more frequent AEs were neutropenia (36% vs 31%), thrombocytopenia (20% vs 19%), peripheral neuropathy (18% vs 12%), infections (14% vs 10%), and gastrointestinal complications (7% vs 8%), respectively. The weekly infusion of bortezomib significantly decreased the incidence of grade 3–4 peripheral neuropathy (9% for VMPT and 3% for VMP). Conclusion: VMPT is superior to VMP in terms of response rates. Longer follow-up is needed to assess their effects on PFS and OS. The weekly infusion of bortezomib significantly reduced the incidence of grade 3–4 peripheral neuropathy without influencing outcome. Table. Complete responses, progression-free survival and peripheral neuropathy in all patients and in those who received weekly infusion of bortezomib VMPT group (n=152) VMP group (n=152) All patients (n=152) Subgroup with bortezomib weekly infusion (n=90) All patients (n=152) Subgroup with bortezomib weekly infusion (n=90) CR rate (%) 31 28 16 10 2-year PFS (%) 84 87 76 78 Grade 3–4 peripheral neuropathy (%) 18 9 12 3
Published: 2008

35. Neuropathy in multiple myeloma patients treated with bortezomib: A multicenter experience

Author: Patrizia Falco, Vincenzo Federico, Maria Teresa Petrucci, Manuela Rizzo, Agostina Siniscalchi, Massimo Offidani, Alessandra Spagnoli, Antonio Palumbo, Tommaso Caravita, and Paolo de Fabritiis
Subjects: medicine.medical_specialty, Chemotherapy, Bortezomib, business.industry, medicine.medical_treatment, Immunology, Cell Biology, Hematology, medicine.disease, Biochemistry, Gastroenterology, Surgery, Discontinuation, Thalidomide, Peripheral neuropathy, Internal medicine, medicine, Proteasome inhibitor, business, Multiple myeloma, Dexamethasone, medicine.drug
Abstract: INTRODUCTION: Bortezomib (B) is the first proteasome inhibitor to be used in clinical practice and has been recently approved for second line treatment of multiple myeloma (MM) patients(pts). Several trials demonstrated that Bortezomib is relatively well tolerated; however, manageable non-hematologic and hematologic toxicity has been reported. The dose limiting toxicity is peripheral neuropathy (PN), reported up to 35% of the patient population. AIM: We evaluated the incidence and severity of PN in 179 MM patients that received B as single agent or in combination. MATERIAL AND METHODS: Patients characteristics were as follows: median age was 66.7 years (range: 32–82) with 52% male; 55 patients were at the onset of the disease, 124 were pre-treated. Median time from diagnosis to treatment with B was 25.4 months (range 0–111), median value of β2-microglobulin was 3.02 (0.2–20). Risk factors for PN included prior use of thalidomide in 68 patients (38%), vincristine in 75 patients (41.8%) and 15 patients (8.8%) had diabetes mellitus. RESULTS: Patients received bortezomib alone (?) or in combination with either dexamethasone (n=52), or chemotherapy (n=114) or thalidomide (n=38). Overall, the response rate (≥PR) was 86%. PN of grade ≥2 was observed in 73 pts (41%); grade 3–4 occurred in 32 (18%). Median time to the onset of bortezomib-related PN was 84 days (range, 10–449) after bortezomib initiation. In most cases (93%), patients had sensory symptoms, while 5 patients (7%) experienced both sensory and motor symptoms. Bortezomib-related PN led to therapy discontinuation in 31 pts (17%). For PN treatment, pts received mostly supportive therapy (analgesics, gabapentin, pregabalin, amitriptyline and vitamin supplements). Of the 31 patients with bortezomib-related PN that required discontinuation, resolution or improvement occurred in 16 (51.6%), at a median time of 140 days (range, 27–346) from B discontinuation. Data analysis of the PN risk factors (age, diabetes, sex, β2M, neurotoxic pre-treatment) showed a significant association with age >75 years (p CONCLUSIONS: In our experience, PN is a relatively frequent side effect of bortezomib treatment, generally manegeable by dose reduction or discontinuation and reversible in the majority of pts. Patients with advanced age can be considered at higher risk, while the combination of thalidomide and bortezomib did not increase the risk of PN. Further studies are needed to better define the PN pathogenesis and develop optimal strategies to improve the B related PN management.
Published: 2007

36. Intravenous Administration of Rituximab in the Treatment of Primary Cutaneous B-Cell Lymphomas (PCBCLs): A Retrospective Study

Author: Ida Provenzano, Livio Pupo, Massimiliano Postorino, Lucia Anemona, Cecilia Angeloni, Daniela Nasso, Sara Vaccarini, Annagiulia Zizzari, Giuseppe Alfonso Lombardo, Giovangiacinto Paterno, Manuela Rizzo, Maria Cantonetti, Alessandro Mauriello, Enrico Scala, Luca Franceschini, Laura Giannì, and Lorenzo Tonialini
Subjects: medicine.medical_specialty, business.industry, medicine.medical_treatment, Immunology, Follicular lymphoma, Retrospective cohort study, Cell Biology, Hematology, medicine.disease, Biochemistry, Gastroenterology, Lymphoma, Surgery, Radiation therapy, Internal medicine, Medicine, Rituximab, Stage (cooking), business, Adverse effect, Diffuse large B-cell lymphoma, medicine.drug
Abstract: Introduction. Rituximab has been demonstrated to be effective either as intralesional or as systemic therapy in PCBCL, We report our experience in the treatment of PCBCL with intravenous Rituximab. P atients and Methods From February 1999 to February 2014 we treated 75 patients: 47 Follicle Center Lymphoma, 23 Marginal Zone Lymphoma, 5 Diffuse Large Lymphoma Leg type. The stage was T1 in 38 pts, T2 in 22 pts and T3 in 15 pts. In 24 patient prior treatment included: CHT (11), Radiotherapy (4), Surgery (4) or alpha2Interferon (IFN) (5). Rituximab at dosage of 375 mg/m2 for a minimum of 4 cycles, was administered alone (51 patients) or in association with CHT (13). RT (2) or IFN (3). Results. No patient presented adverse effects during the Rituximab infusion. A reduction of circulating B lymphocytes was observed for 11 months, on the average, without an increased risk of infections. No added toxicity was observed in patients treated with Rituximab plus CHT. Overall response rate was 97,3% (CR 82,6 %, PR 14,6 %). Five–years Overall Survival (OS) was 86,9% with Disease Free Survival of 57%. According to stage OS was in T1 94,3%, in T2 90,5%, in T3 73,6%. (T1+T2 vs T3: p Conclusions. Rituximab is effective and safe in the treatment of PCBCL even in heavily-treated or elderly patients. In our patients only the stage of disease was significant for the prognosis. A higher number of patients are necessary to indicate Rituximab in biological and clinical subsets of patients as a front-line therapy. Disclosures No relevant conflicts of interest to declare.
Published: 2014

37. A141 Enoxaparin Versus Aspirin Versus Low-Fixed-Dose Warfarin in MM Patients Treated Up Front with Thalidomide

Author: Luca Baldini, Claudia Crippa, A. Palumbo, Chiara Nozzoli, Annamaria Brioli, Francesca Patriarca, Massimo Offidani, Roberto Marasca, Roberto Ria, S Bringhen, Mario Boccadoro, Monica Galli, M.T. Petrucci, Norbert Pescosta, F. Di Raimondo, Manuela Rizzo, Vincenzo Callea, Elena Zamagni, Michele Cavo, and Gianluca Gaidano
Subjects: Cancer Research, medicine.medical_specialty, Aspirin, business.industry, Urology, Warfarin, Hematology, General Medicine, Fixed dose, Thalidomide, Oncology, medicine, business, Front (military), medicine.drug
Published: 2009

38. P086 Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphopma: unicentric experience

Author: Concetta Ditto, Giuseppe Alfonso Lombardo, W. Renzi, Luca Franceschini, S. Faccia, Massimiliano Postorino, Maria Cantonetti, Manuela Rizzo, R Cerretti, L. Di Caprio, Laura Cudillo, Livio Pupo, G De Angelis, Laura Giannì, D. Arcese, and B. Didona
Subjects: Transplantation, Cancer Research, medicine.anatomical_structure, Oncology, business.industry, T cell, medicine, Cancer research, Hematology, Stem cell, business
Published: 2007

39. Overall Survival Benefit for Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance with Bortezomib-Thalidomide (VMPT-VT) Versus Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients

Author: Fortunato Morabito, Maide Cavalli, Valeria Magarotto, Anna Levi, Caterina Musolino, Luca Baldini, Chiara Pautasso, Mariella Grasso, Maria Teresa Petrucci, Davide Rossi, Donatella Vincelli, Vittorio Montefusco, Giulia Benevolo, Paola Omedè, Roberto Ria, Antonio Palumbo, Anna Marina Liberati, Pellegrino Musto, Clotilde Cangialosi, Chiara Nozzoli, Manuela Rizzo, Francesca Patriarca, Giovanna Mansueto, Antonietta Falcone, Sara Bringhen, Daniela Gottardi, Roberto Marasca, Mario Boccadoro, Tommasina Guglielmelli, and Silvia Gentilini
Subjects: Melphalan, education.field_of_study, medicine.medical_specialty, business.industry, Bortezomib, Immunology, Population, Salvage therapy, Cell Biology, Hematology, medicine.disease, Biochemistry, Surgery, Thalidomide, Prednisone, Internal medicine, medicine, education, business, Adverse effect, Multiple myeloma, medicine.drug
Abstract: Abstract 200 Background: In a multicenter phase 3 randomized trial, VMPT-VT was superior to VMP for response rates, progression-free survival and time to next treatment (Palumbo A, et al. J Clin Oncol 2010). Here we report an updated analysis on survival after 4 years of follow-up. Methods: Patients (N=511) were randomly assigned to receive nine 6-week cycles of VMPT-VT (induction: bortezomib 1.3 mg/m2, d 1, 4, 8, 11, 22, 25, 29, 32, cycles 1–4, d 1, 8, 22, 29, cycles 5–9; melphalan 9 mg/m2 d 1–4, prednisone 60 mg/m2, d 1–4, thalidomide 50 mg d 1–42; maintenance: bortezomib 1.3 mg/m2 every 14 days and thalidomide 50 mg/day up to 2 years) or VMP alone. After the inclusion of 139 patients, the protocol was amended: both VMPT-VT and VMP induction schedules were changed to nine 5-week cycles and bortezomib schedule was modified to weekly administration (1.3 mg/m2 d 1,8,15,22, all cycles). Results: After a median follow-up of 47.2 months, median OS was not reached in the VMPT-VT arm and was 58.2 months in the VMP arm; 5-year OS rates were 59.3% and 45.9%, respectively (HR 0.74, p=0.04), with 26% reduced risk of death for patients receiving VMPT-VT (Figure-panel A). This benefit was more evident in patients younger than 75 years (5-year rates 67.8% for VMPT-VT vs 49.9% for VMP, HR 0.63, p=0.01, Figure-panel B) and in patients in complete response (CR) after induction (5-year rates 81.4% for VMPT-VT vs 48.2% for VMP, HR 0.38, p=0.006, Figure-panel C) while no significant differences were evident in patients with standard- or high-risk features detected by FISH (HR 0.99, p=0.99). A 1-year landmark analysis for patients completing induction was performed: the 4-year OS was 64.6% in the VMPT-VT group and 49.7% in the VMP group, with 33% reduced the risk of death for patients receiving VT maintenance (HR 0.67, p=0.02). Forty-nine percent of VMPT-VT and 70% of VMP patients relapsed and received subsequent salvage therapies; there was no difference in survival from relapse in the two groups (2-year OS rates 40.7% vs 50.2%,HR 1.11, p=0.54). The median duration of VT maintenance was 23.8 months. During VT maintenance 7% of patients experienced grade 3–4 peripheral neuropathy, 5% grade 3–4 hematological toxicity, 3% grade 3–4 infection and 12% discontinued due to adverse events. Second primary malignancies were reported in 7/254 patients in the VMPT-VT group and 7/257 patients in the VMP group. These corresponded to incidence rates of 0.9 and 1.05 per 100 patient-years, respectively, and were consistent with background incidence rates in the general population (aged 65–74 years 1.9, aged ≥ 75 years 2.3, SEER database). Conclusions: VMPT-VT significantly prolonged OS compared with VMP, especially in patients younger than 75 years and in patients achieving CR after induction. In patients 67–75 years of age, VMPT-VT reduced the risk of death by 37% and it should be considered a new standard of care. Disclosures: Palumbo: Celgene: Advisory Board, Advisory Board Other, Consultancy, Honoraria; Janssen: Advisory Board Other, Consultancy, Honoraria. Bringhen:Janssen: Honoraria; Celgene: Honoraria. Gentilini:Janssen: Honoraria; Celgene: Honoraria. Patriarca:Janssen: Honoraria. Guglielmelli:Janssen: Honoraria; Celgene: Honoraria. Musto:Janssen: Honoraria, Research Funding; Celgene: Honoraria, Research Funding. Petrucci:Janssen: Honoraria; Celgene: Honoraria. Boccadoro:Janssen: Consultancy, Research Funding, Scientific Advisory Board Other; Celgene: Consultancy, Research Funding, Scientific Advisory Board, Scientific Advisory Board Other.
Published: 2012

40. Achievement of Complete Response Is a Strong Prognostic Factor In Elderly Newly Diagnosed Myeloma: Retrospective Analysis of 1175 Patients

Author: Francesca Gay, Alessandra Larocca, P.W. Wijermans, Sara Bringhen, Tommasina Guglielmelli, Martijn R. Schaafsma, Giulia Benevolo, Vincenzo Callea, Luca Baldini, Fortunato Morabito, Mariella Grasso, Giuseppe Torelli, Manuela Rizzo, Monica Galli, Grazia Sanpaolo, Clotilde Cangialosi, Paola Omedè, Mario Boccadoro, Pieter Sonneveld, and Antonio Palumbo
Subjects: Very Good Partial Response, medicine.medical_specialty, Multivariate analysis, business.industry, Bortezomib, Proportional hazards model, Immunology, Cell Biology, Hematology, medicine.disease, Biochemistry, Confidence interval, Surgery, Thalidomide, Internal medicine, Medicine, business, Multiple myeloma, Complete response, medicine.drug
Abstract: Abstract 1949 Introduction: There is extensive evidence from numerous studies in the transplant setting that achievement of complete response (CR) or at least very good partial response (VGPR) is significantly associated with prolonged progression-free survival (PFS) and overall survival (OS). In elderly myeloma patients CR was a rare event since new drugs has been added to standard melphalan-prednisone (MP). After the introduction of novel agents, CR represents an achievable goal, also outside of the transplant setting. Aims: to assess the impact of response to treatment on time-to-event parameters (PFS and OS) in elderly myeloma patients. Methods: We retrospectively analysed newly diagnosed myeloma patients, older than 65 years old, or younger but not eligible for high-dose chemotherapy and transplant. Patients were enrolled in 3 multicentre randomized European trials of the GIMEMA and Hovon groups, and were treated with MP (n=332), MP plus thalidomide (MPT, n=332), MP plus bortezomib (VMP, n=257) or MP plus bortezomib-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT, n=254). PFS, OS and duration of CR were analysed by the Cox proportional hazards model, comparing the two arms by the Wald test and calculating 95% confidence interval (CI). Univariate and multivariate analyses were performed for the following variables: age at diagnosis (>75 vs. ≤75 yrs), International Staging System (ISS) stages, type of chemotherapy and best response achieved. Best response was treated as a time-dependent variable. Results: A total of 1,175 patients, enrolled from November, 2001 to January, 2009, were retrospectively analysed. The best response to treatment was available in 1,136 patients: CR was reported in 195, VGPR in 212, PR in 397. Baseline characteristics according to best response achieved in patients who obtained CR, VGPR or PR were similar. Since response rates vary according to treatment regimens the proportion of patients who received MP, MPT, VMP, and VMPT-VT was different in the different response categories. After a median follow-up of 29 months, PFS was significantly higher in patients who achieved CR compared to those who obtained VGPR (HR 0.16; 95% CI 0.10–0.24; p 75 years, both PFS and OS were shorter as compared to younger patients. Despite these differences, the impact of CR on outcome was identical. In the subgroup of patients > 75 years, PFS was significantly prolonged in patients who achieved CR, compared with those who obtained VGPR (HR 0.26; 95% CI 0.12–0.58, p = 0.001) or PR (HR 0.20; 95% CI 0.10–0.41, p < 0.001). Accordingly, OS was significantly higher in patients who achieved CR, compared with those who obtained VGPR (HR 0.13; 95% IC 0.03–0.58; p = 0.007), or PR (HR 0.12; 95% IC 0.03–0.51, p = 0.004), (table). No significant PFS differences between patients obtaining CR during the first 6 months of treatment or later were seen (HR 1.06; 95% IC 0.49–2.27; p=0.878). Similarly, no OS differences between these two groups were detected (p = 0.676). Duration of CR was comparable in patients who obtained CR during or after the first 6 months of treatment (HR 0.66; 95% CI 0.30–1.45; p = 0.305). Patients whose CR lasted more than 18 months have a significant OS benefit compared to patients who did not (p=0.006). Conclusions: These finding highlight the importance of CR, also outside of the transplant setting, regardless of age, ISS and treatment administered, and support the use of new drugs, also in patients older than 75 years, to achieve and maintain maximal response. Disclosures: Gay: Celgene: Honoraria. Bringhen:Calgene: Honoraria; Janssen-Cilag: Honoraria. Guglielmelli:Celgene: Honoraria; Janssen Cilag: Honoraria. Boccadoro:Celgene: Membership on an entity's Board of Directors or advisory committees; Janssen-Cilag: Membership on an entity's Board of Directors or advisory committees. Sonneveld:Celgene: Membership on an entity's Board of Directors or advisory committees; Johnson & Johnson : Membership on an entity's Board of Directors or advisory committees. Palumbo:Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen-Cilag: Honoraria, Membership on an entity's Board of Directors or advisory committees.
Published: 2010

41. Efficacy and Safety of Once Weekly Bortezomib In Multiple Myeloma Patients

Author: Sara Bringhen, Alessandra Larocca, Davide Rossi, Alessandra Romano, Mariella Genuardi, Roberto Ria, Pietro Leoni, Francesca Patriarca, Chiara Nozzoli, Tommasina Guglielmelli, Giulia Benevolo, Vincenzo Callea, Fabiana Gentilini, Francesca Elice, Barbara Olivero, Mariella Grasso, Antonietta Pia Falcone, Daniela Gottardi, Vittorio Montefusco, Alessandro Allegra, Manuela Rizzo, Giovanna Leonardi, Daniela Oddolo, Fortunato Morabito, Mario Boccadoro, and Antonio Palumbo
Subjects: Immunology, Cell Biology, Hematology, Biochemistry
Abstract: Abstract 3029 Background. In a recent phase 3 trial, bortezomib–melphalan – prednisone–thalidomide followed by maintenance treatment with bortezomib–thalidomide (VMPT-VT) demonstrated superior efficacy compared with VMP. Peripheral neuropathy (PN) was the most important dose limiting toxicity. To decrease neurologic toxicities, the protocol was amended and patients in both arms received once-weekly instead of the initial twice-weekly bortezomib infusions. This post-hoc analysis assessed the impact of bortezomib dose-modification schedule on clinical outcomes and safety. Methods. Patients (N=511) older than 65 years were randomized to receive nine 6-week cycles of VMPT-VT (N=254; induction:V 1.3 mg/m2, d 1, 4, 8, 11, 22, 25, 29, 32, cycles 1–4, d 1, 8, 22, 29, cycles 5–9; M 9 mg/m2 d 1–4, P 60 mg/m2, d 1–4, T 50 mg d 1–42; maintenance: V 1.3 mg/m2 every 14 days and T 50 mg/day) or VMP (N=257) alone. In March 2007, the protocol was amended: both VMPT-VT and VMP induction schedules were changed to nine 5-week cycles and bortezomib schedule was modified to weekly administration (1.3 mg/m2 d 1,8,15,22, all cycles). Patients receiving VMPT-VT and VMP were pooled together and stratified according to the once-weekly or twice-weekly infusion modality; analyses were also conducted for patients receiving VMP only, to eliminate the influence of thalidomide and of maintenance on efficacy and safety. Results. Patients were evaluated in intention-to-treat: 372 patients received once-weekly and 139 twice-weekly bortezomib infusion. Patient characteristics were similar in the two groups, median age was 71 years. The efficacy data did not appear to be affected by the bortezomib schedule. Overall response rates were 85% with once weekly and 86% with twice- weekly schedule (P = .78), including CR rates of 30% and 35% (P = .27).Three-year PFS was 50% in the once-weekly and 47% in the twice-weekly group (P = 1.00), and 3-year OS was 88% and 89%, respectively (P = .54). Similar outcome was seen in the analyses restricted to VMP patients: CR rates were 23% with once-weekly and 27% with twice-weekly schedule (P = .54), 3-years PFS was 46% in once-weekly and 39% (P = .86) in twice-weekly group and 3-years OS was 87% and 89% (P = .47), respectively. The incidence of grade 3/4 hematologic toxicity was similar in the two groups (44% vs 45%, P = .83), but severe thrombocytopenia was slightly less common in the once-weekly patients (19% vs 26%, P = .08).The incidence of non-hematologic grade 3/4 adverse events was significantly reduced in the once-weekly: 35% vs 51% (P = .003). Grade 3/4 gastrointestinal events (6% vs 11%, P = .08), severe systemic events (4% vs 7%, P = .09) and grade 3/4 dermatologic events (2% vs 7%, P = .006) were less frequent in patients receiving once-weekly bortezomib. There was a significantly reduced overall incidence of grade 3/4 PN (8% vs 28%, P < .001) in the once-weekly group. The median time to onset of grade 3/4 sensory PN was 4.3 months in the once-weekly group and 3.2 months in the twice-weekly group (P = .10). The cumulative incidence of sensory PN appeared to plateau after 12 months of therapy in both groups. Rates of discontinuations (5% versus 15%) and dose reductions (15% versus 41%) due to PN were also significantly lower in the once-weekly group (P < .001). These results were reflected in analysis restricted to VMP patients, in which the incidence of grade 3/4 PN (7% vs 29%, P < .001), the discontinuation rate (4% vs 16%, P = 0.002), and the dose reductions rate (15% vs 41% P < 0.001) were significantly lower in once-weekly group. Despite the cumulative planned dose being lower in the once-weekly group (46.8 vs 67.6 mg/m2), the delivered cumulative dose of bortezomib was similar in the two groups (39.4 mg/m2 vs 40.1 mg/m2). No association of PN with age or other baseline characteristics was outlined. The only significant factor influencing the incidence of PN was the reduction of bortezomib infusion from twice- to once-weekly (p Conclusion. These results demonstrate that 1. both once-weekly and twice-weekly schedules in combination with MP ± thalidomide are highly effective in patients ≥ 65 years; 2. once-weekly schedule significantly reduced the incidence of PN and decreased the rate of discontinuation, resulting in similar cumulative bortezomib doses in the two groups; 3. the improvement in the safety profile was not associated with any reduction in the efficacy. Disclosures: Bringhen: Celgene: Honoraria; Janssen Cilag: Honoraria. Leoni:Celgene: Honoraria; Janssen Cilag: Honoraria. Patriarca:Celgene: Honoraria; Janssen Cilag: Honoraria; Roche: Honoraria; Merck: Membership on an entity's Board of Directors or advisory committees. Guglielmelli:Celgene: Honoraria; Janssen Cilag: Honoraria. Elice:Celgene: Honoraria; Novatis: Honoraria. Boccadoro:Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen-Cilag: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding. Palumbo:Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen-Cilag: Honoraria, Membership on an entity's Board of Directors or advisory committees.
Published: 2010

42. Sequential Approach with Bortezomib as Induction Before Autologous Transplantation, Followed by Lenalidomide as Consolidation-Maintenance in Untreated Multiple Myeloma Patients

Author: Francesca Gay, Patrizia Falco, Claudia Crippa, Anna Marina Liberati, Francesca Patriarca, Clotilde Cangialosi, Vincenzo Capparella, Agostina Siniscalchi, Manuela Rizzo, Luca De Rosa, Antonietta Pia Falcone, Simona Caltagirone, Sara Bringhen, Paolo Corradini, Mario Boccadoro, and Antonio Palumbo
Subjects: medicine.medical_specialty, Bortezomib, business.industry, Immunology, Cell Biology, Hematology, Neutropenia, medicine.disease, Biochemistry, Surgery, Thalidomide, Autologous stem-cell transplantation, Internal medicine, medicine, Autologous transplantation, business, Multiple myeloma, Dexamethasone, Lenalidomide, medicine.drug
Abstract: Abstract 3419 Poster Board III-307 Background Bortezomib induction before autologous stem cell transplantation (ASCT) has shown its efficacy in newly diagnosed multiple myeloma (MM) patients, both in association with dexamethasone alone (Harousseau JL, et al. Blood 110, 2007, abstr 450) and in combination with doxorubicin and dexamethasone (Popat R, et al. Br J Haematol 141:512-516, 2008). Lenalidomide, a less toxic and more potent thalidomide-derivative, lacks the neurotoxic effects of the parent drug and represents an optimal agent to include in maintenance regimens. Aims These observations provided the rationale for investigating a sequential approach including bortezomib as induction and lenalidomide as consolidation-maintenance in MM patients undergoing ASCT. Methods A hundred and two newly diagnosed patients aged 65–75 years were enrolled in 17 Italian centers. Induction (PAD) included four 21-day cycles of bortezomib (1.3 mg/m2 days 1,4,8,11), pegylated-liposomal-doxorubicin (30 mg/m2 day 4), and dexamethasone (40 mg/day: cycle 1, days 1–4, 8–11, 15–18; cycles 2–4, days 1–4). Autologous transplantation was tandem melphalan 100 mg/m2 (MEL100) followed by stem-cell support. After ASCT, patients received consolidation with four 28-day cycles of lenalidomide (25 mg/day days 1–21 every 28 days) plus prednisone (50 mg every other day) (LP), followed by maintenance (L) with lenalidomide alone (10 mg/day days 1–21 every 28 days) until relapse. Primary endpoints were safety (incidence of grade 3–4 adverse events [AEs]) and efficacy (response rate). Secondary endpoints were progression-free survival (PFS) and overall survival (OS). Time-to-event estimates analysis was performed using the Kaplan-Meier method. Results Very good partial response (VGPR) or better was 58% after PAD induction and increased to 82% after MEL100 and to 86% during LP-L. Complete response (CR) rate was 13% after PAD induction, increased to 38% after MEL100 and to 66% during LP-L. After a median follow-up of 2 years, the 2-year PFS was 69%, the 2-year time-to-progression was 75% and the 2-year OS was 86%. During PAD induction, main grade 3–4 AEs were thrombocytopenia (17%), neutropenia (10%), peripheral neuropathy (16%), and pneumonia (10%); treatment-related mortality was 3%. During consolidation-maintenance grade 3–4 AEs included neutropenia (16%), thrombocytopenia (6%), pneumonia (5%), and cutaneous rash (4%). Consolidation-maintenance treatment was well tolerated: only 4% of patients required Granulocyte-colony stimulating factor support and no patient required platelet transfusion; dermatological toxicity was easily manageable with dose-reduction and supportive therapy; no treatment-related deaths were reported. Updated results will be presented at the meeting. Conclusion This is the first phase II study in newly diagnosed MM patients to date, where a sequential approach including bortezomib as induction, and lenalidomide as post ASCT consolidation-maintenance was explored. Treatment was correlated with an increase in response rate and in the depth of response (CR rate) and was generally well tolerated. These data suggest that this is a safe and effective regimen for newly diagnosed MM patients. Randomized trials are needed to confirm these results. Disclosures Patriarca: Celgene: Honoraria; Janssen Cilag: Honoraria. Bringhen:Celgene: Honoraria; Janssen Cilag: Honoraria. Boccadoro:Janssen Cilag : Consultant, advisory committee, Research Funding; Celgene: Consultant, advisory committee, Research Funding; Pharmion: Consultant, advisory committee, Research Funding. Palumbo:Celgene: Honoraria; Janssen Cilag: Honoraria.
Published: 2009

43. A105 A Phase III Study of MEL200 Versus MEL100 in Newly Diagnosed Myeloma Young Patients

Author: A. Falcone, A. Palumbo, Alessandra Larocca, C Di Bello, S Morandi, A. Gabbas, Manuela Rizzo, M.T. Petrucci, Velia Bongarzoni, Pellegrino Musto, Elisabetta Calabrese, Robert Foa, Anna Marina Liberati, Federica Cavallo, Vincenzo Callea, Antonio Capaldi, S Bringhen, V. De Stefano, and Mario Boccadoro
Subjects: Melphalan, Cancer Research, medicine.medical_specialty, Bortezomib, business.industry, Hematology, General Medicine, Neutropenia, medicine.disease, Gastroenterology, Autologous stem-cell transplantation, Oncology, Prednisone, Internal medicine, medicine, business, Dexamethasone, Multiple myeloma, medicine.drug, Lenalidomide
Abstract: Introduction and Aims: New agents have been introduced as induction prior to autologous stem cell transplantation (ASCT) and as consolidation/maintenance thereafter to improve complete response (CR) rates. We evaluate bortezomib plus pegylatedlyposomal-doxorubicin and dexamethasone (PAD) as induction prior to reduced intensity ASCT, followed by consolidation with lenalidomide and prednisone (LP) and maintenance with lenalidomide alone (L). Materials and Methods: Newly diagnosed multiple myeloma patients aged 65-75 years were eligible. Induction consisted of four 21-day PAD cycles (bortezomib 1.3 mg/m2 days 1, 4, 8, 11; pegylated-lyposomal-doxorubicin 30 mg/m2 day 4; dexamethasone 40 mg days 1-4, 8-11, and 15-18). Patients were conditioned with tandem melphalan 100 mg/m2 (MEL100) followed by stem cell support. After ASCT patients received consolidation with four 28-day LP cycles (lenalidomide 25 mg days 1-21, prednisone 50 mg every other day) followed by lenalidomide maintenance (10 mg days 1-21). Primary objectives were safety (grade 3 nonhematologic toxicity 35%). Results: One-hundred and two patients entered the study. After PAD, 94% of patients achieved at least partial response (PR) and 59% at least very good partial response (VGPR) including 13% CR. After tandem MEL100, 88% of patients obtained at least VGPR and 41% CR. After LP all patients achieved PR, 88% at least VGPR including 53% CR. After a median follow-up of 14 months, 1-year progression-free survival (PFS) was 92%, and 1-year overall survival was 92%. PFS was not significantly affected by b2-microglobulin levels (P = .10), presence of chromosome 13 deletion (P = .5) or t(4;14)(P = .61). During PAD, grade 3/4 adverse events included thrombocytopenia (13%), neutropenia (11%), infections (18%), gastrointestinal toxicities (12%), peripheral neuropathy (11%) and deep vein thrombosis (DVT) (6%). During LP, grade 3/4 toxicities included neutropenia (18%), thrombocytopenia (6%), infections (6%) and DVT (6%). The other grade 3/4 toxicities occurred in less than 5% of patients. Conclusion: Bortezomib as induction, followed by lenalidomide as consolidation/maintenance is a highly effective regimen in elderly patients. Updated results will be presented at the meeting.
Published: 2009

44. Decisional Algorithm to Incorporate Hematopoietic Stem Cell Transplantation in the Management of Adult Patients with Acute Myeloid Leukaemia

Author: Adriano Venditti, Chiara Sarlo, Gottardo De Angelis, Manuela Rizzo, William Arcese, Giovanni Del Poeta, Maria Ilaria Del Principe, Selenia Campagna, Francesco Buccisano, Luca Maurillo, Sergio Amadori, Licia Ottaviani, Francesco Lo Coco, Paola Panetta, Micol Quaresima, and Emanuele Ammatuna
Subjects: Oncology, medicine.medical_specialty, Adult patients, business.industry, medicine.medical_treatment, Immunology, Myeloid leukemia, Cell Biology, Hematology, Hematopoietic stem cell transplantation, Human leukocyte antigen, Biochemistry, Minimal residual disease, Transplantation, hemic and lymphatic diseases, Internal medicine, medicine, Myeloid leukaemia, business, Risk assessment
Abstract: Implementation of transplant procedures and the availability of alternative sources of stem cells for patients without HLA identical siblings has made allogeneic stem cell transplant (ASCT) a suitable therapy for many patient affected by acute myeloid leukemia (AML); consequently, in AML patients transplant strategies must be carefully designed according to stringent risk/benefit analysis. To date, risk assessment relies on identification of baseline prognostic parameters such as karyotype, which has become critical in order to choose post-remissional therapy. Furthermore, there are strong evidences that the presence of specific gene abnormalities, such as mutations of FLT3, NPM and c-kit, allow to identify, within homogeneous cytogenetic groups, subsets of patients with distinct clinical outcome. We hypothesized that, in order to guide the post-remission decisional process, more robust informations may derive from the combined evaluation of conventional baseline and delayed prognosticators. Minimal residual disease (MRD) detection is potentially the most efficient tool to investigate the quality of remission and might represent the ideal parameter to be associated with baseline biological features for prognostic purposes. Therefore, we aimed to determine whether combined analysis of karyotype and MRD, using multiparametric flow-cytometry (MPFC), could help to refine risk assessment in adult patients with AML, allowing the most appropriate post-remissional strategy to be selected. We analyzed 132 patients with AML who had intensive chemotherapy with EORTC/GIMEMA protocols. According to MRC classification, 22 (17%), 104 (78%) and 6 (5%), respectively, had good, intermediate and poor risk karyotype. Thirteen of 107 (12%) carried a FLT3-ITD. Within good and intermediate risk categories, MRD positivity (≥ 3.5×10−4 residual leukemic cells at the post-consolidation time-point) was associated with a worse prognosis in terms relapse free (RFS) and overall survival (OS). In fact, we observed that: MRD negative good and intermediate risk categories shared the same favorable prognoses with RFS and OS of 80% vs. 69% and 84% vs 54%, respectively; MRD positive good and intermediate risk categories fared as worse as those with poorrisk karyotype or FLT3-ITD in terms of RFS (28% vs. 17% vs. 0%) and OS (42% vs. 21% vs. 17%). Using this approach the conventional cytogenetic classification that uses three categories is simplified into 2 prognostically defined groups: favorable, including MRD negative good and intermediate risk karyotype; unfavorable, including MRD positive good and intermediate risk karyotype, poor risk karyotype and FLT3-ITD positive cases (Fig. 1). Based on these observations, we believe that ASCT is recommended, not only for poor-risk karyotype or FLT3 positive AML, but also for good/intermediate risk categories not gaining MRD negativity, being this option able to provide a superior chance of prolonged RFS (Maurillo et al, JCO 2008). On the other hand, patients belonging to MRD negative good/intermediate risk categories, who can experience a 5-years survival higher than 60%, may have their life expectancy hampered by the choice of a therapeutic strategy with a disadvantageous risk/benefit ratio: for this category a standard intensification procedure (chemo and/or autologous transplant) is indicated. In conclusion, the combined assessment of baseline prognosticators (cytogenetics) and parameters inherent the quality of response (MRD), is useful to define discrete categories of risk within the respective karyotypic groups, allowing tailored therapeutic approaches to be applied according to the actual clinical risk and avoiding under or over treatments. Figure 1 Figure 1.
Published: 2008

45. Flow-Cytometric Minimal Residual Disease Determination Is a Surrogate Prognosticator in Adult AML Patients Lacking Specific Molecular Signatures

Author: Daniela Fraboni, Massimiliano Postorino, Sabrina Faccia, Maria Irno Consalvo, Sergio Amadori, Maria Cantonetti, Francesco Buccisano, Giovanni Del Poeta, Adriano Venditti, Francesco Lo Coco, Licia Ottaviani, Paola Panetta, Emanuele Ammatuna, Luca Maurillo, Manuela Rizzo, and Maria Ilaria Del Principe
Subjects: Oncology, medicine.medical_specialty, Mutation, NPM1, Immunology, Karyotype, Cell Biology, Hematology, Gene mutation, Biology, medicine.disease_cause, Bioinformatics, Biochemistry, Minimal residual disease, Haematopoiesis, hemic and lymphatic diseases, Internal medicine, medicine, Progenitor cell, Stem cell
Abstract: In a remarkable proportion of adult AML patients (40–50%), no clonal abnormalities are found on standard cytogenetic analysis. In this group of patients, several gene mutations have been described, allowing to discriminate subgroups with distinct clinical outcome. Among these molecular signatures, FLT3, a receptor tyrosine kinase with important roles in hematopoietic stem/progenitor cell survival and proliferation, has been demonstrated to be mutated in about 1/3 of AML cases, identifying a subgroup of patients characterized by disappointing overall cure rates. Therefore, roughly 60% of patients with normal karyotype are not classifiable by this specific mutation. The purpose of the present study was to investigate, in this group of patients with no specific molecular signature the prognostic role of MRD as determined by multiparametric flow-cytometry (MPFC). We analyzed a group of 127 AML cases entered into the EORTC/GIMEMA protocols AML10/AML12 (age 61 yrs). By applying the maximally selected log-rank statistics, the threshold discriminating MRD negative from positive cases was set at 3.5 x10−4 residual leukemic cells, a level that selected, at the post-consolidation time-point, two groups of patients with distinct prognosis. Seventy-two out of 127 (56%) had a normal karyotype. Among these 72, 53 were studied for FLT3 mutational status; in 13 (25%) a mutated variant of FLT3 was detected. Among the remaining 40 patients with normal karyotype and unmutated FLT3, 39 were evaluable for the MRD status at the post-consolidation time-point: 9 patients were MRD− and 30 MRD+. These two subsets showed a distinct outcome in terms of 5-years RFS (83 vs. 23%, p=0.031). Interestingly, the FLT3−MRD+ patients shared with those FLT3 positive a similar poor prognosis (Figure 1). In recent reports, the evaluation of outcome depending on FLT3 status has been integrated with the analysis of the mutated status of other genes: FLT3-mutated cases associated frequently with Nucleophosmin (NPM1) exon-12 gene mutations but rarely with other mutations. The favorable impact of NPM1 mutations on OS and EFS clearly emerged in the group of normal-karyotype AML without FLT3 mutations. In a subset of 44 patients of our series either the mutations were investigated; this combined analysis identified 8 out of 44 (18%) patients FLT3 unmutated/NPM1 mutated with a better outcome (5-years OS 50% and RFS 50%, respectively) as compared to FLT3 unmutated/NPM1 unmutated and FLT3 mutated patients, which was however poorer than that of FLT3 unmutated/MRD− cases (Figure 1). In conclusion, MRD determination at the post-consolidation phase may help at improving the prognostic assessment of AML patients lacking specific chromosomal and/or molecular lesions, allowing risk-adapted post remissional therapies to be designed with more accurate modalities. Figure Figure
Published: 2007

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Database

Publisher

45 results on '"Manuela Rizzo"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources